ML053200303

Calculation CA06452 MSLB, Radiological Consequences Design Basis Calculation Using AST Rev 000

ML053200303
Person / Time
Site:	Calvert Cliffs
Issue date:	11/03/2005
From:	Constellation Energy Group
To:	Office of Nuclear Reactor Regulation
References
CA06452, Rev 000
Download: ML053200303 (111)

Text

Enclosure (3)

CA06452 MSLB Radiological Consequences Design Basis Calculation Using AST Calvert Cliffs Nuclear Power, Inc.

November 3, 2005

EN-1-100 Forms Appendix Revision 3 IESP No.: IES200100401 ISupp No. I000 IRev. No. I 000 IPage 1 of I l FORM 19, CALCULATION COVER SHEET A. INITIATION (Control Doc Type - DCALC) Page lof 110 t AS ,- F.-t _ . .

n,---

IV.. C-114O T} and.A I evision-No.: uV - - I- -

I - -

Vendor Calculation (Check one): El Yes O No Responsible Group: FOSU Responsible Engineer: Gerard'E. Gryczkowski B. CALCULATION ENGINEERING El Civil a Instr & Controls 0j Nuc Engrg DISCIPLINE:

D Electrical. El Mechanical al Nuc Fuel Mngmt D Other: E Reliability Engrg

Title:

MAIN STEAM LINE BREAK EVENT USING ALTERNATE SOURCE TERMS Unit Of 02 0 COMMON Proprietary or Safeguards Calculation El YES 0 NO Comments: NA Vendor Calc No.: NA REVISION No.: NA Vendor Name: NA Safety Class (Check one): 0 SR El AQ El NSR There are assumptions that require Verification during walkdown: AIT#: NA This calculation SUPERSEDES: NA C. REVIEWANDAPPROVAL: A Responsible Engineer: Gerard E. Gryczkowski v 05/09/2005 Printed N,& and ignatye ' . Date ..

Independent Reviewer: Ian Sonunerville 7 -CASK Printed Name and Signature Date Approval:

7C,( , ZV~ z se OA? 72 Date Printed Name and Signature V

IF the results or conclusions of this calculation or revision might affect a procedure or the basis of a procedure, a Change Notification Form (Form 14) shall be forwarded to the Procedure Development Unit with a summary of the calculation's purpose and results.

I

CA06452 Rev.000 Page 2 of 110

2. LIST OF EFFECTIVE PAGES Page Latest Page Latest Page Latest Page Latest Page Latest Rev Rev Rev Rev Rev 001 0 002 0 003 0 004 0 005 0 006 0 007 0 008 0 009 0 010 0 011 0 012 0 013 0 014 0 015 0 016 0 017 0 018 0 019 0 020 0 021 0 022 0 023 0 024 0 025 0 026 0 027 0 028 0 029 0 030 0 031 0 032 0 033 0 034 0 035 0 036 0 037 0 038 0 039 0 040 0 041 0 042 0 043 0 044 0 045 0 046 0 047 0 048 0 049 0 050 0 051 0 052 0 053 0 054 0 055 0 056 0 057 0 058 0 059 0 060 0 061 0 062 0 063 0 064 0 065 0 066 0 067 0 068 0 069 0 070 0 071 0 072 0 073 0 074 0 075 0 076 0 077 0 078 0 079 0 080 0 081 0 082 0 083 0 084 0 085 0 086 0 087 0 088 0 089 0 090 0 091 0 092 0 093 0 094 0 095 0 096 0 097 0 098 0 099 0 100 0 101 0 102 0 103 0 104 0 105 0 106 0 107 0 108 0 109 0 110 0

CA064S2 Rev.000 Page 3 of 110

3. REVIEWER COMMENTS (1) Why don't the lambda's not compare; with CA06421 ?

Response: The values in CA06421 were from the LOCADOSE User's Manual. CCNPP's previous design basis dose calculation code for many accidents. The new data is extracted from the latest Chart of the Nuclides and is consistent with that employed by the new design basis code RADTRAD. The values are close.

(2) Please state the page # with the reference Response: Noted for future references.

(3) XE-138? Where is it from?; not from CA06358?

Response: The Xe-138 core source term 4.9330E+04 Ci/MWt is from CA06358.

(4) p. 11. Where does the AFW = 10,000 cf come from?

Response: It is an arbitrary feedwater source used for SG makeup. It is not used in the MSLB accident analysis.

(5) Why is the power level 1? The sources are in units of Ci/MWt. Also, Why do I see power devel some places of 3412?

Response: The primary and secondary isotopic inventories are in total Curies. Thus a power input of I is required.

No power level of 3412 was found.

(6) Are the results rounded way up?

Response: They are not rounded in this work at all.

(7) What are the cases mslbfffl, 2, 2a ?

Response: Additional cases modeling the main steam pipine room volume and the turbine building volume which were not utilized in the results. Note that regulatory guidance does not allow activity holdup before release into the environment.

(8) What does a transfer path do if it is 0 gpd?

Response: Nothing. Note that the model is a base model used in several accidents.

(9) Where does the 4000 cfm come from (p. 12)

Response: It is the SG leakrate comparable in size to the SG volume. It signifies rapid release of the SG contents with little holdup.

(10) Why not use the X/Q from UFSAR table 2-14 Response: The UFSAR Table 2-14 values are for release from the surface area of the containment. The MSG is more like a point release, which results in a larger X/O.

CA06452 Rev.000 Page 4 of 110

4. TABLE OF CONTENTS

01. COVER SHEET 1

02. LIST OF EFFECTIVE PAGES 2

03. REVIEWER COMMENTS 3

04. TABLE OF CONTENTS 4

05. INTRODUCTION 6

06. INPUT DATA 8

07. TECHNICAL ASSUMPTIONS 13

08. REFERENCES 14

09. METHODS OF ANALYSIS 16 09.1 RADTRAD Computations 16 09.2 Gas Gap, Primary, and Secondary Release Activities 16 09.3 Flashing Fraction Calculations 18

10. CALCULATIONS 19

11. DOCUMENTATION OF COMPUTER CODES 20

12. RESULTS 21

13. CONCLUSIONS 23

14. ATTACHMENTS 24 ATTACHMENT A: MAIN STEAM LINE BREAK RELEASE ACTIVITIES 24 ATTACHMENT B: NUCLEAR INVENTORY FILE GAP 14.NIF 26 ATTACHMENT C: NUCLEAR INVENTORY FILE PR114.NIF 29 ATTACHMENT D: NUCLEAR INVENTORY FILE SEC05.NIF 32 ATTACHMENT E: NUCLEAR INVENTORY FILE PIS.NIF 34 ATTACHMENT F: NUCLEAR INVENTORY FILE CIS500.NIF 37 ATTACHMENT G: NUCLEAR INVENTORY FILE CRCB63.NIF 40 ATTACHMENT H: RELEASE FRACTION AND TIMING FILE MSLBGAP.RFT 51 ATTACHMENT I: RELEASE FRACTION AND TIMING FILE MSLBPRI.RFT 52

CA06452 Rev.o00 Page 5 of 110 ATTACHMENT J: RELEASE FRACTION AND TIMING FILE MSLBSEC.RFT 53 ATTACHMENT K: RELEASE FRACTION AND TIMING FILE PIS.RFT 54 ATTACHMENT L: RELEASE FRACTION AND TIMING FILE CIS500.RFT 55 ATTACHMENT M: RELEASE FRACTION AND TIMING FILE MSLBGCS.RFT 56 ATTACHMENT N: CONVERSION FACTORS FILE FGR14.INP 57 ATTACHMENT 0: CONVERSION FACTORS FILE FGR05.INP 61 ATTACHMENT P: CONVERSION FACTORS FILE FGR63.INP 63 ATTACHMENT Q: MSLBFF OUTPUT FILE 77 ATTACHMENT R: MSLBPRI OUTPUT FILE 79 ATTACHMENT S: MSLBSEC OUTPUT FILE 81 ATTACHMENT T: MSLBPIS OUTPUT FILE 83 ATTACHMENT U: MSLBCIS OUTPUT FILE 85 ATTACHMENT V: MSLBFFCS OUTPUT FILE 86 ATTACHMENT W: ETP 97-064R CONTROL ROOM INLEAKAGE RESULTS 89 ATTACHMENT X: ETP 01-035R PERFLUOROCARBON TRACER GAS TESTING 105 LAST PAGE OF REPORT 110

CA06452 Rev.000 Page 6 of 110

5. INTRODUCTION The Main Steam System carries steam from the Steam Generators (SGs) to the turbine-generators and to other auxiliary equipment. A Main Steam Line Break (MSLB) may occur as a result of thermal stress or cracking in the main steam line. The guillotine-type break assumed in Chapter 14.14 of the Updated Final Safety Analysis Report (UFSAR) is the most adverse transient scenario but its probability of occurrence is extremely low.

A rupture in the Main Steam System increases the rate of heat extraction by the SGs, which causes cooldown of the reactor coolant system (RCS) and causes the affected SG pressure and temperature to rapidly decrease. The steam released through the break in the affected SG extracts heat from the primary side which causes the primary coolant temperature and pressure to rapidly decrease. The decrease in the primary coolant temperature, in combination with a negative Moderator Temperature Coefficient (MTC), results in positive reactivity addition which causes the core power level and core heat flux to increase. The uncontrolled blowdown of the affected SG will initiate one of the following reactor trips: high containment pressure, high power, delta-T power, low SG pressure, or TM/LP. The power increase will be terminated after the Control Element Assemblies (CEAs) are inserted, even assuming most reactive rod stuck out. Following appropriate delays, the Main Steam Isolation Valves (MSIVs) in the main steam lines on both the affected and on the unaffected SGs will close and terminate the blowdown from the unaffected SG.

The MSIV is a gas hydraulic, bi-directional, balanced disk, Y-pattern, globe valve designed to hold pressure from either direction. The blowdown from the affected SG will continue since the MSIV is downstream from the break area. The continued blowdown causes the RCS pressure to decrease until the Safety Injection Actuation Signal (SIAS) is initiated, which automatically starts the High Pressure Safety Injection (HPSI) pumps. Since the shutoff head of the HPSI pumps is approximately 1200 psia, no safety injection (SI) flow is delivered immediately.

Therefore, the pressure continues to decrease and the pressurizer empties. A Loss of Offsite Power (LOOP) is conservatively assumed after a turbine trip resulting in a coast down of the reactor coolant pumps (RCPs). The negative reactivity addition from the inserted CEAs with most reactive rod stuck out will be sufficient to offset the positive reactivity inserted by the moderator and fuel temperature feedbacks. The HPSI and Charging Pump borated flows will also insert negative reactivity, which ensures that the core remains subcritical during the event.

Consequently, the core will remain sufficiently subcritical to prevent any power increase over decay power levels.

UFSAR 14.14 presents the licensing basis evaluation of the MSLB Event. A MSLB Event is defined as the pre-trip guillotine-type rupture of a main steam line outside containment in the Main Steam Piping Room (MSPR). It is assumed that the steam line rupture occurs between the steam generator and the MSIV, allowing blowdown of the affected steam generator to continue. A LOOP with the turbine trip results in the maximum site boundary doses, since the LOOP causes the RCPs to coast down, minimizing core flow, lowering the transient Departure from Nucleate Boiling Ratio (DNBR), and maximizing the number of failed fuel pins.

To maximize control room and offsite doses, the maximum secondary Technical Specification (TS) activity and that fraction of the primary Technical Specification and failed fuel activity which leaks to the secondary from the affected and unaffected steam generators are discharged into the MSPR and out the Main Steam Gooseneck (MSG) on the roof of the auxiliary building. Since the steam generators are designed to withstand RCS operating pressure on the tube side with atmospheric pressure on the shell side, the continued integrity of the RCS barrier is assured.

Thus only the maximum Technical Specification primary-to-secondary leakage is assumed. A partition factor of unity is assumed for all discharged activities.

Previously, power reactor licensees have typically used the U.S.A.E.C Technical Information Document TID-14844, "Calculation of Distance Factors for Power and Test Reactor Sites," (Ref.18) as the basis for Design Basis Analysis (DBA) source terms. TID-14844 is referenced in 10 CFR 100.11, the power reactor siting regulation, which contains offsite dose limits in terms of whole body and thyroid doses. In December 1999, the Nuclear Regulatory Commission (NRC) issued a new regulation, 10 CFR 50.67, "Accident Source Term," which provided a mechanism for licensed power reactors to replace the traditional accident source term used in their DBA analyses with an Alternate Source Term (AST) methodology. Regulatory guidance for the implementation of these ASTs is provided in Regulatory Guide (RG) 1.183, "Alternative Radiological Source Terms for Evaluating Design Basis Accidents at Nuclear Power Reactors" (Ref.08). Section 50.67 of 10 CFR requires a licensee seeking to use AST to

CA06452 Rev. 000 Page 7 of 210 apply for a license amendment and requires that the application contain an evaluation of the consequences of affected DBAs. As part of the implementation of the AST, the Total Effective Dose Equivalent (TEDE) acceptance criterion of 10 CFR 50.67 replaces the previous whole body and thyroid dose guidelines of 10 CFR 100.11 and 10 CFR 50, Appendix A, GDC-19 for the loss-of-coolant accident (LOCA), the main steam line break (MSLB), the steam generator tube rupture (SGTR), the seized rotor event (SRE), the fuel handling accident (FHA), and the control rod ejection accident (CREA). The Nuclear Steam Supply System (NSSS) response to the MSLB was simulated using the CESEC computer code.

The current work utilizes the alternate source term methodology of 10 CFR 50.67 and Regulatory Guide 1.183 to calculate offsite and control room doses for a MSLB. A bounding control room inleakage value of 3500 cfm vwas assumed. Modification of the control room emergency ventilation system to a nominal 10000 cfm flow with a 90%

filtration efficiency for elemental and organic iodine and 99% for particulate iodine was credited. Also credited was installation of automatic isolation dampers and radiation monitors at Access Controls 11 and 13 on the Auxiliary Building Roof. This modification limits activity ingress into the control room from either the West Road Inlet or the Turbine Building, thus limiting the atmospheric dispersion coefficient value. The Technical Specification limit for RCS activity was reduced from 1.0 pCi/gm to 0.5 PCi/gm.

Per RG 1.183 (Ref.08), if no or minimal fuel damage is postulated, the activity should be the maximum coolant activity allowed by the technical specifications, assuming two cases of iodine spiking. Thus, three cases are modeled to determine the maximum offsite and control room doses.

• Failed Fuel Case: The dose analysis of UFSAR 14.14 assumes a conservative 1.35% fuel failure rate and 200 gpd primary-to-secondary leakage. The MSLB analyses of record were generated by Combustion Engineering (CE) in Refs. 11-12, resulting in no failed fuel. To preserve some margin and still meet the 10 CFR 50 App. A GDC 19 limit of 5 rem TEDE in the control room, 0.80% of the fuel pins in the core are assumed to fail.

• Preaccident Iodine Spike (P1S) Case: A reactor transient has occurred prior to the postulated MSLB and has raised the primary coolant iodine concentration to the maximum value permitted by the TSs, which is sixty times the TS 3.4.15 limit of 0.5 pCi/gm.

• Concurrent Iodine Spike (CIS) Case: The primary system transient associated with the MSLB causes an iodine spike in the primary system. The increase in primary coolant iodine concentration is estimated using a spiking model that assumes the iodine release rate from the fuel rods to the primary coolant increases to a value 500 times greater than the release rate corresponding to the iodine concentration at the equilibrium value.

The exclusion area boundary (EAB), low population zone (LPZ), and control room (CR) doses for the design-basis MSLB accidents are detailed in the following table.

I MSLB Results EAB LPZ CR Rem TEDE Rem TEDE Rem TEDE 0.8% Failed Fuel 0.2180 0.0577 4.6301 PIS Case 3.2635E-03 9.2117E-04 8.2508E-02 Regulatory Limits 25 (RG 1.183) 25 (RG 1.183) 5 (IOCFR50.67)

CIS Case 2.2499E-03 1.0446E-03 2.0757E-01 Regulatory Limits 2.5 (RG 1.183) 2.5 (RG 1.183) 5 (IOCFR50.67)

Note that all values are below the regulatory limits.

CA06452 Rev. 000 Page 8 of 110

6. INPUT DATA The input data to determine the exclusion area boundary (EAB), low population zone (LPZ), and control room (CR) doses from a Main Steam Line Break Accident are the following:

(01) Initial thermal power is 2754 MWt (UFSAR 3.2. l/Ref.1).

(02) The pin power peaking factor is 1.70. Per the Core Operating Limits Reports for Units I and 2, (Refs.2-3), the total integrated radial peaking factors (FIT) are less than or equal to 1.65. For conservatism, a pin power peaking factor of 1.70 will be used in this work.

(03) The isotopic half-lives (t1) were extracted from Ref.06 and are listed in column A of Attachment A. The decay constants (N*), listed in column B of Attachment A, are readily calculated via the following algorithm:

N = In(2) / tj (04) Per RG 1.183 (Ref.08), if no or minimal fuel damage is postulated, the activity should be the maximum coolant activity allowed by the technical specifications, assuming two cases of iodine spiking. Thus, three cases are modeled to determine the maximum offsite and control room doses. See Section 9.2 for more details.

• Failed Fuel Case: The dose analysis of UFSAR 14.14 assumes a conservative 1.35% fuel failure rate and 200 gpd primary-to-secondary leakage. The MSLB analyses of record were generated by Combustion Engineering (CE) in Refs. 11-12, resulting in no failed fuel. To preeserve some margin and still meet the 10 CFR 50 App. A GDC 19 limit of 5 rem TEDE in the control room, 0.80% of the fuel pins in the core are assumed to fail.

• Preaccident Iodine Spike (PIS) Case: A reactor transient has occurred prior to the postulated MSLB and has raised the primary coolant iodine concentration to the maximum value permitted by the TSs, which is sixty times the TS 3.4.15 limit of 0.5 ,Cilgm.

• Concurrent Iodine Spike (CIS) Case: The primary system transient associated with the MSLB causes an iodine spike in the primary system. The increase in primary coolant iodine concentration is estimated using a spiking model that assumes the iodine release rate from the fuel rods to the primary coolant increases to a value 500 times greater than the release rate corresponding to the iodine concentration at the equilibrium value.

(05) Per Ref.07, damaged fuel rods are assumed to release their gas gap activities consisting of the following isotopes (Attachment A Column D).

• 16% I-131

• 10% other iodines

• 20% Kr-85

• 10% other noble gases 24% alkali metals (06) Per Refs.8 and 37, the failed fuel gas gap activities are assumed to be released instantaneously and homogeneously throughout the primary system at the initiation of the accident. Per Ref.8, the primary TS and PIS activities are assumed to be homogeneously distributed throughout the primary system at the beginning of the accident. Per Ref.8, the secondary TS activities are assumed to be homogeneously distributed throughout the secondary system at the beginning of the accident. Per Ref.8, the primary CIS iodine activities are linearly and homogeneously released over a 9 hour1.041667e-4 days <br />0.0025 hours <br />1.488095e-5 weeks <br />3.4245e-6 months <br /> period into the primary system, %whilethe primary CIS noble gas activities are assumed to be homogeneously distributed throughout the primary system at the beginning of the accident. These release assumptions are incorporated into the release fraction and timing files.

(07) Based on Inputs 5, 6, and 7, the release fraction and timing input files can be generated.

CA06452 Rev.000 Page 9 of 110 Files Release Timing Iodine Noble Gas Alkali Metal Attachment Hours Release Fraction Release Fraction Release Fraction MSLBGAP.RFT 0.0001 0.0080 0.0080 0.0000 H MSLBPRI.RFT 0.0001 1.0000 1.0000 0.0000 I MSLBSEC.RFT 0.0001 0.0000 1.0000 0.0000 J PIS.RFT 0.0001 1.0000 1.0000 0.0000 K CIS500.RFT 0.0001 0.0000 1.0000 0.0000 L 9.0000 1.0000 0.0000 0.0000 MSLBGCS.RFT 0.0001 0.0000 0.0000 0.00192 M (08) The dose conversion factors (DCFs) were extracted from Refs.20-21 and inserted into input files for use by RADTRAD. This data is included in the Conversion Factor Files FGR63.INP in Attachment P for use with failed fuel isotopics, FGR14.JNP in Attachment N for use with gas gap and primary system isotopics, and FGRO5.INP in for use with secondary system isotopics. Note that the cloudshine data in the Conversion Factor Files corresponds to the FGR-12 data, wvhile the inhaled chronic data in the Conversion Factor Files corresponds to the worst-case effective data in FGR-I 1. The remaining data in the Conversion Factor Files is extraneous and not used by RADTRAD.

(09) Per Ref.08, iodine releases from the steam generators to the environment should be assumed to be 97%

elemental and 3% organic. Iodine released from the failed fuel is assumed to be 95% particulate, 4.85% elemental, and 0.15% organic.

(10) Per Ref.08, the primary to secondary leakage of 200 gpd (TS 3.4.13) is assumed to continue until the primary system pressure is less than the secondary system pressure or until the temperature of the leakage is less than 1000 C (212TF). In this work, the release of radioactivity from the affected steam generator is assumed to continue until the RCS reaches 212TF. Per Ref.33, assuming a concurrent LOOP, failure of a diesel generator, and failure of the ADVs, operators would require a maximum of 9 hours1.041667e-4 days <br />0.0025 hours <br />1.488095e-5 weeks <br />3.4245e-6 months <br /> to cool the RCS to below 212TF.

Also per Ref.08, "the leakage should be apportioned between affected and unaffected steam generators in such a manner that the calculated dose is maximized." Thus, since the flashing fraction for the affected steam generator is 100% while that for the unaffected is less than 10% and since the most-limiting atmospheric dispersion coefficients for the Atmospheric Dump Valve (ADV) to Turbine Building (TB) are within 10% of the most-limiting atmospheric dispersion coefficients of the MSG to TB, all of the primary to secondary leakage is assumed to flow to the affected steam generator.

(11) The breathing rates are extracted from Ref.08:

Time Breathing Rate (hours) (m3/sec) 0-8 3.5E-04 8-24 1.8E-04 24-720 2.3E-04 (12) The control room occupan lcy factors are extracted from Ref.08:

Time Occupancy (hours) Factor 0-24 1.0 24-96 0.6 96-720 0.4

CA06452 Rev.000 Page 10 of 110 (13) Control room inleakage: The control room inleakages for the two trains Air Conditioning Units (ACU) 11 and 12 were measured by NUCON International Inc. via sulfur hexaflouride (SF 6) tracer gas tests as documented in Refs.23-26 (Attachment W). An additional inleakage test was performed by Brookhaven National Laboratory (BNL) via a perfl l orocarbon tracer gas (PF test as documented in Re ;27 (Attachment X).

ACU 11 ACU 12 SF6 Test I I 1/97 4300+/-300 cfm 3000+/-300 cfm SF6 Test 11/11/97 3600+/-600 cfm 2550+/-450 cfm SF6 Test 11/11/97 2900+/-250 cfm 2750+/-380 cfm SF6 Test 1/1 8/00 2600+/-200 cfm 3000+/-250 cfm PFT Test 5/1/02 2930+/-185 cfm 2930+/-185 cfm The latest SF6 and PFT tests show fairly good agreement, as indicated above. A conservative value of 3500 cfm will be utilized in this work.

The control room inleakage points were deduced from the PFT testing carried out by Brookhaven National Laboratory and include the Auxiliary Building West Road inlet (WR), the Turbine Building inlet (TB), Access Control 11 (ACI 1), Access Control 13 (AC13), the Switchgear Rooms (SWGRs), and the Main Steam Isolation Valve Rooms (MSIVs). ACI I and AC13 will be equipped with dampers and radiation monitors, which will isolate this leakage path in case of an accident. The SWGRs are in continual recirculation mode and thus are also isolated from the environment. The MSIV rooms are also isolated from the environment, except for the Main Steam Line Break Accident which occurs in these rooms, due to the thermal buoyancy of the air in these rooms and due to the J-neck exhaust. For conservatism, all of the measured inleakage will be assumed to enter the control room from the most conservative pathway of either the West Road or Turbine Building inlets.

(14) Control room recirculation flow:

• Flowrate: 10000.+/- 1000 cfm (Note that this value will be the result of a new modification.)

• Initiation delay time: 20 minutes (Ref.29 conservatively assumes a 20 minute time delay for a manual start of the Control Room Emergency Ventilation System.)

• Filter efficiencies: 90% for elemental and organic iodine species (Ref.28 and Technical Specification 5.5.11 allow a 95% filter efficiency for a 2" activated carbon bed depth; however, NRC Generic Letter 99-02 (Ref.30) requires plants that test their activated charcoal to the ASTM D3803-1989 standards to use a safety factor of two. This results in a maximum credited efficiency of 90% for accident analyses.)

• Filter efficiencies: 99% for particulate iodine (Per Ref.28, an engineered-safety-feature air filtration system satisfying a filter penetration less than 0.05% at rated flow can be considered to warrant a 99% removal efficiency for particulates in accident dose evaluations.)

(15) The main steam gooseneck (MSG) - to - site boundary, two-hour, atmospheric dispersion coefficient of 1.44E-4 sec/m 3 was calculated via the Gifford wake model extracted from UFSAR 2.3.6, as follows XYQ = 1/[Lz * (nyua. + cA)] = 1.44E-4 sec/m3 where for 1150 m exclusion area boundary distance and 5% frequency ja = average wind speed = I mrsec uy= standard deviation of the distribution in the lateral direction = 92 m (UFSAR Table 2-14) uz= standard deviation of the distribution in the vertical direction = 24 m (UFSAR Table 2-14) c= wake factor A= cross-sectional area of structure from which material is released = 0 m (16) Atmospheric dispersion coefficients from the MSG to low population zone (2 miles)

CA06452 Rev.000 Page 11 of 110 (UFSAR Fig.2.3-3/UFSAR 14.24.3)

Time X/Q (hours) (sec/m 3 )

0-2 3.39E-05 2-24 2.20E-06 24-720 5.40E-07 Note that the 0-2 hour value was adjusted via the Gifford wake model for a point release rather than a containment release.

(17) Atmospheric dispersion coefficients from the Main Steam Gooseneck (MSG) to the Control Room: (Ref.19)

The initial secondary activity together with initial primary activity and failed fuel activity released to the primary that then leaks into the secondary will escape out of the steam generators via the MSG. The main control room inleakage points include the west road inlets, the turbine building, and Access Controls 11 and 13 on the Auxiliary Building roof. Installation of automatic isolation dampers and radiation monitors at Access Controls 11 and 13 on the Auxiliary Building Roof are credited in this work.

Atmospheric Dispersion Coefcidents (seclm3 )

msg1-wr msg2-wr msgl-tb msg2-tb 0-2 hr 1.54E-03 1.48E-03 3.38E-03 3.48E-03 2-8 hr 1.19E-03 1.02E-03 2.56E-03 2.97E-03 8-24hr 5.15E-04 4.11 E-04 9.45E-04 1.21 E-03 1-4 days 3.81 E-04 2.73E-04 7.73E-04 9.22E-04 4-30 days 2.67E-04 1.81 E-04 5.91 E-04 7.41 E-04 The atmospheric dispersion coefficients corresponding to the Unit 2 MSG to the turbine building will be conservatively utilized in this work. Note that neither thermal buoyancy nor vertical effluent velocity are credited in this work.

(18) Masses and Volumes I RCS(cf) 7286.18 Total RCS and PZR volumes normalized to STP Vrcs(cf) 9576 RCS volume per UFSAR T4.1 Vpzr(o 600 PZR volume per UFSAR T4.7 vrcs(cf/lbm) 0.022132 Ref.31 Specific Vol @ 574.5 F and 2250 psia - UFSAR T4.1 F4.9 vpzr(cf/bm) 0.02703 Ref.31 Specific Vol @ 653 F and 2250 psia - UFSAR T4.7 Mrcs(Ibm) 432676.67 RCS mass: Vrcs/vrcs Mpzr(lbm) 22197.56 PZR mass: Vpzr/vpzr Mtot(Ibm-g) 454874.23 206327482 RCS + PZR mass: Mrcs+Mpzr vstp(cfdlbm) 0.016018 _ Ref.31 Specific Vol @ I gmtcc Vtot(cf) 7286.18 _ Mtotvstp 0_ STP 2 Gf)0.04 _ Total SG volume normalized to STP M2sg(lbm-g) 275942.00 125165188 SG mass per Ref.32 Sheet 30 - 102% Full Power sg(cf) 4420.04 MsvM2svstp @ STP 3 (cf) 10000.00 _ Auxiliary Feedwater Volume 4 Environment _ _

5 Control Room 289194 cf Control Room Volume (Ref.19)

(19) The volume of the Main Steam Piping Rooms (309/315) can be estimated from Ref.34. Using the net flood area of 1294.75 ft2, a floor elevation of 27 ft, and a ceiling elevation of 45'-2'=43', a volume of 20716 ft3 can be calculated.

CA06452 Rev. 000 Page 12 of 110 (20) The volume of the turbine building can be determined from Refs.35-37. Per Ref.35, the floor area is approximately 130' x 560' = 72800 ft2. Per Ref.36, the roof elevation is 134' 1.5", while per Ref.37 the floor elevation is 11'7'. Thus the internal height of the turbine building is 134.125' - 11.5833' = 122.54'. The resulting gross volume is 8921033 ft3. Tis value will be reduced by 10% to 8000000 ft3 to account for internal equipment and structures.

(21) Additional RADTRAD Inputs for the failed fuel, primary, and secodary release pathways:

Pathways I _Failed FuelPrimary Secondar _

cfm cfm I rcs-env 200 gpd 0.01857 0 gpd 0 2 env-cr 3500 dm 3500 3500 cfm 3500 3 cr-env 3500dm 3500 3500dm 3500 4 rcs-sg 0 0 0 0 5 sg-env 0 0 4000dm 4000 6 afw-sg 0 0 0 0

CA06452 Rev. 000 Page 13 of 110

7. TECHNICAL ASSUMPTIONS The following technical assumptions were utilized in this work:

(01) The 0.8% rod fuel failure is assumed to occur in the highest powered fuel rods.

(02) No credit is taken for atmospheric cleanup systems except control room filters.

(03) No credit is taken for deposition of the plume on the ground or decay of isotopes in transit to the site boundary.

(04) Buildup of daughter nuclides is taken into account as source term nuclides decay.

(05) All of the secondary Technical Specification activity from the affected and unaffected steam generators is assumed to be released at the start of the MSLB through the MSPR and thus the MSG.

(06) All of the Technical Specification primary-to-secondary leakage occurs in the affected steam generator and thus is totally and immediately released through the MSG into the environment.

(07) Note that per the requirements of Regulatory Guide (RG) 1.183 (Ref.08), the release of fission products from the secondary system should be evaluated with the assumption of a coincident loss of offsite power (LOOP). Thus, the use of condensers can not be credited in this work.

(08) No holdup of the released activity in the SG or MSPR is assumed. Note that this conservatism increases the failed fuel component of the control room dose by a factor of four.

CA06452 Rev.000 Page 14 of 110

8. REFERENCES (01) "Power Levels of Nuclear Power Plants", Regulatory Guide 1.49 Rev.1, 12/73.

(02) CCNPP Core Operating Limits Report for Unit I Cycle 17 Rev.1 (03) CCNPP Core Operating Limits Report for Unit 2 Cycle 16 Rev.0 (04) "Primary and Secondary Isotopic Calculations", CA06422 (05) "Control Room Habitability Source Term Calculations", CA06358.

(06) "Chart of the Nuclides - Nuclides and Isotopes", GE Nuclear Energy, Fifteenth Edition.

(07) "Gas Gap Isotopic Fraction Calculations", CA06421.

(08) "Alternate Radiological Source Terms for Evaluating Design Basis Accidents at Nuclear Power Reactors",

Regulatory Guide 1.183 (09) CA05738, Calvert Cliffs Unit I Cycle 16 Post-Trip Steam Line Break (10) CA05739, Calvert Cliffs Units I and 2 Pre-Trip Steam Line Break Event (11) CA06383, Calvert Cliffs Units I and 2 Pre-Trip Steam Line Break Event (12) CA06382, Calvert Cliffs Unit I Cycle 17 Post-Trip Steam Line Break Event (13) "RADTRAD: A Simplified Model for Radionuclide Transport and Removal and Dose Estimation",

NUREG/CR-6604, SAND98-0272 (14) "RADTRAD: A Simplified Model for Radionuclide Transport and Removal and Dose Estimation",

NUREG/CR-6604, SAND98-0272/1, Supplement 1.

(15) "RADTRAD: A Simplified Model for Radionuclide Transport and Removal and Dose Estimation",

NUREG/CR-6604, Supplement 2 (16) "RADTRAD 3.03 Installation and Verification on PCB386", CA06210 (17) "RADTRAD 3.03 Validation", CA06207 (18) "Calculation of Distance Factors for Power and Test Reactor Sites", TID-14844, 3/23/62.

(19) CA06012: CRHVAC Atmospheric Dispersion Coefficient Calculations (20) Federal Guidance Report (FGR) I1, "Limiting Values of Radionuclide Intake and Air Concentration and Dose Conversion Factors," 1989 (21) Federal Guidance Report (FGR) 12, "External Exposure to Radionuclides in Air, Water, and Soil," 1993, (22) "Fuel Performance Analysis", Westinghouse Calculation CN-WFE-02-45, Rev.0

CA06452 Rev.000 Page 15 of 110 (23) "Control Room HVAC Inleakage Test", ETP-97-064R Rev.0, 11/11/1997 (First Run)

(24) "Control Room HVAC Inleakage Test", ETP-97-064R Rev.0, 11/11/1997 (Third Run)

(25) "Control Room HVAC Inleakage Test", ETP-97-064R Rev.0, 11/11/1997 (Fourth Run)

(26) "Control Room HVAC Inleakage Test", ETP-97-064R Rev.0, 1/18/2000.

(27) "Perfluorocarbon Tracer Gas Testing", ETP-01-035R Rev.0, 5/1/2002 (28) ) Regulatory Guide 1.52 Rev.2: "Design, Testing, and Maintenance Criteria for Post Accident ESF Atmosphere Cleanup System Air Filtration and Absorption Units of LWRs" (29) "Control Room Recirculation Filter Initiation Time Delay", NEU-95-026 (30) NRC Generic Letter 99-02: Laboratory Testing of Nuclear-Grade Activated Charcoal (31) ASME Steam Tables, 5th Edition, United Engineering Center, N.Y., N.Y.

(32) CA05725, WEC-222-781 1-A45: Parameter Listing for RSG Inputs for Calvert Cliffs Units I & 2 (33) NEU-98-027, ES199800165-000, Engineering Evaluation to Determine the Time Required to Cool the RCS to 212TF During a Main Steam Line Break Scenario (34) Calculation M-90-175: Internal Plant Flooding for the Main Steam Piping Areas (35) BGE Drawing 62012SH0001 Rev.5: Turbine Building Partial Roof Plan (36) BGE Drawing 62013SH0001 Rev.3: Turbine Building and Heater Bay - Exterior Elevations East (37) BGE Drawing 61638SH0001 Rev.3: Turbine Building Elevation - Col Line 101

CA06452 Rev.000 Page 16 of 110

9. METHODS OF ANALYSIS (9.1) RADTRAD Computations The current work re-analyzes control room habitability for a MSLB based on the alternate source term methodology of Ref.08 and control room inleakage of 3500 cfm This was accomplished by utilizing the RADTRAD computer code (Refs.13-15).

The RADTRAD computer code calculates TEDE and thyroid doses to personnel at the site boundary, low population zone, and control room per 10 CFR 50.67 resulting from any postulated accident which releases radioactivity within the containment, spent fuel pool, or within any primary or secondary system. RADTRAD models the transport of up to 63 radionuclides from the source region, through a secondary region if any, and then to the environment and to the control room. The code includes the capability to model time-dependent activity release; time-dependent spray/filtration/deposition removal processes, piping/filter/inleakage transfer mechanisms, atmospheric dispersion; and natural decay. RADTRAD is documented and benchmarked in Refs.13-17.

The failed fuel MSLB model is constructed in four parts: gas gap iodine and noble gas releases, gas gap alkali metal releases, TS primary iodine and noble gas activity releases, and TS secondary iodine activity releases. The MSLB occurs at time t=0 releasing the failed fuel gas gap iodine, noble gas, and alkali metal activities immediately and homogeneously into the primary system. The gas gap and TS primary activities are released at a 200 gpd rate into the affected steam generator and then via flashing directly through the MSGs into the environment with no holdup in the SG or MSPR. Note that no auxiliary feedwater is added to the affected steam generator, which is assumed to immediately blow dry. The TS activity from both SGs is assumed to be immediately released to the environment via the affected MSG. No cleanup mechanisms (spray, filtration, plateout) are assumed in the primary or secondary systems. The activity released to the environment is transported to the site boundary and to the control room via appropriate atmospheric dispersion coefficients. While time-dependent control room inleakage can be modeled by RADTRAD, it is a constant in this work. Control room filtration is credited in this work. The control room and site boundary doses are calculated based on appropriate breathing rates and occupancy factors and on FGR 11 and 12 dose conversion factors.

The MSLB model with no failed fuel is isentical to the above TS primary release model except that it assumes TS primary activity adjusted by the appropriate PIS or CIS factor.

(9.2) Gas Gap, Primary, and Secondary Release Activities An EXCEL spreadsheet (Attachment A) 'vas developed to calculate the activity released to the primary and secondary systems post-MSLB. Five sets of isotopic activities were generated:

• Gas gap iodine, noble gas, and alkali metal activities released via fuel failure

• Technical Specification Primary iodine and noble gas activities

• Technical Specification Secondary iodine activities

• Technical Specification Primary iodine and noble gas activities increased by the PIS factor

• Technical Specification Primary iodine and noble gas activities increased by the CIS factor (9.2.a) Gas Gap Release Activities The initial failed fuel isotopic activity in Ci/MWt contained in the gas gaps of all of the assemblies in the core for isotope 'i' is listed in Attachment A Column E and is based on the following algorithm:

AO = ASTi

• RF; where ASTi = Isotopic activity per unit power (Ci/MWT) (Ref.05 and Attachment A Column C)

RF; = Isotopic gas gap release fraction (Ref.07 and Attachment A Column D)

CA06452 Rev.000 Page 17 of 110 The iodine and noble gas isotopic activities were inserted into the nuclear inventory file GAP 14.NIF for use by RADTRAD. The file is listed in Attachment B and consist of the 14 gas-gap noble gas and iodine isotopes. The corresponding iodine and noble gas release fractions in MSLBGAP.RFT are 0.008. The alkali metal isotopic activities are contained in the base deck CRCB63.NIF ilisted in Attachment G. The corresponding alkalai metal release fraction in MSLBGCS.RFT is 0.008*0.24 = 0.00192, where 0.008 is the failed fuel fraction and 0.24 is twice the non-LOCA alkali metal release fraction of Table 3 of RG 1.183. The factor of two is per the results of Ref.7, where all gas gap release fractions were conservatively doubled.

(9.2.b) Primary Specific Activities The initial primary specific activities in utCi/gm consistent with the TS 3.4.15 1.0 pCi/gm limit were extracted from Ref.4 and are listed in column F of Attachment A. These were converted to total primary isotopic source terms in Ci in Attachment A column G via the following algorithm:

Ajo = AST1

• MRCS

• 0.000001 where AST; = Isotopic activity per unit mass (pCi/gm) (Ref.04 and Attachment A Column F)

MRCS = Water mass in RCS (gm)

The primary iodine isotopic source terms were then halved in Attachment A column H to reflect that the TS 3.4.15 limit for primary activity will be reduced from 1.0 pCi/gm to 0.5 pCi/gm.

These isotopic activities were inserted into the nuclear inventory file PRI14.NIF for use by RADTRAD. The file is listed in Attachment C and consist of the 14 primary noble gas and iodine isotopes. The activities are the total primary activities and are not per unit power. Thus a power of one should be designated when employing these files.

(9.2.c) Secondary Specific Activities The initial secondary specific activities in pCi/gm consistent with the TS 3.7.14 0.1 uCi/gm limit were extracted from Ref.4 and are listed in column I of Attachment A. These were converted to total secondary isotopic source terms in Attachment A column J via the following algorithm:

A1o = AST1

• MSG

• 0.000001 where AST1 = Isotopic activity per unit mass (,LCi/gm) (Ref.04)

MSG = Water mass in SG (gm)

These isotopic activities were inserted into the nuclear inventory file SECO5.NIF for use by RADTRAD. The file is listed in Attachment D and consist of the 5 iodine isotopes. The activities are the total secondary activities and are not per unit power. Thus a power of one should be designated when employing these files.

(9.2.d) Primary Specific Activities with a PIS Factor The initial primary specific activities in pCi/gm consistent with the TS 3.4.15 1.0 yCi/gm limit and a PIS factor of 60 were extracted from Ref.4 and are listed in column K of Attachment A. These were converted to total primary isotopic source terms in Attachment A column L via the following algorithm:

AiO = AST1

• MRCS

• 0°00000 where AST1 = PIS isotopic activity per unit mass (piCi/gm) (Ref.04 and Attachment A Column K)

MRCS = Water mass in RCS (gm)

Note that the PIS iodine isotopic source terms were then halved in Attachment A column L to reflect that the TS 3.4.15 limit for primary activity will be reduced from 1.0 pCi/gm to 0.5 pCilgm.

CA06452 Rev. o00 Page 18 of 110 These isotopic activities were inserted into the nuclear inventory file PIS.NIF for use by RADTRAD. The file is listed in Attachment E and consist of the 14 primary noble gas and iodine isotopes. The activities are the total PIS activities and are not per unit power. Thus a power of one should be designated when employing these files.

(9.2.e) Primary Specific Activities with a CIS Factor The initial primary specific activities in ,uCi/gm consistent with the TS 3.4.15 1.0 LCi/gm limit and a CIS factor of 500 were extracted from Ref.4 and are listed in column M of Attachment A. These were converted to total primary isotopic source terms in Attachment A column N via the following algorithm:

Ajo = AST;

• MRcs

• 0.000001 where AST, = CIS isotopic activity per unit mass (pCi/gm) (Ref.04 and Attachment A Column M)

MRCS = Water mass in RCS (gm)

Note that the PIS iodine isotopic source terms were then halved in Attachment A column N to reflect that the TS 3.4.15 limit for primary activity will be reduced from 1.0 pCi/gm to 0.5 pCi/gm. The iodine activities were then increased by a factor of 9/8 to account for a 9 hour1.041667e-4 days <br />0.0025 hours <br />1.488095e-5 weeks <br />3.4245e-6 months <br /> accident, rather than 8.

These isotopic activities were inserted into the nuclear inventory file CIS.NIF for use by RADTRAD. The file is listed in Attachment F and consist of the 14 primary noble gas and iodine isotopes. The activities are the total CIS activities and are not per unit power. Thus a power of one should be designated when employing these files.

(9.3) Flashing Fraction Calculations Per Regulatory Guide 1.183 (Ref.8), upon periods of steam generator dryout, all of the primary-to-secondary leakage is assumed to flash to vapor and be released to the environment with no mitigation.

CA06452 Rev.O000 Page 19 of 110

10. CALCULATIONS The following computational calculations were performned in this calculational package:

Activity Source Failed Fuel Failed Fuel Primary Secondary PIS CIS Iodine/ Alkali Metals Iodine/ Iodine Iodine/ Iodine/

Radionuclide Component Noble Gas Noble Gas Noble Gas Noble Gas Case Input Files mslbffpsf mslbffcs.psf mslbpri.psf mslbsec.psf mslbpis.psf mnslbcis.psf Dose Conversion Factor File fgrl4.inp fgr63.inp fgrl4.inp fgrO5.inp fgrl4.inp fgrl4.inp Release FractiontTiming File mslbgap.rft mslbgcs.rft mslbpri.rft rnslbsec.rft pis.rft cis5OO.rft Nuclear Inventory File gapl4.nif crcb63.nif pril4.nif secO5.nif pis.nif cis500.nif Case Output Files mslbff.oO mslbffcs.oO mslbpri.oO mslbsec.oO rnscbpis.oO

-Msbcis.oO

CA06452 Rev.000 Page 20 of 110

11. DOCUMENTATION OF COMPUTER CODES This work employed the RADTRAD computer code, which was verified, benchmarked, and documented in Refs. 13-17 and which models the transport of halogen and noble gas isotopes from a primary containment to a secondary containment and thence to the environment and control room. The installation of RADTRAD is detailed in Ref.16 and the validation in Ref.17.

The RADTRAD computer code can calculates TEDE and thyroid doses to personnel at the site boundary, low population zone, and control room per the alternate source term methodology 10 CFR 50.67 and Regulatory Guide 1.183 or can calculates whole body and thyroid doses to personnel at the site boundary, low population zone, and control room per the standard source term methodology of TID-14844 (Ref.18) resulting from any postulated accident which releases radioactivity within the containment, spent fuel pool, or within any primary system.

RADTRAD models the transport of radioactivity from up to 63 radioisotopes from the sprayed and unsprayed regions of a primary containment or a SFP area, through the secondary containment if any, and then to the environment and to the control room. The code includes the capability to model time-dependent activity release; containment spray, filtration, and leakage; control room filtration and inleakage; primary and secondary containment purge filters; control room intake filters; atmospheric dispersion; and natural decay. Doses are calculated for individuals residing at the site boundary or low population zone and in the control room.

Some inputs for the RADTRAD computer program were generated via an EXCEL spreadsheet.

CA06452 Rev.000 Page 21 of 110

12. RESULTS UFSAR 14.14 presents the licensing basis evaluation of the MSLB Event. A MSLB Event is defined as the pre-trip guillotine-type rupture of a main steam line outside containment in the Main Steam Piping Room (MSPR). It is assumed that the steam line rupture occurs between the steam generator and the MSIV, allowing blowdown of the affected steam generator to continue. A LOOP with the turbine trip results in the maximum site boundary doses, since the LOOP causes the RCPs to coast down, minimizing core flow, lowering the transient Departure from Nucleate Boiling Ratio (DNBR), and maximizing the number of failed fuel pins.

To maximize control room and offsite doses, the maximum secondary Technical Specification (TS) activity and that fraction of the primary Technical Specification and failed fuel activity which leaks to the secondary from the affected and unaffected steam generators are discharged into the MSPR and out the Main Steam Gooseneck (MSG) on the roof of the auxiliary building. Since the steam generators are designed to withstand RCS operating pressure on the tube side with atmospheric pressure on the shell side, the continued integrity of the RCS barrier is assured.

Thus only the maximum Technical Specification primary-to-secondary leakage is assumed. A partition factor of unity is assumed for all discharged activities.

Previously, power reactor licensees have typically used TID-14844 (Ref.18) as the basis for DBA source terms.

TID-14844 is referenced in 10 CFR 100.11, the power reactor siting regulation, which contains offsite dose limits in terms of whole body and thyroid doses. In December 1999, the NRC issued a new regulation, 10 CFR 50.67, "Accident Source Term," which provided a mechanism for licensed power reactors to replace the traditional accident source term used in their DBA analyses with an Alternate Source Term (AST) methodology. Regulatory guidance for the implementation of these ASTs is provided in RG 1.183 (Ref.08). Section 50.67 of 10 CFR requires a licensee seeking to use AST to apply for a license amendment and requires that the application contain an evaluation of the consequences of affected DBAs. As part of the implementation of the AST, the Total Effective Dose Equivalent (TEDE) acceptance criterion of 10 CFR 50.67 replaces the previous whole body and thyroid dose guidelines of 10 CFR 100.11 and 10 CFR 50, Appendix A, GDC-19 for the DBA accidents.

The current work utilizes the alternate source term methodology of 10 CFR 50.67 and Regulatory Guide 1.183 to calculate offsite and control room doses for a MSLB. A bounding control room inleakage value of 3500 cfm was assumed. Modification of the control room emergency ventilation system to a nominal 10000 cfm flow with a 90%

filtration efficiency for elemental and organic iodine and 99% for particulate iodine was credited. Also credited was installation of automatic isolation dampers and radiation monitors at Access Controls 11 and 13 on the Auxiliary Building Roof. This modification limits activity ingress into the control room from either the West Road Inlet or the Turbine Building, thus limiting the atmospheric dispersion coefficient value. The Technical Specification limit for RCS activity was reduced from 1.0 ,Ci/gm to 0.5 juCi/gm.

Per RG 1.183 (Ref.08), if no or minimal fuel damage is postulated, the activity should be the maximum coolant activity allowed by the technical specifications, assuming two cases of iodine spiking. Thus, three cases are modeled to determine the maximum offsite and control room doses.

• Failed Fuel Case: The dose analysis of UFSAR 14.14 assumes a conservative 1.35% fuel failure rate and 200 gpd primary-to-secondary leakage. The MSLB analyses of record were generated by Combustion Engineering (CE) in Refs. 11-12, resulting in no failed fuel. To preeserve some margin and still meet the 10 CFR 50 App. A GDC 19 limit of 5 rem TEDE in the control room, 0.80% of the fuel pins in the core are assumed to fail.

• Preaccident Iodine Spike (PIS) Case: A reactor transient has occurred prior to the postulated MSLB and has raised the primary coolant iodine concentration to the maximum value permitted by the TSs, which is sixty times the TS 3.4.15 limit of 0.5 ,Ci/gm.

• Concurrent Iodine Spike (CIS) Case: The primary system transient associated with the MSLB causes an iodine spike in the primary system. The increase in primary coolant iodine concentration is estimated using a spiking model that assumes the iodine release rate from the fuel rods to the primary coolant increases to a value 500 times greater than the release rate corresponding to the iodine concentration at the equilibrium value.

CA06452 Rev.000 Page 22 of 110 The exclusion area boundary (EAB), low population zone (LPZ), and control room (CR) doses for the design-basis MSLB assuming 0.8% failed fuel are detailed in the following table.

MSLB 0.8% Failed Fuel Results EAB LPZ CR Rem TEDE Rem TEDE Rem TEDE Failed Fuel Iodine/Noble Gas 1.1659E-01 3.2681 E-02 2.6375E+00 Failed Fuel Alkali Metals 7.0290E-02 2.0046E-02 1.7803E+00 Primary 9.0575E-05 2.5313E-05 1.5238E-03 Secondary 3.1067E-02 4.9595E-03 2.1082E-01 Total 0.2180 0.0577 4.6301 Regulatory Limit 25 (RG 1.183) 25 (RG 1.183) 5 (IOCFR50.67)

The EAB, LPZ, and CR doses for the MSLB assuming no failed fuel but assuming maximum TS activity with a PIS and CIS are detailed in the following table.

MSLB No Failed Fuel Results EA3 LPZ CR

_ Rem TEDE Rem TEDE Rem TEDE PIS Case 3.2635E-03 9.2117E-04 8.2508E-02 Regulatory Limits 25 (RG 1.183) 25 (RG 1.183) 5 (IOCFR50.67)

CIS Case 2.2499E-03 I1.0446E-03 2.0757E-01 Regulatory Limits 2.5 (RG 1.183) 2.5 (RG 1.183) 5 (IOCFR50.67)

Note that all values are below the regulatory limits.

CA06452 Rev. 000 Page 23 of 110

13. CONCLUSIONS The exclusion area boundary (EAB), low population zone (LPZ), and control room (CR) doses for the design-basis MSLB accidents are detailed in the following table.

MSLB Results EAB LPZ CR Rem TEDE Rem TEDE Rem TEDE 0.8% Failed Fuel 0.2180 0.0577 4.6301 PIS Case 3.2635E-03 9.2117E-04 8.2508E-02 Regulatory Limits 25 (RG 1.183) 25 (RG 1.183) 5 (IOCFR50.67)

CIS Case 2.2499E-03 1.0446E-03 2.0757E-01 Regulatory Limits 2.5 (RG 1.183) 2.5 (RG 1.183) 5 (IOCFR50.67)

All MSLB offsite and control room doses are below the regulatory limits.

This work supports the following changes in plant operation:

• This analysis supports a pin power peaking factor of 1.70

• A time to shutdown cooling of 9 hours1.041667e-4 days <br />0.0025 hours <br />1.488095e-5 weeks <br />3.4245e-6 months <br /> was assumed..

• This analysis supports an upper limit of 0.8% failed fuel.

This work relies on the following modifications and new methodologies:

• Modification of the control room emergency ventilation system to a nominal 10000 cfm flow with a 90%

filtration efficiency for elemental and organic iodine and a 99% efficiency for particulate iodine was credited.

• Installation of automatic isolation dampers and radiation monitors at Access Controls 11 and 13 on the Auxiliary Building Roof was credited.

• Alternate Source Term Methodology was employed.

• The Technical Specification limit for RCS activity was reduced from 1.0 pCilgm to 0.5 pCi/gm.

CA06452 Rev. OO0 Page 24 of 110

14. ATTACHMENTS ATTACHMENT A MAIN STEAM LINE BREAK RELEASE ACTIVITIES Calculation of Main Steam Une Break Release Activities l Halflife lambda Core Gas Gap Gas Gap TTISource Fractions Source r sec 1/sec Cl/MWT CIIMWr A B C D E Kr-85 3.3830E+08 2.0489E-09 3.7180E+02 0.20 7.4360E+01 Kr-85m 1.6128E+04 4.2978E-05 7.9679E+03 0.10 7.9679E+02 Kr-87 4.5780E+03 1.5141 E-04 1.6208E+04 0.10 1.6208E+03 Kr-88 1.0224E+04 6.7796E-05 2.2658E+04 0.10 2.2658E+03 1-131 6.9466E+05 9.9783E-07 2.7562E+04 0.16 4.4099E+03 1-132 8.2800E+03 8.3713E205 3.9464E+04 0.10 3.9464E+03 1-133 7.4880E+04 9.2568E-06 5.5715E+04 0.10 5.5715E+03 1-134 3.1560E+03 2.1963E-04 6.2858E+04 0.10 6.2858E+03 1-135 2.3796E+04 2.91292-05 5.2964E+04 0.10 5.2964E+03 Xe-133 4.5317E+05 1.5296E-06 5.5707E+04 0.10 5.5707E+03 Xe-135 3.2724E+04 2.1182E-05 1.7708E+04 0.10 1.7708E+03 Xe133m 1.8922E+05 3.6632E-06 1.7354E+03 0.10 1.7354E+02 Xe135m 9.1800E+02 7.5506E-04 1.1635E+04 0.10 1.1635E+03 Xe138 8.4600E+02 8.1932E-04 4.9330E+04 0.10 4.9330E+03 Rb-86 1.6122E+06 4.2994E-07 5.9034E+01 0.24 1.4168E+01 Cs-134 6.5072E+07 1.0652E-08 7.1917E+03 0.24 1.7260E+03 Cs-136 1.1318E+06 6.1241 E-07 1.7111 E+03 0.24 4.1066E+02 Cs-137 9.4673E+08 7.3215E-10 4;7857E+03 0.24 1.1486E+03 1 _ICi/g I tiCii/g 0.5 pCilg 0.1 ACi/g 0.1 ,zCi/g Primary Primary Primary Secondary Secondary Source Source Source Source Source microCi/g Ci Ci microCi/g Ci F G H IJ Kr-85 3.8761E+01 7.9975E+03 7.9975E+03 Kr-85m 2.0344E+00 4.1975E+02 4.1975E+02 Kr-87 1.1747E+00 2.4238E+02 2.4238E+02 Kr-88 3.6579E+00 7.5473E+02 7.5473E+02 1-131 7.7893E-01 1.6071E+02 8.0357E+01 8.9260E-02 1.1172E+01 1-132 2.5868E-01 5.3372E+01 2.6686E+01 2.2758E-03 2.8485E-01 1-133 1.0972E+00 2.2638E+02 1.1319E+02 5.7417E-02 7.1866E+00 1-134 1.4798E-01 3.0532E+01 1.5266E+01 5.2168E-04 6.5297E-02 1-135 6.0207E-01 1.2422E+02 6.2112E+01 1.3584E-02 1.7003E+00 Xe-I 33 4.0021 E+02 8.2574E+04 8.2574E+04 Xe-i 35 9.5607E+00 1.9726E+03 1.9726E+03

CA06452 Rev.000 Page 25 of 110 Xe133m 5.7016E+00 1.1764E+03 I .1764E+03 Xe135m 1.2511E+00 2.5814E+02 2.5814E+02 Xel38 6.6019E-01 1.3622E+02 1.3622E+02

.I Ci/g 0.5 tLCilg 0.5 uCii/g 60 rCilg 30 gCiI/g 500 SF 500 SF 500 SF PIS PIS 8 Hr CIS 8 Hr CIS 9 Hr CIS Primary Primary Primary Primary Primary Source Source Source Source Source miroCig Cl Ci Ci Ci K L M N 0 Kr-85 3.8761 E+01 7.9975E+03 7.9975E+03 7.9975E+03 7.9975E+03 Kr-85m 2.0344E+00 4.1975E+02 4.1975E+02 4.1975E+02 4.1975E+02 Kr-87 1.1747E+00 2A238E+02 2.4238E+02 2.4238E+02 2.4238E+02 Kr-88 3.6579E+00 7.5473E+02 7.5473E+02 7.5473E+02 7.5473E+02 1-131 4.6736E+01 4.8214E+03 4.4459E+04 2.2229E+04 2.5008E+04 1-132 1.5521E+01 1.6012E+03 7.8899E+04 3.9449E+04 4.4381 E+04 1-133 6.5831E+01 6.7914E+03 8.9540E+04 4.4770E+04 5.0366E+04 1-134 8.8786E+00 9.1595E+02 1.0457E+05 5.2284E+04 5.8819E+04 1-135 3.6124E+01 3.7267E+03 8.4998E+04 4.2499E+04 4.7811 E+04 Xe-133 4.0021 E+02 8.2574E+04 8.2574E+04. 8.2574E+04 8.2574E+04 Xe-135 9.5607E+00 1.9726E+03 1.9726E+03 1.9726E+03 1.9726E+03 Xe133m 5.7016E+00 1.1764E+03 1.1764E+03 1.1764E+03 1.1764E+03 Xel35m 1.2511 E+00 2.5814E+02 2.5814E+02 2.5814E+02 2.5814E+02 Xe138 6.6019E-01 1.3622E+02 1.3622E+02 1.3622E+02 1.3622E+02 A Half-lives: Chart of the Nuclides Fifteenth Edition' B Decay constants: Ln(2yA(i)

C Core source In CUMWt: CA06358 D Gas Gap Fractions: CA06421 E Gas Gap Source In CU/MWt G(i)=E(i)*F(i)

F Primary Source In microCilgm: CA06422 G Primary Source In Ci for 1.0 microCigm total: CA06422 H Primary Source In Ci for 0.5 microCigm total: CA06422 I Secondary Source In microCVgm: CA06422 J Secondary Source in Cl for 0.1 microCi/gm total: CA06422 K PIS Source In microCigm for 60.0 microCi/gm total: CA06422 L PIS Source In Ci for 30.0 microCi/gm total M CIS Source in Ci for 1.0 microCVgm total&500 Spiking Factor: CA06422 N 8 Hr CIS Source in Ci for 0.5 microCi/gm total&500 Spiking Factor 0 9 Hr CIS Source In Ci for 0.5 microCi/gm total&500 Spiking Factor

CA06452 Rev.000 Page 26 of 110 ATTACHMENT B NUCLEAR INVENTORY FILE GAP 14.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 MWth PWR Core Inventory Power Level:

0.1000E+01 Nuclides:

14 Nuclide 001:

Kr-85 1

0.3382974720E+09 0.8500E+02 7.4360E+01 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 002:

Kr-85m 1

0.1612800000E+05 0.8500E+02 7.9679E+02 Kr-85 0.2100E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

Kr-87 1

0.4578000000E+04 0.8700E+02 1.6208E+03 Rb-87 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 004:

Kr-88 1

0.1022400000E+05 0.8800E+02 2.2658E+03 Rb-88 0.lOOOE+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 005:

1-131 2

0.6946560000E+06 0.1310E+03 4.4099E+03 Xe-131m 0.l1OOE-01 none O.OOOOE+00

CA06452 Rev.000 Page 27 of 110 none O.OOOOE+00 Nuclide 006:

1-132 2

0.8280000000E+04 0.1320E+03 3.9464E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 007:

1-133 2

0.7488000000E+05 0.1330E+03 5.5715E+03 Xe-133m 0.2900E-01 Xe-133 0.9700E+00 none O.OOOOE+00 Nuclide 008:

1-134 2

0.3156000000E+04 0.1340E+03 6.2858E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 009:

1-135 2

0.2379600000E+05 0.1350E+03 5.2964E+03 Xe-135m 0.1500E+00 Xe-135 0.8500E+00 none O.OOOOE+00 Nuclide 010:

Xe-133 1

0.4531680000E+06 0.1330E+03 5.5707E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 011:

Xe-135 1

0.3272400000E+05 0.1350E+03 1.7708E+03 Cs-135 0.1000E+01 none O.OOOOE+00

- ^

CA06452 Rev.000 Page 28 of 110 none O.OOOOE+00 Nuclide 012:

Xe-133m 1

0.1892200000E+06 0.1330E+03 1.7354E+02 Xe-133 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 013:

Xe-135m 1

0.9180000000E+03 0.1350E+03 1.1635E+03 Xe-135 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 014:

Xe-138 1

0.8460000000E+03 0.1380E+03 4.9330E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 End of Nuclear Inventory File

CA06452 Rev.000 Page 29 of 110 ATTACHMENT C NUCLEAR INVENTORY FILE PRI14.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 MWth PWR Core Inventory Power Level:

0.1000E+01 Nuclides:

14 Nuclide 001:

Kr-85 1

0.3382974720E+09 0.8500E+02 7.9975E+03 none O.OOOOE+00 none O.OOOOE+00

,none O.OOOOE+0O Nuclide 002:

Kr-85m 1

0.1612800000E+05 0.8500E+02 4.1975E+02 Kr-85 0.2100E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

Kr-87 1

0.4578000000E+04 0.8700E+02 2.4238E+02 Rb-87 0.lOOOE+Ol none O.OOOOE+0O none O.OOOOE+O0 Nuclide 004:

Kr-88 1

0.1022400000E+05 0.8800E+02 7.5473E+02 Rb-88 0.lOOOE+0l none O.OOOOE+0O none O.OOOOE+00 Nuclide 005:

I-131 2

0.6946560000E+06 0.1310E+03 8.0357E+01 Xe-131m 0.1lOOE-01 none O.OOOOE+O0

CA06452 Rev.000 Page 30 of 110 none O.OOOOE+00 Nuclide 006:

1-132 2

0.8280000000E+04 0.1320E+03 2.6686E+01 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 007:

I-133 2

0.7488000000E+05 0.1330E+03 1.1319E+02 Xe-133m 0.2900E-01 Xe-133 0.9700E+00 none O.OOOOE+00 Nuclide 008:

I-134 2

0.3156000000E+04 0.1340E+03 1.5266E+01 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 009:

1-135 2

0.2379600000E+05 0.1350E+03 6.2112E+01 Xe-135m 0.1500E+00 Xe-135 0.8500E+00 none O.OOOOE+00 Nuclide 010:

Xe-133 1

0.4531680000E+06 0.1330E+03 8.2574E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 011:

Xe-135 1

0.3272400000E+05 0.1350E+03

1. 9726E+03 Cs-135 0.1000E+01 none O.OOOOE+00

CA06452 Rev. 000 Page 31 of 110 none O.OOOOE+00 Nuclide 012:

Xe-133m 1

0.1892200000E+06 o.1330E+03 1.1764E+03 Xe-133 0.1000E+01 none O.OOOOE+O0 none O.OOOOE+00 Nuclide 013:

Xe-135m 1

0.9180000000E+03 0.1350E+03 2.5814E+02 Xe-135 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 014:

Xe-138 1

0.8460000000E+03 0.1380E+03 1.3622E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 End of Nuclear Inventory File

CA06452 Rev. 000 Page 32 of 110 ATTACHMENT D NUCLEAR INVENTORY FILE SEC05.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 MWth PWR Core Inventory Power Level:

0.1000E+01 Nuclides:

05 Nuclide 001:

I-131 2

0.6946560000E+06 0.1310E+03 1.1172E+01 Xe-131m 0.1100E-01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 002:

I-132 2

0.8280000000E+04 0.1320E+03 2.8485E-01 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

I-133 2

0.7488000000E+05 0.1330E+03 7.1866E+00 Xe-133m 0.2900E-01 Xe-133 0.9700E+00 none O.OOOOE+00 Nuclide 004:

I-134 2

0.3156000000E+04 0.1340E+03 6.5297E-02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 005:

I-135 2

0.2379600000E+05 0.1350E+03 1.7003E+00 Xe-135m 0.1500E+00 Xe-135 0.8500E+00

CA06452 Rev.000 Page 33 of 110 none O.OOOOE+OO End of Nuclear Inventory File

CA06452 Rev.000 Page 34 of 110 ATTACHMENT E NUCLEAR INVENTORY FILE PIS.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 MWth PWR Core Inventory Power Level:

0.1000E+0l Nuclides:

14 Nuclide 001:

Kr-85 1

0.3382974720E+09 0.8500E+02 7.9975E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 002:

Kr-85m 1

0.1612800000E+05 0.8500E+02 4.1975E+02 Kr-85 0.2100E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

Kr-87 1

0.4578000000E+04 0.8700E+02 2.4238E+02 Rb-87 0.lOOOE+0l none O.OOOOE+00 none O.OOOOE+00 Nuclide 004:

Kr-88 1

0.1022400000E+05 0.8800E+02 7.5473E+02 Rb-88 0.lOOOE+0l none O.OOOOE+00 none O.OOOOE+00 Nuclide 005:

1-131 2

0.6946560000E+06 0.1310E+03 4.8214E+03 Xe-131m 0.11OOE-01 none O.OOOOE+00

CA06452 Rev.000 Page 35 of 110 none O.OOOOE+00 Nuclide 006:

X-132 2

0.8280000000E+04 0.1320E+03 1.6012E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 007:

I-133 2

0.7488000000E+05 0.1330E+03 6.7914E+03 Xe-133m 0.2900E-01 Xe-133 0.9700E+00 none O.OOOOE+00 Nuclide 008:

1-134 2

0.3156000000E+04 0.1340E+03 9.1595E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 009:

I-135 2

0.2379600000E+05 0.1350E+03 3.7267E+03 Xe-135m 0.1500E+00 Xe-135 0.8500E+00 none O.OOOOE+00 Nuclide 010:

Xe-133 1

0.4531680000E+06 0.1330E+03 8.2574E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 011:

Xe-135 1

0.3272400000E+05 0.1350E+03 1.9726E+03 Cs-135 0.1000E+01 none O.OOOOE+00

CA06452 Rev.000 Page 36 of 110 none O.OOOOE+00 Nuclide 012:

Xe-133m 1

0.1892200000E+06 0.1330E+03 1.1764E+03 Xe-133 O.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 013:

Xe-135m 1

0.9180000000E+03 0.1350E+03 2.5814E+02 Xe-135 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 014:

Xe-138 1

0.8460000000E+03 0.1380E+03 1.3622E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 End of Nuclear Inventory File

CA06452 Rev.000 Page 37 of 110 ATTACHMENT F NUCLEAR INVENTORY FILE CIS500.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 MWth PWR Core Inventory Power Level:

0.1000E+01 Nuclides:

14 Nuclide 001:

Kr-85 1

0.3382974720E+09 0.8500E+02 7.9975E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 002:

Kr-85m 1

0.1612800000E+05 0.8500E+02 4.1975E+02 Kr-85 0.2100E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

Kr-87 1

0.4578000000E+04 0.8700E+02 2.4238E+02 Rb-87 0.lOOOE+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 004:

Kr-88 1

0.1022400000E+05 0.8800E+02 7.5473E+02 Rb-88 0.lOOOE+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 005:

I-131 2

0.6946560000E+06 0.1310E+03 2.5008E+04 Xe-131m 0.l1OOE-01 none O.OOOOE+00

CA06452 Rev. 000 Page 38 of 110 none O.OOOOE+Oo Nuclide 006:

1-132 2

0.8280000000E+04 0.1320E+03 4.4381E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 007:

1-133 2

0.7488000000E+05 0.1330E+03 5.0366E+04 Xe-133m 0.2900E-01 Xe-133 0.9700E+00 none O.OOOOE+00 Nuclide 008:

I-134 2

0.3156000000E+04 0.1340E+03 5.8819E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 009:

I-135 2

0.2379600000E+05 0.1350E+03 4.7811E+04 Xe-135m 0.1500E+00 Xe-135 0.8500E+00 none O.OOOOE+00 Nuclide 010:

Xe-133 1

0.4531680000E+06 0.1330E+03 8.2574E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 011:

Xe-135 1

0.3272400000E+05 0.1350E+03 1.9726E+03 Cs-135 0.1000E+01 none O.OOOOE+00

CA06452 Rev.000 Page 39 of 110 none O.OOOOE+00 Nuclide 012:

Xe-133m 1

0.1892200000E+06 0.1330E+03 1.1764E+03 Xe-133 0.1000E+01 none O.OOOOE+00 none O.OOOOE+0O Nuclide 013:

Xe-135m 1

0.9180000000E+03 0.1350E+03 2.5814E+02 Xe-135 0.lOOOE+0l none O.OOOOE+00 none O.OOOOE+00 Nuclide 014:

Xe-138 1

0.8460000000E+03 0.1380E+03 1.3622E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 End of Nuclear Inventory File

- w CA06452 Rev.000 Page 40 of 110 ATTACHMENT G NUCLEAR INVENTORY FILE CRCB63.NIF Nuclide Inventory Name:

Normalized MACCS Sample 3412 Mwth PWR Core Inventory Power Level:

O.1000E+01 Nuclides:

63 Nuclide 001:

Co-58 7

0.6117120000E+07 0.5800E+02 8.0012E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 002:

Co-60 7

0.1663401096E+09 0.6000E+02 9.8625E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 003:

Kr-85 1

0.3382974720E+09 0.8500E+02 3.7180E+02 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 004:

Kr-85m 1

0.1612800000E+05 0.8500E+02 7.9679E+03 Kr-85 0.2100E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 005:

Kr-87 1

0.4578000000E+04 0.8700E+02 1.6208E+04 Rb-87 0.lOOOE+01 none O.OOOOE+00

CA06452 Rev.000 Page 41 of 110 none O.OOOOE+Oo Nuclide 006:

Kr-88 1

0.1022400000E+05 0.8800E+02 2.2658E+04 Rb-88 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 007:

Rb-86 3

0.1612224000E+07 0.8600E+02 5.9034E+01 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 008:

Sr-89 5

0.4363200000E+07 0.8900E+02 3.3293E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 009:

Sr-90 S

0.9189573120E+09 0.9000E+02 3.1769E+03 Y-90 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 010:

Sr-91 5

0.3420000000E+05 0.9100E+02 3.8931E+04 Y-91m 0.5800E+00 Y-91 0.4200E+00 none O.OOOOE+00 Nuclide 011:

Sr-92 5

0.9756000000E+04 0.9200E+02 4.0190E+04 Y-92 0.1000E+01 none O.OOOOE+00

CA06452 Rev. 000 Page 42 of 110 none O.OOOOE+00 Nuclide 012:

Y-90 9

0.2304000000E+06 0.9000E+02 3.4567E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 013:

Y-91 9

0.5055264000E+07 0.9100E+02 4.2527E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 014:

Y-92 9

0.1274400000E+05 0.9200E+02 4.0519E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 015:

Y-93 9

0.3636000000E+05 0.9300E+02 2.9622E+04 Zr-93 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 016:

Zr-95 9

0.5527872000E+07 0.9500E+02 5.8246E+04 Nb-95m 0.7000E-02 Nb-95 0.9900E+00 none O.OOOOE+00 Nuclide 017:

Zr-97 9

0.6084000000E+05 0.9700E+02 4.9425E+04 Nb-97m 0.9500E+00 Nb-97 0.5300E-01

CA06452 Rev.000 Page 43 of 110 none O.OOOOE+00 Nuclide 018:

Nb-95 9

0.3036960000E+07 0.9500E+02 6.0839E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 019:

Mo-99 7

0.2376000000E+06 o.9900E+02 5.0834E+04 Tc-99m 0.8800E+00 Tc-99 0.1200E+00 none O.OOOOE+00 Nuclide 020:

Tc-99m 7

0.2167200000E+05 0.9900E+02 4.5424E+04 Tc-99 0.1000E+01 none 0.0000E+00 none O.OOOOE+00 Nuclide 021:

Ru-103 7

0.3393792000E+07 0.1030E+03 4.8774E+04 Rh-103m 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 022:

Ru-105 7

0.1598400000E+05 0.1O50E+03 3.1455E+04 Rh-105 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 023:

Ru-106 7

0.3181248000E+08 0.1060E+03 1.9695E+04 Rh-106 0.1000E+01 none O.OOOOE+00

CA06452 Rev.000 Page 44 of 110 none O.OOOOE+00 Nuclide 024:

Rh-105 7

0.1272960000E+06 0.1050E+03 2.8507E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 025:

Sb-127 4

0.3326400000E+06 0.1270E+03 2.4299E+03 Te-127m 0.1800E+00 Te-127 0.8200E+00 none O.OOOOE+00 Nuclide 026:

Sb-129 4

0.1555200000E+05 0.1290E+03 8.7888E+03 Te-129m 0.2200E+00 Te-129 0.7700E+00 none O.OOOOE+00 Nuclide 027:

Te-127 4

0.3366000000E+05 0.1270E+03 2.4664E+03 none 0.OOOOE+00 none O.OOOOE+00 none 0.OOOOE+00 Nuclide 028:

Te-127m 4

0.9417600000E+07 0.1270E+03 4.6272E+02 Te-127 0.9800E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 029:

Te-129 4

0.4176000000E+04 0.1290E+03 8.4012E+03 I-129 0.1000E+01 none O.OOOOE+00

CA06452 Rev. 000 Page 45 of 110 none O.OOOOE+00 Nuclide 030:

Te-129m 4

0.2903040000E+07 0.1290E+03 1.8872E+03 Te-129 0.6500E+00 1-129 0.3500E+00 none O.OOOOE+00 Nuclide 031:

Te-131m 4

0.1080000000E+06 0.1310E+03 5.0686E+03 Te-131 0.2200E+00 1-131 0.7800E+00 none O.OOOOE+00 Nuclide 032:

Te-132 4

0.2815200000E+06 0.1320E+03 3.8391E+04 I-132 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 033:

1-131 2

0.6946560000E+06 0.1310E+03 2.7562E+04 Xe-131m 0.11OOE-01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 034:

I-132 2

0.8280000000E+04 0.1320E+03 3.9464E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 035:

I-133 2

0.7488000000E+05 0.1330E+03 5.5715E+04 Xe-133m 0.2900E-01 Xe-133 0.9700E+00

CA06452 Rev.000 Page 46 of 110 none O.OOOOE+00 Nuclide 036:

1-134 2

0.3156000000E+04 0.1340E+03 6.2858E+04 none 0.OOOOE+00 none O.OOOOE+00 none

• O.OOOOE+00 Nuclide 037:

I-135 2

0.2379600000E+OS 0.1350E+03 5.2964E+04 Xe-135m 0.1500E+00 Xe-135 0.8500E+00 none O.OOOOE+00 Nuclide 038:

Xe-133 1

0.4531680000E+06 0.1330E+03 5.5707E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 039:

Xe-135 1

0.3272400000E+05 0.1350E+03 1.7708E+04 Cs-135 0.l000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 040:

Cs-134 3

0.6507177120E+08 0.1340E+03 7.1917E+03 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 041:

Cs-136 3

0.1131840000E+07 0.1360E+03 1.7111E+03 none O.OOOOE+00 none O.OOOOE+00

CA06452 Rev.000 Page 47 of 110 none O.OOOOE+00 Nuclide 042:

Cs-137 3

0.9467280000E+09 0.1370E+03 4.7857E+03 Ba-137m 0.9500E+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 043:

Ba-139 6

0.4962000000E+04 0.1390E+03 5.1001E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 044:

Ba-140 6

0.1100736000E+07 0.1400E+03 5.2928E+04 La-140 0.1000E+01 none 0.0000E+00 none O.OOOOE+00 Nuclide 045:

La-140 9

0.1449792000E+06 0.1400E+03 5.4255E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 046:

La-141 9

0.1414800000E+05 0.1410E+03 4.6433E+04 Ce-141 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 047:

La-142 9

0.5550000000E+04 0.1420E+03 4.4898E+04 none O.OOOOE+00 none O.OOOOE+00

CA06452 Rev.000 Page 48 of 210 none O.OOOOE+00 Nuclide 048:

Ce-141 8

0.2808086400E+07 0.1410E+03 5.1883E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 049:

Ce-143 8

0.1188000000E+06 0.1430E+03 4.4327E+04 Pr-143 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 050:

Ce-144 8

0.2456352000E+08 0.1440E+03 4.2317E+04 Pr-144m 0.1800E-01 Pr-144 0.9800E+00 none O.OOOOE+00 Nuclide 051:

Pr-143 9

0.1171584000E+07 0.1430E+03 4.6904E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 Nuclide 052:

Nd-147 9

0.9486720000E+06 0.1470E+03 1.9151E+04 Pm-147 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 053:

Np-239 8

0.2034720000E+06 0.2390E+03 5.5833E+05 Pu-239 0.1000E+01 none O.OOOOE+00

CA06452 Rev.000 Page 49 of 110 none O.OOOOE+00 Nuclide 054:

Pu-238 8

0.2768863824E+10 0.2380E+03 1.7259E+02 U-234 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 055:

Pu-239 8

0.7594336440E+12 0.2390E+03 1.1469E+01 U-235 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 056:

Pu-240 8

0.2062920312E+12 0.2400E+03 2.0026E+01 U-236 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 057:

Pu-241 8

0.4544294400E+09 0.2410E+03 4.9593E+03 U-237 0.2400E-04 Am-241 0.1000E+01 none O.OOOOE+00 Nuclide 058:

Am-241 9

0.1363919472E+ll 0.2410E+03 7.3183E+00 Np-237 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 059:

Cm-242 9

0.1406592000E+08 0.2420E+03 2.0078E+03 Pu-238 0.1000E+01 none O.OOOOE+00

CA06452 Rev.000 Page 50 of 110 none O.OOOOE+00 Nuclide 060:

Cm-244 9

0.571508136E+9 0.2440E+03 3.1650E+02 Pu-240 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 061:

Xe-133m 1

1.8922000000E+05 0.1330E+03 1.7354E+03 Xe-133 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 062:

Xe-135m 1

9.1800000000E+02 0.1350E+03 1.1635E+04 Xe-135 0.1000E+01 none O.OOOOE+00 none O.OOOOE+00 Nuclide 063:

Xe-138 1

8.4600000000E+02 0.1380E+03 4.9330E+04 none O.OOOOE+00 none O.OOOOE+00 none O.OOOOE+00 End of Nuclear Inventory File

CA06452 Rev.000 Page 51 of 110 ATTACHMENT H RELEASE FRACTION AND TIMING FILE MSLBGAP.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident O.OOOlE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Noble Gases:

0.0080E+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Iodine:

0.0080E+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cesium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Tellurium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Strontium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Barium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Ruthenium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cerium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Lanthanum:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Non-Radioactive Aerosols (kg):

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 End of Release File

CA06452 Rev. 000 Page 52 of 110 ATTACHMENT I RELEASE FRACTION AND TIMING FILE MSLBPRI.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident O.OOOlE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Noble Gases:

l.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+00 Iodine:

1.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Cesium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Tellurium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Strontium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Barium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+0O Ruthenium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Cerium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Lanthanum:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+0O Non-Radioactive Aerosols (kg):

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO End of Release File

CA06452 Rev.000 Page 53 of 110 ATTACHMENT J RELEASE FRACTION AND TIMING FILE MSLBSEC.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident O.OOOlE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Noble Gases:

O.OOOOE+00O O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Iodine:

l.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cesium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Tellurium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Strontium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Barium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Ruthenium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cerium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Lanthanum:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Non-Radioactive Aerosols (kg):

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 End of Release File

CA06452 Rev.000 Page 54 of 110 ATTACHMENT K RELEASE FRACTION AND TIMING FILE PIS.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident O.OOOlE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Noble Gases:

1.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.ODOOE+OO Iodine:

l.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Cesium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Tellurium:

O.OOOOE+00 O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Strontium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Barium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Ruthenium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Cerium:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Lanthanum:

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO Non-Radioactive Aerosols (kg):

O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO O.OOOOE+OO End of Release File

CA06452 Rev.000 Page 55 of 210 ATTACHMENT L RELEASE FRACTION AND TIMING FILE CIS500.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident 0.0001E+00 9.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Noble Gases:

l.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Iodine:

O.OOOOE+00 l.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cesium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Tellurium:

O.OOOOE+00O O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Strontium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Barium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Ruthenium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cerium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Lanthanum:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Non-Radioactive Aerosols (kg):

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 End of Release File

CA06452 Rev.000 Page 56 of 110 ATTACHMENT M RELEASE FRACT1ON AND TIMING FILE MSLBGCS.RFT Release Fraction and Timing Name:

PWR, RG 1.183, Table 2 Section 3.2 Duration (h): Design Basis Accident 0.OOOlE+00 0.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Noble Gases:

0.0000+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Iodine:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cesium:

1.920E-03 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Tellurium:

0.OOOOE+00 O.OOOOE+00 0.OOOOE+00 O.OOOOE+00 Strontium:

0.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Barium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Ruthenium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Cerium:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Lanthanum:

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 Non-Radioactive Aerosols (kg):

O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 End of Release File

CA06452 Rev.000 Page 57 of 110 ATTACHMENT N CONVERSION FACTORS FILE FGR14.1NP FGRDCF 10/24/95 03:24:50 beta-test version 1.10, minor FORTRAN fixes 5/4/95 Implicit daughter halflives (m) less than 90 and less than 0.100 of parent 9 ORGANS DEFINED IN THIS FILE:

GONADS BREAST LUNGS RED MARR BONE SUR THYROID REMAINDER EFFECTIVE SKIN(FGR) 14 NUCLIDES DEFINED IN THIS FILE:

Kr-85 Kr-85m Kr-87 Kr-88 I-131 D I-132 D 1-133 D I-134 D I-135 D Including:Xe-135m Xe-133 Xe-135 Xe-133m Xe-135m Xe-138 CLOUDSHINE GROUND GROUND GROUND INHALED INHALED INGESTION SHINE 8HR SHINE 7DAY SHINE RATE ACUTE CHRONIC Kr-85 GONADS 1.170E-16 8.121E-14 1.704E-12 2.820E-18-1.OOOE+00 0.000E+00 0.000E+00 BREAST 1.340E-16 7.891E-14 1.656E-12 2.740E-18-1.000E+00 O.O00E+00 O.OOOE+00 LUNGS 1.140E-16 7.056E-14 1.481E-12 2.450E-18-1.OOOE+00 0.000E+00 0.000E+00 RED MARR 1.090E-16 6.998E-14 1.469E-12 2.430E-18-1.000E+00 O.000E+00 0.OOOE+00 BONE SUR 2.200E-16 1.287E-13 2.702E-12 4.470E-18-1.000E+00 O.OOOE+00 0.000E+00 THYROID 1.180E-16 7.459E-14 1.565E-12 2.590E-18-1.OOOE+00 0.OOOE+00 0.OOOE+00 REMAINDER 1.090E-16 6.941E-14 1.457E-12 2.410E-18-1.000E+00 0.000E+00 0.OOOE+00 EFFECTIVE 1.190E-16 7.603E-14 1.596E-12 2.640E-18-1.000E+00 0.000E+00 0.000E+00 SKIN(FGR) 1.320E-14 2.304E-11 4 .835E-10 8.000E-16-1.000E+00 0.000E+00 0.000E+00 Kr-85m GONADS 7.310E-15 2.594E-12 3.653E-12 1.570E-16-1.OO0E+00 0.000E+00 0.000E+00 BREAST 8.410E-15 2.527E-12 3.560E-12 1.530E-16-1.000E+00 0.OOOE+00 0.OOOE+00 LUNGS 7.040E-15 2.379E-12 3.351E-12 1.440E-16-1.000E+00 0.000E+00 0.000E+00 RED MARR 6.430E-15 2.346E-12 3.304E-12 1.420E-16-1.OOOE+00 O.OOOE+00 0.000E+00 BONE SUR 1.880E-14 5.286E-12 7.446E-12 3.200E-16-1.000E+00 0.OOOE+00 0.OOOE+00 THYROID 7.330E-15 2.395E-12 3.374E-12 1.450E-16-1.000E+00 0.000E+00 0.000E+00 REMAINDER 6.640E-15 2.313E-12 3.257E-12 1.400E-16-1.OOOE+00 0.000E+00 0.000E+00 EFFECTIVE 7.480E-15 2.511E-12 3.537E-12 1.520E-16-1.000E+00 0.000E+00 0.000E+00 SKIN(FGR) 2.240E-14 2.247E-11 3.164E-11 1.360E-15-1.000E+00 O.OOOE+00 O.000E+00 Kr-87

CA06452 Rev.000 Page 58 of 110 GONADS 4.OOOE-14 4.962E-12 5.026E-12 7.610E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 4.SOOE-14 4.740E-12 4.802E-12 7.270E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 4.040E-14 4.603E-12 4.663E-12 7.060E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 4.OOOE-14 4.708E-12 4.769E-12 7.220E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 6.020E-14 6.514E-12 6.598E-12 9.990E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 4.130E-14 4.473E-12 4.531E-12 6.860E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 3.910E-14 4.590E-12 4.650E-12 7.040E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 4.120E-14 4.773E-12 4.835E-12 7.320E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.370E-13 8.802E-11 8.916E-11 1.350E-14-1.OOOE+OO O.OOOE+OO O.OOOE+OO Kr-88 GONADS 9.900E-14 2.278E-11 2.655E-11 1.800E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.110E-13 2.177E-11 2.537E-11 1.720E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.OlOE-13 2.139E-11 2.493E-11 1.690E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.OOOE-13 2.190E-11 2.552E-11 1.730E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 1.390E-13 2.886E-11 3.363E-11 2.280E-15-l.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.030E-13 2.012E-11 2.345E-11 1.590E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 9.790E-14 2.139E-11 2.493E-11 1.690E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.020E-13 2.202E-11 2.567E-11 1.740E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.350E-13 5.607E-11 6.534E-11 4.430E-15-l.OOOE+OO 0.OOOE+00 O.OOOE+00 I-131 GONADS 1.780E-14 l.119E-11 1.789E-10 3.940E-16-l.OOOE+00 2.530E-11 4.070E-11 BREAST 2.040E-14 1.082E-11 1.730E-10 3.810E-16-l.OOOE+00 7.880E-11 1.210E-10 LUNGS 1.760E-14 1.016E-11 1.626E-10 3.580E-16-l.OOOE+00 6.570E-10 1.020E-10 RED MARR 1.680E-14 1.022E-11 1.635E-10 3.600E-16-1.OOOE+00 6.260E-11 9.440E-ll BONE SUR 3.450E-14 1.675E-11 2.679E-10 5.900E-16-1.OOOE+00 5.730E-11 8.720E-ll THYROID 1.810E-14 1.053E-11 1.68SE-10 3.710E-16-1.OOOE+00 2.920E-07 4.760E-07 REMAINDER 1.670E-14 9.908E-12 1.585E-10 3.490E-16-l.OOOE+00 8.030E-11 1.570E-10 EFFECTIVE 1.820E-14 1.067E-11 1.707E-10 3.760E-16-l.OOOE+00 8.890E-09 1.440E-08 SKIN(FGR) 2.980E-14 1.825E-11 2.920E-10 6.430E-16-l.OOOE+0O O.OOOE+00 O.OOOE+00 1-132 GONADS l.090E-13 2.523E-11 2.771E-11 2.320E-15-l.OOOE+00 9.950E-12 2.330E-ll BREAST 1.240E-13 2.414E-11 2.652E-11 2.220E-15-l.OOOE+00 1.410E-11 2.520E-ll LUNGS l.090E-13 2.305E-11 2.532E-11 2.120E-15-l.OOOE+00 2.710E-10 2.640E-ll RED MARR 1.070E-13 2.360E-11 2.592E-11 2.170E-15-1.OOOE+00 1.400E-11 2.460E-ll BONE SUR 1.730E-13 3.327E-11 3.655E-11 3.060E-15-l.OOOE+00 1.240E-11 2.190E-ll THYROID 1.120E-13 2.381E-11 2.616E-11 2.190E-15-l.OOOE+00 1.740E-09 3.870E-09 REMAINDER 1.050E-13 2.283E-11 2.509E-11 2.100E-15-1.OOOE+00 3.780E-11 1.650E-10 EFFECTIVE 1.120E-13 2.403E-11 2.640E-11 2.210E-15-l.OOOE+00 1.030E-10 1.820E-10 SKIN(FGR) 1.580E-13 8.199E-11 9.007E-11 7.540E-15-l.OOOE+00 O.OOOE+00 O.OOOE+00 I-133 GONADS 2.870E-14 1.585E-11 6.748E-11 6.270E-16-l.OOOE+00 1.950E-11 3.630E-ll BREAST 3.280E-14 1.519E-11 6.468E-11 6.010E-16-l.OOOE+00 2.940E-11 4.680E-l1 LUNGS 2.860E-14 1.446E-11 6.156E-11 5.720E-16-1.OOOE+00 8.200E-10 4.530E-ll RED MARR 2.770E-14 1.466E-11 6.242E-11 5.800E-16-l.OOOE+00 2.720E-11 4.300E-ll BONE SUR 4.870E-14 2.161E-11 9.202E-11 8.550E-16-l.OOOE+00 2.520E-11 4.070E-il THYROID 2.930E-14 1.502E-11 6.393E-11 5.940E-16-l.OOOE+00 4.860E-08 9.100E-08 REMAINDER 2.730E-14 1.418E-11 6.038E-11 5.610E-16-l.OOOE+00 5.000E-11 1.5SOE-10 EFFECTIVE 2.940E-14 1.509E-11 6.425E-11 5.970E-16-l.OOOE+00 1.580E-09 2.800E-09 SKIN(FGR) 5.830E-14 1.150E-10 4.897E-10 4.550E-15-1.OOOE+O0 O.OOOE+00 O.OOOE+00 I-134 GONADS 1.270E-13 1.200E-11 1.202E-11 2.640E-15-l.OOOE+00 4.250E-12 1.lOOE-ll BREAST 1.440E-13 1.145E-11 1.147E-11 2.520E-15-l.OOOE+00 6.170E-12 1.170E-ll LUNGS 1.270E-13 1.100E-li 1.102E-11 2.420E-15-l.OOOE+00 1.430E-10 1.260E-li RED MARR 1.250E-13 1.127E-11 1.129E-11 2.480E-15-l.OOOE+00 6.080E-12 l.090E-ll

CA06452 Rev.O000 Page 59 of 110 BONE SUR 1.960E-13 1.568E-11 1.571E-11 3.450E-15-1.OOOE+00 5.310E-12 9.320E-12 THYROID 1.300E-13 1.127E-11 1.129E-11 2.480E-15-1.OOOE+00 2.880E-10 6.210E-10 REMAINDER 1.220E-13 1.091E-11 1.093E-11 2.400E-15-1.OOOE+00 2.270E-11 1.340E-10 EFFECTIVE 1.300E-13 1.150E-11 1.152E-11 2.530E-15-l.OOOE+00 3.550E-11 6.660E-11 SKIN(FGR) 1.870E-13 4.477E-11 4.485E-11 9.8SOE-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-135 GONADS 8.078E-14 3.113E-11 5.489E-11 1.599E-15-1.OOOE+00 1.700E-11 3.610E-11 BREAST 9.143E-14 2.971E-11 5.240E-11 1.526E-15-1.OOOE+00 2.340E-11 3.850E-11 LUNGS 8.145E-14 2.886E-11 5.089E-11 1.482E-15-1.OOOE+00 4.410E-10 3.750E-11 RED MARR 8.054E-14 2.965E-11 5.228E-11 1.523E-15-1.OOOE+00 2.240E-11 3.650E-11 BONE SUR 1.184E-13 3.983E-11 7.024E-11 2.046E-15-1.OOOE+00 2.010E-11 3.360E-11 THYROID 8.324E-14 2.852E-11 5.030E-11 1.465E-15-1.OOOE+00 8.460E-09 1.790E-08 REMAINDER 7.861E-14 2.883E-11 5.084E-11 1.481E-15-1.OOOE+00 4.700E-11 1.540E-10 EFFECTIVE 8.294E-14 2.989E-11 5.271E-11 1.535E-15-1.OOOE+00 3.320E-10 6.080E-10 SKIN(PGR) 1.156E-13 9.826E-11 1.733E-10 5.047E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-133 GONADS 1.610E-15 1.465E-12 2.052E-11 5.200E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.960E-15 1.505E-12 2.107E-11 5.340E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.320E-15 1.045E-12 1.464E-11 3.710E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.070E-15 8.791E-13 1.231E-11 3.120E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 5.130E-15 4.254E-12 5.958E-11 1.510E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.510E-15 1.181E-12 1.653E-11 4.190E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.240E-15 1.042E-12 1.460E-11 3.700E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.560E-15 1.299E-12 1.819E-11 4.610E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 4.970E-15 1.953E-12 2.734E-11 6.930E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-135 GONADS 1.170E-14 5.455E-12 1.194E-11 2.530E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.330E-14 5.325E-12 1.166E-11 2.470E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.130E-14 4.959E-12 1.086E-11 2.300E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.070E-14 4.959E-12 1.086E-11 2.300E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 2.570E-14 9.120E-12 1.997E-11 4.230E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.180E-14 5.023E-12 1.10E-11 2.330E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.080E-14 4.829E-12 1.058E-11 2.240E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.190E-14 5.217E-12 1.142E-11 2.420E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 3.120E-14 4.506E-11 9.867E-11 2.090E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-133m GONADS 1.420E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.700E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS l.190E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.100E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 3.230E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.360E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.150E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.370E-15 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-135m GONADS 2.OOOE-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 2.290E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.980E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR l.910E-14 0.OOOE+OO O.OOOE+00 O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 3.500E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 2.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.890E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 2.040E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO

CA06452 Rev. 000 Page 60 of 110 SKIN(FGR) 2.970E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-138 GONADS 5.590E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 6.320E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 5.660E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 5.600E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 8.460E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 5.490E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.070E-13 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO

CA06452 Rev.000 Page 61 of 110 ATTACHMENT 0 CONVERSION FACTORS FILE FGR05.INP FGRDCF 10/24/95 03:24:50 beta-test version 1.10, minor FORTRAN fixes 5/4/95 Implicit daughter halflives (m) less than 90 and less than 0.100 of parent 9 ORGANS DEFINED IN THIS FILE:

GONADS BREAST LUNGS RED MARR BONE SUR THYROID REMAINDER EFFECTIVE SKIN(FGR) 05 NUCLIDES DEFINED IN THIS FILE:

I-131 D 1-132 D 1-133 D I-134 D 1-135 D Including:Xe-135m CLOUDSHINE GROUND GROUND GROUND INHALED INHALED INGESTION SHINE 8HR SHINE 7DAY SHINE RATE ACUTE CHRONIC I-131 GONADS 1.780E-14 1.119E-11 1.789E-10 3.940E-16-1.OOOE+00 2.530E-11 4.070E-11 BREAST 2.040E-14 1.082E-11 1.730E-10 3.810E-16-1.OOOE+00 7.880E-11 1.210E-10 LUNGS 1.760E-14 1.016E-11 1.626E-10 3.580E-16-1.OOOE+00 6.570E-10 1.020E-10 RED MARR 1.680E-14 1.022E-11 1.635E-10 3.600E-16-1.O00E+00 6.260E-11 9.440E-11 BONE SUR 3.450E-14 1.675E-11 2.679E-10 5.900E-16-1.OOOE+00 5.730E-11 8.720E-11 THYROID 1.810E-14 1.053E-11 1.685E-10 3.710E-16-1.OOOE+00 2.920E-07 4.760E-07 REMAINDER 1.670E-14 9.908E-12 1.585E-10 3.490E-16-1.OOOE+00 8.030E-11 1.570E-10 EFFECTIVE 1.820E-14 1.067E-11 1.707E-10 3.760E-16-1.OOOE+00 8.890E-09 1.440E-08 SKIN(FGR) 2.980E-14 1.825E-11 2.920E-10 6.430E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 I-132 GONADS 1.090E-13 2.523E-11 2.771E-11 2.320E-15-1.OOOE+00 9.950E-12 2.330E-11 BREAST 1.240E-13 2.414E-11 2.652E-11 2.220E-15-1.OOOE+00 1.410E-11 2.520E-11 LUNGS 1.090E-13 2.305E-11 2.532E-11 2.120E-15-1.OOOE+00 2.710E-10 2.640E-11 RED MARR 1.070E-13 2.360E-11 2.592E-11 2.170E-15-1.OOOE+00 1.400E-11 2.460E-11 BONE SUR 1.730E-13 3.327E-11 3.655E-11 3.060E-15-1.OOOE+00 1.240E-11 2.190E-11 THYROID 1.120E-13 2.381E-11 2.616E-11 2.190E-15-1.OOOE+00 1.740E-09 3.870E-09 REMAINDER 1.O50E-13 2.283E-11 2.509E-11 2.100E-15-1.OOOE+00 3.780E-11 1.650E-10 EFFECTIVE 1.120E-13 2.403E-11 2.640E-11 2.210E-15-1.OOOE+00 1.030E-10 1.820E-10 SKIN(FGR) 1.580E-13 8.199E-11 9.007E-11 7.540E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 I-133 GONADS 2.870E-14 1.585E-11 6.748E-11 6.270E-16-1.OOOE+00 1.950E-11 3.630E-11 BREAST 3.280E-14 1.519E-11 6.468E-11 6.010E-16-1.OOOE+00 2.940E-11 4.680E-11 LUNGS 2.860E-14 1.446E-11 6.156E-11 5.720E-16-1.OOOE+00 8.200E-10 4.530E-11 RED MARR 2.770E-14 1.466E-11 6.242E-11 5.800E-16-1.OOOE+00 2.720E-11 4.300E-11 BONE SUR 4.870E-14 2.161E-11 9.202E-11 8.550E-16-1.OOOE+00 2.520E-11 4.070E-11 THYROID 2.930E-14 1.502E-11 6.393E-11 5.940E-16-1.OOOE+00 4.860E-08 9.100E-08 REMAINDER 2.730E-14 1.418E-11 6.038E-11 5.610E-16-1.OOOE+00 5.000E-1l 1.550E-10 EFFECTIVE 2.940E-14 1.509E-11 6.425E-11 5.970E-16-1.OOOE+00 1.580E-09 2.800E-09 SKIN(FGR) 5.830E-14 1.150E-10 4.897E-10 4.550E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00

CA06452 Rev.O000 Page 62 of 110 I-134 GONADS 1.270E-13 1.200E-11 1.202E-11 2.640E-15-1.OOOE+00 4.250E-12 1.100E-11 BREAST 1.440E-13 1.145E-11 1.147E-11 2.520E-15-1.OOOE+00 6.170E-12 1.170E-11 LUNGS 1.270E-13 1.100E-11 1.102E-11 2.420E-15-1.OOOE+00 1.430E-10 1.260E-11 RED MARR 1.250E-13 1.127E-11 1.129E-11 2.480E-15-1.OOOE+00 6.080E-12 1.090E-11 BONE SUR 1.960E-13 1.568E-11 1.571E-11 3.450E-15-1.OOOE+00 5.310E-12 9.320E-12 THYROID 1.300E-13 1.127E-11 1.129E-11 2.480E-15-1.OOOE+00 2.880E-10 6.210E-10 REMAINDER 1.220E-13 1.091E-11 1.093E-11 2.400E-15-1.OOOE+00 2.270E-11 1.340E-10 EFFECTIVE 1.300E-13 1.150E-11 1.152E-11 2.530E-15-1.OOOE+00 3.550E-11 6.660E-11 SKIN(FGR) 1.870E-13 4.477E-11 4.485E-11 9.850E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-135 GONADS 8.078E-14 3.113E-11 5.489E-11 l.S99E-15-1.OOOE+00 1.700E-11 3.610E-11 BREAST 9.143E-14 2.971E-11 5.240E-11 1.S26E-15-l.OOOE+00 2.340E-11 3.850E-11 LUNGS 8.145E-14 2.886E-11 5.089E-11 1.482E-15-1.OOOE+00 4.410E-10 3.750E-11 RED MARR 8.054E-14 2.965E-11 5.228E-11 1.523E-15-1.OOOE+00 2.240E-11 3.650E-1l BONE SUR 1.184E-13 3.983E-11 7.024E-11 2.046E-15-1.OOOE+00 2.010E-11 3.360E-ll THYROID 8.324E-14 2.852E-11 5.030E-11 1.465E-15-l.OOOE+00 8.460E-09 1.790E-08 REMAINDER 7.861E-14 2.883E-11 5.084E-11 1.481E-15-l.OOOE+00 4.700E-11 1.540E-10 EFFECTIVE 8.294E-14 2.989E-11 5.271E-11 1.535E-15-l.OOOE+00 3.320E-10 6.080E-10 SKIN(FGR) 1.156E-13 9.826E-11 1.733E-10 5.047E-15-i.OOOE+OO O.OOOE+CO O.OOOE+OO

CA06452 Rev.000 Page 63 of 110 ATTACHMENT P CONVERSION FACTORS FILE FGR63.INP FGRDCF 10/24/95 03:24:50 beta-test version 1.10, minor FORTRAN fixes 5/4/95 Implicit daughter halflives (m) less than 90 and less than 0.100 of parent 9 ORGANS DEFINED IN THIS FILE:

GONADS BREAST LUNGS RED MARR BONE SUR THYROID REMAINDER EFFECTIVE SKIN(FGR) 63 NUCLIDES DEFINED IN THIS FILE:

Co-58 Y Co-60 Y Kr-85 Kr-85m Kr-87 Kr-88 Rb-86 Sr-89 Sr-90 Sr-91 Including:Y-91m Sr-92 Y-90 Y-91 Y-92 Y-93 Zr-95 Zr-97 Including:Nb-97m , Including:Nb-97 Nb-95 Mo-99 Tc-99m Ru-103 Including:Rh-103m Ru-105 Ru-106 Including:Rh-106 Rh-105 Sb-127 Sb-129 Te-127 Te-127m Te-129 Te-129m Including:Te-129 Te-131m Including:Te-131 Te-132 1-131 1-132 I-133 I-134 I-135 Including:Xe-135m

CA06452 Rev. 000 Page 64 of 110 Xe-133 Xe-135 Cs-134 D Cs-136 D Cs-137 D Including:Ba-137m Ba-139 D Ba-140 D La-140 w La-141 D La-142 D Ce-141 Y Ce-143 Y Ce-144 Y Including:Pr-144m, Including:Pr-144 Pr-143 Y Nd-147 Y Np-239 w Pu-238 y Pu-239 Y Pu-240 Y Pu-241 Y Am-241 U Cm-242 U Cm-244 U Xe-133m Xe-135m Xe-138 CLOUDSHINE GROUND GROUND GROUND INHALED INHALED INGESTION SHINE 8HR SHINE 7DAY SHINE RATE ACUTE CHRONIC Co-58 GONADS 4 .660E-14 2.867E-11 5 .828E-10 9 .970E-16-1 . 00E+00 6.170E-10 1.040E-09 BREAST 5.300E-14 2.737E-11 5.56SE-10 9. 520E-16-1 . 00E+00 9.370E-10 1. 790E-10 LUNGS 4 .640E-14 2.617E-11 S.319E-10 9. 100E-16-1 . 00E+00 1.600E-08 8.530E-11 RED MARR 4 .530E-14 2.671E-11 5S.430E-10 9.290E-16-1 .000E+00 9.230E-10 2.600E-10 BONE SUR 7.410E-14 3.795E-l1 7. 716E-10 1.32DE-25-2 .000E+00 6.930E-10 1.250E-10 THYROID 4 .770E-14 2.720E-11 5.530E-10 9.460E-16-1 .000E+00 8. 720E-10 6.310E-11 REMAINDER 4 .440E-14 2.585E-11 5 .25SE-10 8. 990E-16-1 . 00E+00 1.890E-09 1.580E-09 EFFECTIVE 4.760E-14 2.732E-11 5.SS3E-10 9 .SOOE-16-1.000E+00 2.940E-09 8.090E-10 SKIN(FGR) 5.580E-14 3.278E-11 6.664E-10 12.140E-15-1. 000E+00 0.000E+00 0.000E+00 Co-60 GONADS 1.230E-13 7.056E-11 1.4 80E-09 2 .4S0E-15-1.000E+00 4.760E-09 3.190E-09 BREAST 1.390E-13 6.739E-11 1.413E-09 2 .340E-15-1.000E+00 1.840E-08 1.100E-09 LUNGS 1.240E-13 6.537E-ll 1.371E-09 2. 270E-15-12.OOOE+00 3.450E-07 8.770E-10 RED MARR 1.230E-13 6.710E-11 1.407E-09 2 .330E-15-1 .000E+00 1.720E-08 1.320E-09 BONE SUR 1.780E-13 8.956E-11 1. 879E-09 3 .110E-15-1 .000E+00 1.350E-08 9.390E-10 THYROID 1.270E-13 6.480E-11 1.359E-09 2 .250E-15-1 .000E+00 1.620E-08 7.880E-10 REMAINDER 1.200E-13 6.508E-11 12.365E-09 2. 260E-15-1 .000E+00 3.600E-08 4.970E-09 EFFECTIVE 1.260E-13 6.768E-11 1.419E-09 2. 350E-15-1 . 00E+00 S. 910E-08 2.770E-09 SKIN(FGR) 1.450E-13 7.94BE-li 1. 667E-09 2. 760E-15-1 . 00E+00 0.000E+00 0.OOOE+00 Kr-85 GONADS 1.170E-16 8.121E-14 1. 704E-12 2.820E-18-2 .OOOE+00 O.OOOE+00 O.OOOE+00 BREAST 1.340E-16 7.891E-14 1.656E-12 2.74 0E-18-1.OOOE+00 0.OOOE+00 0.OOOE+00 LUNGS 1.140E-16 7.056E-14 1 .481E-12 2.450E-18-1.000E+00 0.OOOE+00 O.000E+00 RED MARR 1.090E-16 6.998E-14 1 .469E-12 2.430E-18-1.000E+00 0.OOOE+00 0.000E+00 BONE SUR 2.200E-16 1.287E-13 2.702E-12 4 .470E-16-1.000E+00 0. 000E+00 0. 000E+00

CA06452 Rev. 000 Page 65 of 110 THYROID 1.180E-16 7.459E-14 1.565E-12 2.590E-18-1.OOOE+00 0.000E+00 O.OOOE+00 REMAINDER 1.090E-16 6.941E-14 1.457E-12 2.410E-18-1.OOOE+00 O.OOOE+00 O.OOOE+00 EFFECTIVE 1.190E-16 7.603E-14 1.596E-12 2.640E-18-1.OOOE+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 1.320E-14 2.304E-11 4.835E-10 8.000E-16-1.000E+00 O.OOOE+00 O.OOOE+00 Kr-85m GONADS 7.310E-15 2.594E-12 3:653E-12 1.570E-16-1.000E+00 O.OOOE+00 O.OOOE+00 BREAST 8.410E-15 2.527E-12 3.560E-12 1.530E-16-1.OOOE+OO O.OOOE+00 O.OOOE+00 LUNGS 7.040E-15 2.379E-12 3.351E-12 1.440E-16-1.OOOE+00 O.OOOE+O0 O.OOOE+00 RED MARR 6.430E-15 2.346E-12 3.304E-12 1.420E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 BONE SUR 1.880E-14 5.286E-12 7.446E-12 3.200E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 THYROID 7.330E-15 2.395E-12 3.374E-12 1.450E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 REMAINDER 6.640E-15 2.313E-12 3.257E-12 1.400E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 EFFECTIVE 7.480E-15 2.511E-12 3.537E-12 1.520E-16-1.000E+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 2.240E-14 2.247E-11 3.164E-11 1.360E-15-1.000E+00 O.OOOE+00 O.OOOE+00 Kr-87 GONADS 4.000E-14 4.962E-12 5.026E-12 7.610E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 BREAST 4.500E-14 4.740E-12 4.802E-12 7.270E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 LUNGS 4.040E-14 4.603E-12 4.663E-12 7.060E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 RED MARR 4.000E-14 4.708E-12 4.769E-12 7.220E-16-1.OOOE+00 O.OOOE+00 0.000E+00 BONE SUR 6.020E-14 6.514E-12 6.598E-12 9.990E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 THYROID 4.130E-14 4.473E-12 4.531E-12 6.860E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 REMAINDER 3.910E-14 4.590E-12 4.650E-12 7.040E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 EFFECTIVE 4.120E-14 4.773E-12 4.835E-12 7.320E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 1.370E-13 8.802E-11 8.916E-11 1.350E-14-1.OOOE+00 O.OOOE+00 O.OOOE+00 Kr-88 GONADS 9.900E-14 2.278E-11 2.655E-11 1.800E-15-1.000E+00 O.OOOE+00 O.OOOE+00 BREAST 1.110E-13 2.177E-11 2.537E-11 1.720E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 LUNGS 1.010E-13 2.139E-11 2.493E-11 1.690E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 RED MARR 1.000E-13 2.190E-11 2.552E-11 1.730E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 BONE SUR 1.390E-13 2.886E-11 3.363E-11 2.280E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 THYROID 1.030E-13 2.012E-11 2.345E-11 1.590E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 REMAINDER 9.790E-14 2.139E-11 2.493E-11 1.690E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 EFFECTIVE 1.020E-13 2.202E-11 2.567E-11 1.740E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 1.350E-13 5.607E-11 6.534E-11 4.430E-15-1.000E+00 O.OOOE+00 O.OOOE+00 Rb-86 GONADS 4.710E-15 2.788E-12 S.187E-11 9.740E-17-1.000E+00 1.340E-09 2.150E-09 BREAST 5.340E-15 2.662E-12 4.953E-11 9.300E-17-1.OOOE+00 1.330E-09 2.140E-09 LUNGS 4.710E-15 2.553E-12 4.750E-11 8.920E-17-l.OOOE+00 3.300E-09 2.140E-09 RED MARR 4.640E-15 2.619E-12 4.873E-11 9.150E-17-1.OOOE+00 2.320E-09 3.720E-09 BONE SUR 7.050E-15 3.635E-12 6.764E-11 1.270E-16-1.OOOE+00 4.270E-09 6.860E-09 THYROID 4.840E-15 2.599E-12 4.836E-11 9.080E-17-1.OOOE+00 1.330E-09 2.140E-09 REMAINDER 4.520E-15 2.542E-12 4.729E-11 8.880E-17-1.OOOE+00 1.380E-09 2.330E-09 EFFECTIVE 4.810E-15 2.665E-12 4.958E-11 9.310E-17-1.OOOE+00 1.790E-09 2.530E-09 SKIN(FGR) 4.850E-14 2.210E-10 4.111E-09 7.720E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Sr-89 GONADS 7.730E-17 7.155E-14 1.436E-12 2.490E-18-1.OOOE+00 7.950E-12 8.050E-12 BREAST 9.080E-17 7.212E-14 1.447E-12 2.510E-18-1.OOOE+00 7.960E-12 7.980E-12 LUNGS 7.080E-17 5.689E-14 1.142E-12 1.980E-18-1.OOOE+00 8.350E-08 7.970E-12 RED MARR 6.390E-17 5.345E-14 1.073E-12 1.860E-18-1.000E+00 1.070E-10 1.080E-10 BONE SUR 1.940E-16 1.560E-13 3.131E-12 5.430E-18-1.OOOE+00 1.590E-10 1.610E-10 THYROID 7.600E-17 6.063E-14 1.217E-12 2.110E-18-1.OOOE+00 7.960E-12 7.970E-12 REMAINDER 6.710E-17 5.603E-14 1.124E-12 1.950E-18-1.OOOE+00 3.970E-09 8.250E-09 EFFECTIVE 7.730E-17 6.523E-14 1.309E-12 2.270E-18-1.OOOE+00 1.120E-08 2.500E-09 SKIN(FGR) 3.690E-14 1.914E-10 3.841E-09 6.660E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00

CA06452 Rev.000 Page 66 of 110 Sr-90 GONADS 7.780E-18 9.590E-15 2.014E-13 3.330E-19-1.OOOE+00 2.690E-10 5.040E-11 BREAST 9.490E-18 1.008E-14 2.116E-13 3.500E-19-1.OOOE+00 2.690E-10 5.040E-11 LUNGS 6.440E-18 6.307E-15 1.324E-13 2.190E-19-1.OOOE+00 2.860E-06 5.040E-ll RED MARR 5.440E-18 5.558E-1S 1.167E-13 1.930E-19-1.OOOE+00 3.280E-08 6.450E-09 BONE SUR 2.280E-17 2.393E-14 5.025E-13 8.310E-19-1.OOOE+00 7.090E-08 1.390E-08 THYROID 7.330E-18 7.171E-15 1.506E-13 2.490E-19-1.OOOE+00 2.690E-10 5.040E-11 REMAINDER 6.110E-18 6.422E-15 1.348E-13 2.230E-19-1.OOOE+00 5.730E-09 6.700E-09 EFFECTIVE 7.530E-18 8.179E-15 1.717E-13 2.840E-19-1.OOOE+00 3.510E-07 3.230E-09 SKIN(FGR) 9.200E-15 4.032E-12 8.465E-11 1.400E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Sr-91 GONADS 4.819E-14 2.155E-11 5.062E-11 1.026E-15-1.OOOE+00 5.669E-11 2.520E-10 BREAST 5.477E-14 2.059E-11 4.838E-11 9.806E-16-1.OOOE+00 1.775E-11 3.676E-11 LUNGS 4.803E-14 1.970E-11 4.626E-11 9.376E-16-1.OOOE+00 2.170E-09 1.055E-11 RED MARR 4.691E-14 2.011E-11 4.722E-11 9.570E-16-1.OOOE+00 2.275E-11 5.659E-11 BONE SUR 7.674E-14 2.852E-11 6.709E-11 1.360E-15-1.OOOE+00 1.306E-11 2.070E-11 THYROID 4.938E-14 2.035E-11 4.782E-11 9.693E-16-1.OOOE+00 9.930E-12 1.968E-12 REMAINDER 4.610E-14 1.948E-11 4.573E-11 9.268E-16-1.OOOE+00 5.802E-10 2.557E-09 EFFECTIVE 4.924E-14 2.057E-11 4.832E-11 9.793E-16-1.OOOE+00 4.547E-10 8.455E-10 SKIN(FGR) 9.938E-14 1.748E-10 3.987E-10 8.080E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Sr-92 GONADS 6.610E-14 1.593E-11 1.830E-11 1.300E-15-1.OOOE+00 1.020E-11 8.180E-11 BREAST 7.480E-14 1.520E-11 1.745E-11 1.240E-15-1.OOOE+00 6.490E-12 1.700E-11 LUNGS 6.670E-14 1.483E-11 1.703E-11 1.210E-15-1.OOOE+00 1.050E-09 7.220E-12 RED MARR 6.620E-14 1.520E-11 1.745E-11 1.240E-15-1.OOOE+00 6.980E-12 2.290E-11 BONE SUR 9.490E-14 2.010E-11 2.308E-11 1.640E-15-1.OOOE+00 4.360E-12 8.490E-12 THYROID 6.820E-14 1.446E-11 1.661E-11 1.180E-15-1.OOOE+00 3.920E-12 1.300E-12 REMAINDER 6.450E-14 1.471E-11 1.689E-11 1.200E-15-1.000E+00 2.900E-10 1.720E-09 EFFECTIVE 6.790E-14 1.532E-11 1.759E-11 1.250E-15-1.OOOE+00 2.180E-10 5.430E-10 SKIN(FGR) 8.560E-14 2.280E-11 2.618E-11 1.860E-15-1.OOOE+00 O.OOOE+00 0.000E+00 Y-90 GONADS 1.890E-16 1.586E-13 1.601E-12 5.750E-18-1.OOOE+00 5.170E-13 1.430E-14 BREAST 2.200E-16 1.578E-13 1.593E-12 5.720E-18-1.000E+00 5.170E-13 1.270E-14 LUNGS 1.770E-16 1.313E-13 1.326E-12 4.760E-18-1.000E+00 9.310E-09 1.260E-14 RED MARR 1.620E-16 1.261E-13 1.273E-12 4.570E-18-1.000E+00 1.520E-11 3.700E-13 BONE SUR 4.440E-16 3.228E-13 3.259E-12 1.170E-17-1.OOOE+00 1.510E-11 3.670E-13 THYROID 1.870E-16 1.385E-13 1.398E-12 5.020E-18-1.OOOE+00 5.170E-13 1.260E-14 REMAINDER 1.680E-16 1.291E-13 1.303E-12 4.680E-18-1.OOOE+00 3.870E-09 9.680E-09 EFFECTIVE 1.900E-16 1.468E-13 1.482E-12 5.320E-18-1.OOOE+00 2.280E-09 2.910E-09 SKIN(FGR) 6.240E-14 2.897E-10 2.924E-09 1.050E-14-1.000E+00 O.OOOE+00 O.OOOE+00 Y-91 GONADS 2.560E-16 1.756E-13 3.546E-12 6.110E-18-1.OOOE+00 8.200E-12 3.540E-12 BREAST 2.930E-16 1.713E-13 3.459E-12 5.960E-18-1.OOOE+00 8.920E-12 5.540E-13 LUNGS 2.500E-16 1.526E-13 3.082E-12 5.310E-18-1.OOOE+00 9.870E-08 2.020E-13 RED MARR 2.410E-16 1.521E-13 3.070E-12 5.290E-18-1.OOOE+00 3.190E-10 6.590E-12 BONE SUR 4.560E-16 2.903E-13 5.862E-12 1.010E-17-1.000E+00 3.180E-10 6.130E-12 THYROID 2.600E-16 1.564E-13 3.157E-12 5.440E-18-1.OOOE+00 8.500E-12 1.290E-13 REMAINDER 2.390E-16 1.509E-13 3.047E-12 5.250E-18-1.OOOE+00 4.200E-09 8.570E-09 EFFECTIVE 2.600E-16 1.650E-13 3.332E-12 5.740E-18-1.OOOE+00 1.320E-08 2.570E-09 SKIN(FGR) 3.850E-14 1.989E-10 4.016E-09 6.920E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Y-92 GONADS 1.270E-14 3.855E-12 4.872E-12 2.650E-16-1.000E+00 2.610E-12 1.960E-11 BREAST 1.440E-14 3.680E-12 4.652E-12 2.530E-16-1.OOOE+00 1.500E-12 3.550E-12 LUNGS 1.270E-14 3.535E-12 4.468E-12 2.430E-16-1.OOOE+00 1.240E-09 1.390E-12

CA06452 Rev. 000 Page 67 of 110 RED MARR 1.250E-14 3.608E-12 4.560E-12 2.480E-16-1.OOOE+00 2.070E-12 4.910E-12 BONE SUR 1.950E-14 5.091E-12 6.435E-12 3.500E-16-l.OOOE+00 1.510E-12 1.750E-12 THYROID 1.300E-14 3.579E-12 4.523E-12 2.460E-16-1.OOOE+00 1.050E-12 1.770E-13 REMAINDER 1.220E-14 3.506E-12 4.431E-12 2.410E-16-1.OOOE+00 2.030E-10 1.700E-09 EFFECTIVE 1.300E-14 3.680E-12 4.652E-12 2.530E-16-1.OOOE+00 2.110E-10 5.150E-10 SKIN(FGR) 1.140E-13 2.022E-10 2.556E-10 1.390E-14-1.OOOE+OO O.OOOE+OO O.OOOE+OO Y-93 GONADS 4.670E-15 2.108E-12 4.989E-12 9.510E-17-1.OOOE+00 5.310E-12 2.200E-11 BREAST 5.300E-15 2.026E-12 4.794E-12 9.140E-17-1.OOOE+00 1.740E-12 3.130E-12 LUNGS 4.680E-15 1.937E-12 4.585E-12 8.740E-17-1.OOOE+00 2.520E-09 8.670E-13 RED MARR 4.580E-15 1.972E-12 4.669E-12 8.900E-17-1.OOOE+00 4.040E-12 4.930E-12 BONE SUR 7.580E-15 2.948E-12 6.977E-12 1.330E-16-1.OOOE+00 3.140E-12 1.730E-12 THYROID 4.790E-15 1.908E-12 4.516E-12 8.610E-17-1.OOOE+00 9.260E-13 1.260E-13 REMAINDER 4.510E-15 1.919E-12 4.543E-12 8.660E-17-1.OOOE+00 9.250E-10 4.090E-09 EFFECTIVE 4.800E-15 2.021E-12 4.784E-12 9.120E-17-1.OOOE+00 5.820E-10 1.230E-09 SKIN(FGR) 8.500E-14 2.726E-10 6.452E-10 1.230E-14-1.OOOE+OO O.OOOE+OO O.OOOE+OO Zr-95 GONADS 3.530E-14 2.182E-11 4.421E-10 7.590E-16-1.OOOE+00 1.880E-09 8.160E-10 BREAST 4.010E-14 2.084E-11 4.223E-10 7.250E-16-1.OOOE+OO 1.910E-09 1.050E-10 LUNGS 3.510E-14 1.989E-11 4.030E-10 6.920E-16-1.OOOE+00 2.170E-09 2.340E-11 RED MARR 3.430E-14 2.030E-11 4.112E-10 7.060E-16-1.OOOE+00 1.300E-08 2.140E-10 BONE SUR 5.620E-14 2.875E-11 5.824E-10 1.OOOE-15-1.OOOE+00 1.030E-07 4.860E-10 THYROID 3.610E-14 2.076E-11 4.205E-10 7.220E-16-1.OOOE+00 1.440E-09 8.270E-12 REMAINDER 3.360E-14 1.963E-11 3.978E-10 6.830E-16-1.OOOE+00 2.280E-09 2.530E-09 EFFECTIVE 3.600E-14 2.078E-11 4.211E-10 7.230E-16-1.OOOE+00 6.390E-09 1.020E-09 SKIN(FGR) 4.500E-14 2.561E-11 5.190E-10 8.910E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Zr-97 GONADS 4.331E-14 2.179E-11 7.799E-11 9.253E-16-1.OOOE+00 1.840E-10 6.228E-10 BREAST 4.928E-14 2.083E-11 7.455E-11 8.846E-16-1.OOOE+00 4.706E-11 8.137E-11 LUNGS 4.322E-14 1.992E-11 7.127E-11 8.456E-16-1.OOOE+00 4.108E-09 1.770E-11 RED MARR 4.224E-14 2.034E-11 7.279E-11 8.634E-16-1.OOOE+00 6.376E-11 1.302E-10 BONE SUR 6.897E-14 2.881E-11 1.031E-10 1.224E-15-1.OOOE+00 3.504E-11 4.558E-11 THYROID 4.443E-14 2.061E-11 7.377E-11 8.755E-16-1.OOOE+00 2.315E-11 2.671E-12 REMAINDER 4.139E-14 1.966E-11 7.035E-11 8.345E-16-1.OOOE+00 2.041E-09 6.990E-09 EFFECTIVE 4.432E-14 2.078E-11 7.438E-11 8.824E-16-1.OOOE+00 1.171E-09 2.283E-09 SKIN(FGR) 9.835E-14 2.281E-10 8.148E-10 9.587E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Nb-95 GONADS 3.660E-14 2.253E-11 4.435E-10 7.850E-16-1.OOOE+00 4.320E-10 8.050E-10 BREAST 4.160E-14 2.150E-11 4.231E-10 7.490E-16-1.OOOE+00 4.070E-10 1.070E-10 LUNGS 3.650E-14 2.055E-11 4.045E-10 7.160E-16-l.OOOE+00 8.320E-09 2.740E-11 RED MARR 3.560E-14 2.101E-11 4.135E-10 7.320E-16-1.OOOE+00 4.420E-10 1.990E-10 BONE SUR 5.790E-14 2.957E-11 5.819E-10 1.030E-15-1.OOOE+00 5.130E-10 2.940E-10 THYROID 3.750E-14 2.144E-11 4.220E-10 7.470E-16-1.OOOE+00 3.580E-10 1.180E-11 REMAINDER 3.490E-14 2.032E-11 4.000E-10 7.080E-16-1.000E+00 1.070E-09 1.470E-09 EFFECTIVE 3.740E-14 2.147E-11 4.226E-10 7.480E-16-1.OOOE+00 1.570E-09 6.950E-10 SKIN(FGR) 4.300E-14 2.598E-11 5.112E-10 9.050E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Mo-99 GONADS 7.130E-15 4.282E-12 4.403E-11 1.550E-16-1.OOOE+00 9.510E-11 2.180E-10 BREAST 8.130E-15 4.116E-12 4.233E-11 1.490E-16-1.OOOE+00 2.750E-11 3.430E-11 LUNGS 7.060E-15 3.867E-12 3.977E-11 1.400E-16-1.OOOE+00 4.290E-09 1.510E-11 RED MARR 6.820E-15 3.923E-12 4.034E-11 1.420E-16-1.OOOE+00 5.240E-11 8.320E-11 BONE SUR 1.240E-14 6.105E-12 6.278E-11 2.210E-16-1.OOOE+00 4.130E-11 6.320E-11 THYROID 7.270E-15 4.033E-12 4.147E-11 1.460E-16-1.OOOE+00 1.520E-11 1.030E-11 REMAINDER 6.740E-15 3.812E-12 3.920E-11 1.380E-16-1.OOOE+00 1.740E-09 4.280E-09

CA06452 Rev.000 Page 68 of 110 EFFECTIVE 7.280E-15 4.061E-12 4.176E-11 1.470E-16-l.OOOE+00 1.070E-09 1.360E-09 SKIN(FGR) 3.140E-14 1.039E-10 1.068E-09 3.760E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Tc-99m GONADS 5.750E-15 2.334E-12 3.877E-12 1.240E-16-1.OOOE+00 2.770E-12 9.750E-12 BREAST 6.650E-15 2.258E-12 3.752E-12 1.200E-16-1.OOOE+00 2.150E-12 3.570E-12 LUNGS 5.490E-15 2.127E-12 3.533E-12 1.130E-16-1.OOOE+00 2.280E-11 3.140E-12 RED MARR 4.910E-15 2.070E-12 3.439E-12 1.100E-16-1.OOOE+00 3.360E-12 6.290E-12 BONE SUR 1.630E-14 5.383E-12 8.942E-12 2.860E-16-1.000E+00 2.620E-12 4.060E-12 THYROID 5.750E-15 2.145E-12 3.564E-12 1.140E-16-1.OOOE+00 5.010E-11 8.460E-11 REMAINDER 5.150E-15 2.070E-12 3.439E-12 1.100E-16-1.OOOE+00 1.020E-11 3.340E-11 EFFECTIVE 5.890E-15 2.277E-12 3.783E-12 1.210E-16-1.OOOE+00 8.800E-12 1.680E-11 SKIN(FGR) 7.140E-15 2.710E-12 4.502E-12 1.440E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Ru-103 GONADS 2.191E-14 1.404E-11 2.783E-10 4.892E-16-1.OOOE+00 3.070E-10 5.720E-10 BREAST 2.512E-14 1.350E-11 2.677E-10 4.705E-16-1.OOOE+00 3.110E-10 1.200E-10 LUNGS 2.180E-14 1.273E-11 2.522E-10 4.432E-16-1.OOOE+00 1.561E-08 7.310E-11 RED MARR 2.100E-14 1.287E-11 2.551E-10 4.483E-16-1.OOOE+00 3.190E-10 1.660E-10 BONE SUR 3.892E-14 1.958E-11 3.882E-10 6.823E-16-1.OOOE+00 2.370E-10 9.631E-11 THYROID 2.241E-14 1.331E-11 2.639E-10 4.638E-16-1.OOOE+00 2.570E-10 6.250E-11 REMAINDER 2.080E-14 1.248E-11 2.472E-10 4.346E-16-1.OOOE+00 1.250E-09 2.110E-09 EFFECTIVE 2.251E-14 1.332E-11 2.641E-10 4.642E-16-1.OOOE+00 2.421E-09 8.271E-10 SKIN(FGR) 2.774E-14 1.785E-11 3.543E-10 6.229E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Ru-105 GONADS 3.720E-14 1.327E-11 1.861E-11 8.070E-16-1.OOOE+00 1.590E-11 9.670E-11 BREAST 4.240E-14 1.271E-11 1.783E-11 7.730E-16-1.OOOE+00 6.610E-12 1.590E-11 LUNGS 3.700E-14 1.210E-11 1.697E-11 7.360E-16-1.OOOE+00 5.730E-10 6.210E-12 RED MARR 3.590E-14 1.230E-11 1.725E-11 7.480E-16-1.OOOE+00 7.700E-12 2.350E-11 BONE SUR 6.280E-14 1.809E-11 2.537E-11 1.100E-15-1.000E+00 4.620E-12 8.890E-12 THYROID 3.800E-14 1.260E-11 1.766E-11 7.660E-16-1.OOOE+00 4.150E-12 1.820E-12 REMAINDER 3.540E-14 1.189E-11 1.667E-11 7.230E-16-1.OOOE+00 1.610E-10 8.540E-10 EFFECTIVE 3.810E-14 1.265E-11 1.773E-11 7.690E-16-1.OOOE+00 1.230E-10 2.870E-10 SKIN(FGR) 6.730E-14 7.368E-11 1.033E-10 4.480E-15-1.OOOE+00 O.OOOE+00 O.OOOE+00 Ru-106 GONADS 1.010E-14 6.411E-12 1.340E-10 2.230E-16-1.OOOE+00 1.300E-09 1.640E-09 BREAST 1.160E-14 6.152E-12 1.286E-10 2.140E-16-1.000E+00 1.780E-09 1.440E-09 LUNGS 1.010E-14 5.836E-12 1.220E-10 2.030E-16-1.OOOE+00 1.040E-06 1.420E-09 RED MARR 9.750E-15 5.893E-12 1.232E-10 2.050E-16-1.OOOE+00 1.760E-09 1.460E-09 BONE SUR 1.720E-14 8.883E-12 1.856E-10 3.090E-16-1.OOOE+00 1.610E-09 1.430E-09 THYROID 1.030E-14 6.066E-12 1.268E-10 2.110E-16-1.OOOE+00 1.720E-09 1.410E-09 REMAINDER 9.630E-15 5.721E-12 1.196E-10 1.990E-16-1.OOOE+00 1.200E-08 2.110E-08 EFFECTIVE 1.040E-14 6.095E-12 1.274E-10 2.120E-16-1.OOOE+00 1.290E-07 7.400E-09 SKIN(FGR) 1.090E-13 4.082E-10 8.531E-09 1.420E-14-1.OOOE+00 O.OOOE+00 O.OOOE+00 Rh-105 GONADS 3.640E-15 2.127E-12 1.411E-11 7.980E-17-1.OOOE+00 2.110E-11 5.800E-11 BREAST 4.160E-15 2.063E-12 1.369E-11 7.740E-17-1.OOOE+00 5.610E-12 8.970E-12 LUNGS 3.570E-15 1.935E-12 1.284E-11 7.260E-17-1.OOOE+00 9.580E-10 3.860E-12 RED MARR 3.380E-15 1.946E-12 1.291E-11 7.300E-17-1.OOOE+00 7.770E-12 1.470E-11 BONE SUR 7.530E-15 3.332E-12 2.210E-11 1.250E-16-1.OOOE+00 4.460E-12 6.750E-12 THYROID 3.680E-15 1.983E-12 1.316E-11 7.440E-17-1.OOOE+00 2.880E-12 2.910E-12 REMAINDER 3.390E-15 1.885E-12 1.250E-11 7.070E-17-1.OOOE+00 4.530E-10 1.270E-09 EFFECTIVE 3.720E-15 2.031E-12 1.347E-11 7.620E-17-1.OOOE+00 2.580E-10 3.990E-10 SKIN(FGR) 1.070E-14 4.691E-12 3.112E-11 1.760E-16-1.OOOE+00 O.OOOE+00 O.OOOE+00 Sb-127 GONADS 3.260E-14 1.985E-11 2.441E-10 7.100E-16-1.OOOE+00 2.520E-10 6.140E-10

CA06452 Rev. 000 Page 69 of 110 BREAST 3.720E-14 1.904E-11 2.341E-10 6.810E-16-1.OOOE+00 9.120E-11 7.600E-11 LUNGS 3.240E-14 1.809E-11 2.224E-10 6.470E-16-1.OOOE+00 6.940E-09 1.570E-11 RED MARR 3.140E-14 1.834E-11 2.255E-10 6.560E-16-1.OOOE+00 1.610E-10 1.330E-10 BONE SUR 5.520E-14 2.720E-11 3.345E-10 9.730E-16-l.OOOE+00 1.340E-10 5.240E-1l THYROID 3.330E-14 1.884E-11 2.317E-10 6.740E-16-1.OOOE+00 6.150E-11 4.640E-12 REMAINDER 3.090E-14 1.775E-11 2.183E-10 6.350E-16-1.OOOE+00 2.330E-09 5.870E-09 EFFECTIVE 3.330E-14 1.890E-11 2.324E-10 6.760E-16-1.OOOE+00 1.630E-09 1.950E-09 SKIN(FGR) 5.580E-14 7.967E-11 9.799E-10 2.850E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Sb-129 GONADS 6.970E-14 2.336E-11 3.231E-11 1.440E-15-1.OOOE+00 2.150E-11 1.510E-10 BREAST 7.910E-14 2.222E-11 3.074E-11 1.370E-15-1.OOOE+00 1.280E-11 2.560E-11 LUNGS 6.980E-14 2.141E-11 2.962E-11 1.320E-15-1.OOOE+00 8.980E-10 9.390E-12 RED MARR 6.860E-14 2.190E-11 3.029E-11 1.350E-15-1.OOOE+00 1.700E-11 3.670E-1l BONE SUR 1.070E-13 3.033E-11 4.196E-11 1.870E-15-1.OOOE+00 1.460E-11 1.340E-11 THYROID 7.160E-14 2.174E-11 3.007E-11 1.340E-15-1.OOOE+00 9.720E-12 1.470E-12 REMAINDER 6.710E-14 2.125E-11 2.939E-11 1.310E-15-1.OOOE+00 1.870E-10 1.450E-09 EFFECTIVE 7.140E-14 2.238E-11 3.096E-11 1.380E-15-1.OOOE+00 1.740E-10 4.840E-10 SKIN(FGR) 1.050E-13 8.273E-11 1.144E-10 5.100E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-127 GONADS 2.370E-16 1.191E-13 2.661E-13 5.480E-18-1.OOOE+00 2.020E-12 4.020E-12 BREAST 2.730E-16 1.158E-13 2.588E-13 5.330E-18-1.OOOE+00 1.880E-12 3.OOOE-12 LUNGS 2.320E-16 1.060E-13 2.370E-13 4.880E-18-1.OOOE+00 4.270E-10 2.890E-12 RED MARR 2.210E-16 1.058E-13 2.365E-13 4.870E-18-1.OOOE+00 4.090E-12 6.570E-12 BONE SUR 4.650E-16 1.862E-13 4.162E-13 8.570E-18-1.OOOE+00 4.090E-12 6.460E-12 THYROID 2.400E-16 1.106E-13 2.472E-13 5.090E-18-1.OOOE+00 1.840E-12 2.860E-12 REMAINDER 2.210E-16 1.036E-13 2.316E-13 4.770E-18-1.OOOE+OO 1.11OE-10 6.130E-10 EFFECTIVE 2.420E-16 1.125E-13 2.515E-13 5.180E-18-1.OOOE+00 8.600E-11 1.870E-10 SKIN(FGR) 1.140E-14 1.173E-11 2.622E-11 5.400E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-127m GONADS 1.900E-16 4.689E-13 9.642E-12 1.630E-17-1.OOOE+OO 1.100E-10 1.250E-10 BREAST 2.690E-16 5.150E-13 1.059E-11 1.790E-17-1.OOOE+OO 1.100E-10 9.740E-11 LUNGS 7.620E-17 1.602E-13 3.295E-12 5.570E-18-1.OOOE+00 3.340E-08 9.620E-11 RED MARE 6.430E-17 1.249E-13 2.567E-12 4.340E-18-1.OOOE+00 S.360E-09 5.430E-09 BONE SUR 3.940E-16 9.005E-13 1.852E-11 3.130E-17-1.OOOE+00 2.040E-08 2.070E-08 THYROID 1.500E-16 2.779E-13 5.714E-12 9.660E-18-1.OOOE+00 9.660E-11 9.430E-11 REMAINDER 8.640E-17 1.999E-13 4.111E-12 6.950E-18-1.OOOE+00 1.660E-09 2.980E-09 EFFECTIVE 1.470E-16 3.251E-13 6.684E-12 1.130E-17-1.OOOE+00 5.810E-09 2.230E-09 SKIN(FGR) 8.490E-16 1.496E-12 3.076E-11 5.200E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-129 GONADS 2.710E-15 3.889E-13 3.922E-13 6.510E-17-1.OOOE+O 5.050E-13 1.590E-12 BREAST 3.120E-15 3.800E-13 3.832E-13 6.360E-17-1.OOOE+00 5.390E-13 6.050E-13 LUNGS 2.640E-1S 3.298E-13 3.326E-13 5.520E-17-1.OOOE+00 1.530E-10 4.910E-13 RED MARR 2.540E-15 3.298E-13 3.326E-13 5.520E-17-1.OOOE+00 6.190E-13 7.640E-13 BONE SUR 4.880E-15 5.753E-13 5.802E-13 9.630E-17-1.OOOE+00 6.220E-13 5.400E-13 THYROID 2.740E-15 3.525E-13 3.555E-13 5.900E-17-1.OOOE+00 5.090E-13 3.360E-13 REMAINDER 2.520E-15 3.262E-13 3.289E-13 5.460E-17-1.OOOE+00 7.280E-12 1.790E-10 EFFECTIVE 2.750E-15 3.590E-13 3.621E-13 6.010E-17-1.OOOE+00 2.090E-11 5.450E-11 SKIN(FGR) 3.570E-14 3.429E-11 3.458E-11 5.740E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-129m GONADS 3.321E-15 2.206E-12 4.7§9E-11 8.561E-17-1.OOOE+00 1.783E-10 2.420E-10 BREAST 3.838E-15 2.181E-12 4.739E-11 8.454E-17-1.OOOE+00 1.694E-10 1.664E-10 LUNGS 3.176E-15 1.741E-12 3.815E-11 6.808E-17-1.OOOE+00 4.040E-08 1.593E-10 RED MARR 3.071E-15 1.729E-12 3.793E-11 6.768E-17-1.OOOE+00 3.100E-09 3.500E-09 BONE SUR 5.772E-15 3.287E-12 7.147E-11 1.275E-16-1.000E+00 7.050E-09 7.990E-09

CA06452 Rev. 000 Page 70 of 110 THYROID 3.341E-15 1.923E-12 4.201E-11 7.495E-17-1.OOOE+00 1.563E-10 1.572E-10 REMAINDER 3.048E-15 1.746E-12 3.822E-11 6.819E-17-1.OOOE+00 3.275E-09 7.196E-09 EFFECTIVE 3.337E-15 1.974E-12 4.308E-11 7.686E-17-1.OOOE+00 6.484E-09 2.925E-09 SKIN(FGR) 3.811E-14 1.501E-10 3.360E-09 6.001E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-131m GONADS 7.292E-14 4.020E-11 2.343E-10 1.535E-15-1.OOOE+00 2.345E-10 7.415E-10 BREAST 8.286E-14 3.853E-11 2.246E-10 1.472E-15-1.OOOE+00 9.309E-11 1.361E-10 LUNGS 7.265E-14 3.657E-11 2.131E-10 1.397E-15-1.OOOE+00 2.296E-09 6.335E-11 RED MARR 7.097E-14 3.736E-11 2.178E-10 1.427E-15-1.OOOE+00 1.417E-10 2.435E-10 BONE SUR 1.174E-13 5.467E-11 3.189E-10 2.090E-15-1.OOOE+00 2.276E-10 3.248E-10 THYROID 7.471E-14 3.741E-11 2.181E-10 1.429E-15-1.OOOE+00 3.669E-08 4.383E-08 REMAINDER 6.965E-14 3.626E-11 2.113E-10 1.385E-15-1.OOOE+00 9.509E-10 3.153E-09 EFFECTIVE 7.463E-14 3.825E-11 2.229E-10 1.461E-15-1.OOOE+00 1.758E-09 2.514E-09 SKIN(FGR) 1.038E-13 1.033E-10 6.188E-10 4.056E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Te-132 GONADS 1.020E-14 6.812E-12 7.706E-11 2.450E-16-1.OOOE+00 4.150E-10 5.410E-10 BREAST 1.180E-14 6.756E-12 7.643E-11 2.430E-16-1.OOOE+00 3.630E-10 3.500E-10 LUNGS 9.650E-15 5.727E-12 6.479E-11 2.060E-16-1.OOOE+00 1.670E-09 3.300E-10 RED MARR 8.950E-15 5.588E-12 6.322E-11 2.010E-16-1.OOOE+00 4.270E-10 4.440E-10 BONE SUR 2.420E-14 1.273E-11 1.441E-10 4.580E-16-1.OOOE+00 7.120E-10 8.300E-10 THYROID 1.020E-14 5.978E-12 6.762E-11 2.150E-16-1.OOOE+00 6.280E-08 5.950E-08 REMAINDER 9.160E-15 5.644E-12 6.385E-11 2.030E-16-1.OOOE+00 7.890E-10 1.490E-09 EFFECTIVE 1.030E-14 6.339E-12 7.171E-11 2.280E-16-1.OOOE+00 2.550E-09 2.540E-09 SKIN(FGR) 1.390E-14 8.313E-12 9.405E-11 2.990E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-131 GONADS 1.780E-14 1.119E-11 1.789E-10 3.940E-16-1.OOOE+00 2.530E-11 4.070E-11 BREAST 2.040E-14 1.082E-11 1.730E-10 3.810E-16-1.OOOE+00 7.880E-11 1.210E-10 LUNGS 1.760E-14 1.016E-11 1.626E-10 3.580E-16-1.OOOE+00 6.570E-10 1.020E-10 RED MARR 1.680E-14 1.022E-11 1.635E-10 3.600E-16-1.OOOE+00 6.260E-11 9.440E-11 BONE SUR 3.450E-14 1.675E-11 2.679E-10 5.900E-16-1.OOOE+00 5.730E-11 8.720E-11 THYROID 1.810E-14 1.053E-11 1.685E-10 3.710E-16-1.OOOE+00 2.920E-07 4.760E-07 REMAINDER 1.670E-14 9.908E-12 1.585E-10 3.490E-16-1.OOOE+00 8.030E-11 1.570E-10 EFFECTIVE 1.820E-14 1.067E-11 1.707E-10 3.760E-16-1.OOOE+00 8.890E-09 1.440E-08 SKIN(FGR) 2.980E-14 1.825E-11 2.920E-10 6.430E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-132 GONADS 1.090E-13 2.523E-11 2.771E-11 2.320E-15-1.OOOE+00 9.950E-12 2.330E-11 BREAST 1.240E-13 2.414E-11 2.652E-11 2.220E-15-1.OOOE+00 1.410E-11 2.520E-11 LUNGS 1.090E-13 2.305E-11 2.532E-11 2.120E-15-1.OOOE+00 2.710E-10 2.640E-11 RED MARR 1.070E-13 2.360E-11 2.592E-11 2.170E-15-1.OOOE+00 1.400E-11 2.460E-11 BONE SUR 1.730E-13 3.327E-11 3.655E-11 3.060E-15-1.OOOE+00 1.240E-11 2.190E-11 THYROID 1.120E-13 2.381E-11 2.616E-11 2.190E-15-1.OOOE+00 1.740E-09 3.870E-09 REMAINDER 1.050E-13 2.283E-11 2.509E-11 2.100E-15-1.OOOE+00 3.780E-11 1.650E-10 EFFECTIVE 1.120E-13 2.403E-11 2.640E-11 2.210E-15-1.OOOE+00 1.030E-10 1.820E-10 SKIN(FGR) 1.580E-13 8.199E-11 9.007E-11 7.540E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-133 GONADS 2.870E-14 1.585E-11 6.748E-11 6.270E-16-1.OOOE+00 1.950E-11 3.630E-11 BREAST 3.280E-14 1.519E-11 6.468E-11 6.010E-16-1.OOOE+00 2.940E-11 4.680E-11 LUNGS 2.860E-14 1.446E-11 6.15GE-11 5.720E-16-1.OOOE+00 8.200E-10 4.530E-11 RED MARR 2.770E-14 1.466E-11 6.242E-11 5.800E-16-1.OOOE+00 2.720E-11 4.300E-11 BONE SUR 4.870E-14 2.161E-11 9.202E-11 8.550E-16-1.OOOE+00 2.520E-11 4.070E-11 THYROID 2.930E-14 1.502E-11 6.393E-11 5.940E-16-1.OOOE+00 4.860E-08 9.100E-08 REMAINDER 2.730E-14 1.418E-11 6.038E-11 5.610E-16-1.OOOE+00 5.OOOE-11 1.550E-10 EFFECTIVE 2.940E-14 1.509E-11 6.425E-11 5.970E-16-1.OOOE+00 1.580E-09 2.800E-09 SKIN(FGR) 5.830E-14 1.150E-10 4.897E-10 4.550E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO

CA06452 Rev.O00 Page 71 of 110 I-134 GONADS 1.270E-13 1.200E-11 1.202E-11 2.640E-15-1.OOOE+00 4.250E-12 l.lOOE-l1 BREAST 1.440E-13 1.145E-11 1.147E-11 2.520E-15-1.OOOE+00 6.170E-12 1.170E-11 LUNGS 1.270E-13 1.100E-11 1.102E-11 2.420E-15-1.OOOE+00 1.430E-10 1.260E-l1 RED MARR 1.250E-13 1.127E-11 1.129E-11 2.480E-15-1.OOOE+00 6.080E-12 1.090E-11 BONE SUR 1.960E-13 1.568E-11 1.571E-11 3.450E-15-1.OOOE+00 5.310E-12 9.320E-12 THYROID 1.300E-13 1.127E-11 1.129E-11 2.480E-15-1.OOOE+00 2.880E-10 6.210E-10 REMAINDER 1.220E-13 1.091E-11 1.093E-11 2.400E-15-1.OOOE+00 2.270E-11 1.340E-10 EFFECTIVE 1.300E-13 1.150E-11 1.152E-11 2.530E-15-1.OOOE+00 3.550E-11 6.660E-11 SKIN(FGR) 1.870E-13 4.477E-11 4.485E-11 9.850E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO I-135 GONADS 8.078E-14 3.113E-11 5.489E-11 1.599E-15-1.OOOE+00 1.700E-11 3.610E-11 BREAST 9.143E-14 2.971E-11 5.240E-11 1.526E-15-1.OOOE+00 2.340E-11 3.850E-11 LUNGS 8.145E-14 2.886E-11 5.089E-11 1.482E-15-1.OOOE+00 4.410E-10 3.750E-11 RED MARR 8.054E-14 2.965E-11 5.228E-11 1.523E-15-1.OOOE+00 2.240E-11 3.650E-11 BONE SUR , 1.184E-13 3.983E-11 7.024E-11 2.046E-15-1.OOOE+00 2.010E-11 3.360E-11 THYROID 8.324E-14 2.852E-11 5.030E-11 1.465E-15-1.OOOE+00 8.460E-09 1.790E-08 REMAINDER 7.861E-14 2.883E-11 5.084E-11 1.481E-15-1.OOOE+00 4.700E-11 1.540E-10 EFFECTIVE 8.294E-14 2.989E-11 5.271E-11 1.535E-15-1.OOOE+00 3.320E-10 6.080E-10 SKIN(FGR) 1.156E-13 9.826E-11 1.733E-10 5.047E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-133 GONADS 1.610E-15 1.465E-12 2.052E-11 5.200E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.960E-15 1.505E-12 2.107E-11 S.340E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.320E-15 1.045E-12 1.464E-11 3.710E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.070E-15 8.791E-13 1.231E-11 3.120E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 5.130E-15 4.254E-12 5.958E-11 1.510E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.510E-15 1.181E-12 1.653E-11 4.190E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.240E-15 1.042E-12 1.460E-11 3.700E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.560E-15 1.299E-12 1.819E-11 4.610E-17-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 4.970E-15 1.953E-12 2.734E-11 6.930E-17-l.OOOE+OO O.OOOE+OO O.OOOE+OO Xe-135 GONADS 1.170E-14 5.455E-12 1.194E-11 2.530E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 1.330E-14 5.325E-12 1.166E-11 2.470E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 1.130E-14 4.959E-12 1.086E-11 2.300E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 1.070E-14 4.959E-12 1.086E-11 2.300E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 2.570E-14 9.120E-12 1.997E-11 4.230E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 1.180E-14 5.023E-12 1.100E-11 2.330E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 1.080E-14 4.829E-12 1.058E-11 2.240E-16-l.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 1.190E-14 5.217E-12 1.142E-11 2.420E-16-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 3.120E-14 4.506E-11 9.867E-11 2.090E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Cs -134 GONADS 7.400E-14 4.607E-11 9.646E-10 1.600E-15-l.OOOE+00 1.300E-08 2.060E-08 BREAST 8.430E-14 4.406E-11 9.224E-10 1.530E-15-1.OOOE+00 1.080E-08 1.720E-08 LUNGS 7.370E-14 4.204E-11 8.802E-10 1.460E-15-1.OOOE+00 1.180E-08 1.760E-08 RED MARR 7.190E-14 4.262E-11 8.922E-10 1.480E-15-1.OOOE+00 1.180E-08 1.870E-08 BONE SUR 1.200E-13 6.105E-11 1.278E-09 2.120E-15-1.OOOE+00 l.100E-08 1.740E-08 THYROID 7.570E-14 4.377E-11 9.163E-10 1.520E-15-1.OOOE+00 1.110E-08 1.760E-08 REMAINDER 7.060E-14 4.147E-11 8.681E-10 1.440E-15-1.000E+00 1.390E-08 2.210E-08 EFFECTIVE 7.570E-14 4.377E-11 9.163E-10 1.520E-15-1.OOOE+00 1.250E-08 1.980E-08 SKIN(FGR) 9.450E-14 6.249E-11 1.308E-09 2.170E-15-1.OO0E+00 O.OOOE+00 O.OOOE+00 Cs-136 GONADS 1.040E-13 6.223E-11 1.102E-09 2.180E-15-1.OOOE+00 1.880E-09 3.040E-09 BREAST 1.180E-13 5.966E-11 1.056E-09 2.090E-15-1.OOOE+00 1.670E-09 2.650E-09 LUNGS 1.040E-13 5.710E-11 1.011E-09 2.000E-15-1.000E+00 2.320E-09 2.620E-09

CA06452 Rev. 000 Page 72 of 110 RED MARR 1.OlOE-13 5.824E-11 1.031E-09 2.040E-15-1.OOOE+00 1.860E-09 2.950E-09 BONE SUR 1.660E-13 8.422E-11 1.491E-09 2.950E-15-1.OOOE+00 1.700E-09 2.710E-09 THYROID 1.070E-13 5.852E-11 1.036E-09 2.050E-15-1.OOOE+00 1.730E-09 2.740E-09 REMAINDER 9.950E-14 5.652E-11 1.OO1E-09 1.980E-15-1.OOOE+00 2.190E-09 3.520E-09 EFFECTIVE 1.060E-13 5.966E-11 1.056E-09 2.090E-15-1.OOOE+00 1.980E-09 3.040E-09 SKIN(FGR) 1.250E-13 7.251E-11 1.284E-09 2.540E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Cs-137 GONADS 2.669E-14 1.669E-11 3.530E-10 5.840E-16-1.OOOE+00 8.760E-09 1.390E-08 BREAST 3.047E-14 1.596E-11 3.376E-10 5.585E-16-1.OOOE+00 7.840E-09 1.240E-08 LUNGS 2.649E-14 1.517E-11 3.209E-10 5.309E-16-1.OOOE+00 8.820E-09 1.270E-08 RED MARR 2.583E-14 1.542E-11 3.260E-10 5.394E-16-1.OOOE+00 8.300E-09 1.320E-08 BONE SUR 4.382E-14 2.238E-11 4.734E-10 7.832E-16-1.OOOE+00 7.940E-09 1.260E-08 THYROID 2.725E-14 1.588E-11 3.358E-10 5.556E-16-1.OOOE+00 7.930E-09 1.260E-08 REMAINDER 2.536E-14 1.490E-11 3.152E-10 5.215E-16-1.OOOE+00 9.120E-09 1.450E-08 EFFECTIVE 2.725E-14 1.585E-11 3.353E-10 5.546E-16-1.OOOE+00 8.630E-09 1.350E-08 SKIN(FGR) 4.392E-14 5.253E-11 1.11OE-09 1.836E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO Ba-139 GONADS 2.130E-15 3.368E-13 3.429E-13 4.790E-17-1.OOOE+00 2.560E-12 1.560E-12 BREAST 2.450E-15 3.297E-13 3.357E-13 4.690E-17-1.OOOE+00 2.460E-12 5.170E-13 LUNGS 2.030E-15 3.002E-13 3.057E-13 4.270E-17-1.OOOE+00 2.530E-10 3.890E-13 RED MARR 1.870E-15 2.932E-13 2.985E-13 4.170E-17-1.OOOE+00 3.410E-12 8.590E-13 BONE SUR 5.290E-15 6.841E-13 6.965E-13 9.730E-17-1.OOOE+00 2.490E-12 4.380E-13 THYROID 2.130E-15 3.044E-13 3.100E-13 4.330E-17-1.OOOE+00 2.400E-12 2.660E-13 REMAINDER 1.920E-15 2.932E-13 2.985E-13 4.170E-17-1.OOOE+00 4.820E-11 3.570E-10 EFFECTIVE 2.170E-15 3.227E-13 3.286E-13 4.590E-17-1.OOOE+00 4.640E-11 1.080E-10 SKIN(FGR) 6.160E-14 7.241E-11 7.373E-11 1.030E-14-1.OOOE+OO O.OOOE+OO O.OOOE+OO Ba-140 GONADS 8.410E-15 5.451E-12 9.607E-11 1.910E-16-1.OOOE+00 4.300E-10 9.960E-10 BREAST 9.640E-15 5.280E-12 9.305E-11 1.850E-16-1.OOOE+00 2.870E-10 1.590E-10 LUNGS 8.270E-15 4.852E-12 8.550E-11 1.700E-16-1.OOOE+00 1.660E-09 6.630E-11 RED MARR 7.930E-15 4.880E-12 8.601E-11 1.710E-16-1.OOOE+00 1.290E-09 4.390E-10 BONE SUR 1.550E-14 8.020E-12 1.413E-10 2.810E-16-1.OOOE+00 2.410E-09 5.530E-10 THYROID 8.530E-15 5.109E-12 9.003E-11 1.790E-16-1.OOOE+00 2.560E-10 5.250E-11 REMAINDER 7.890E-15 4.766E-12 8.399E-11 1.670E-16-1.OOOE+00 1.410E-09 7.370E-09 EFFECTIVE 8.580E-15 5.137E-12 9.053E-11 1.800E-16-1.OOOE+OO 1.OlOE-09 2.560E-09 SKIN(FGR) 2.520E-14 5.565E-11 9.808E-10 1.950E-15-1.OOOE+OO O.OOOE+OO O.OOOE+OO La-140 GONADS 1.140E-13 6.027E-11 4.425E-10 2.240E-15-1.OOOE+00 4.540E-10 1.340E-09 BREAST 1.290E-13 5.758E-11 4.228E-10 2.140E-15-1.OOOE+00 1.450E-10 1.800E-10 LUNGS 1.150E-13 5.596E-11 4.109E-10 2.080E-15-1.OOOE+00 4.210E-09 4.010E-11 RED MARR 1.140E-13 5.731E-11 4.208E-10 2.130E-15-1.OOOE+00 2.140E-10 2.810E-10 BONE SUR 1.690E-13 7.776E-11 5.709E-10 2.890E-15-1.OOOE+00 1.410E-10 9.770E-11 THYROID 1.180E-13 5.462E-11 4.010E-10 2.030E-15-1.OOOE+00 6.870E-11 6.400E-12 REMAINDER 1.11OE-13 5.569E-11 4.089E-10 2.070E-15-1.OOOE+00 2.120E-09 6.260E-09 EFFECTIVE 1.170E-13 5.812E-11 4.267E-10 2.160E-15-1.OOOE+00 1.310E-09 2.280E-09 SKIN(FGR) 1.660E-13 2.217E-10 1.628E-09 8.240E-15-1.OOOE+00 O.OOOE+O0 O.OOOE+0O La-141 GONADS 2.330E-15 7.315E-13 9.675E-13 4.740E-17-1.OOOE+O0 1.OlOE-11 3.770E-12 BREAST 2.640E-15 7.007E-13 9.267E-13 4.540E-17-1.OOOE+00 9.840E-12 7.070E-13 LUNGS 2.340E-15 6.713E-13 8.879E-13 4.350E-17-1.OOOE+00 6.460E-10 2.720E-13 RED MARR 2.310E-15 6.852E-13 9.063E-13 4.440E-17-1.OOOE+00 2.930E-11 1.070E-12 BONE SUR 3.490E-15 9.923E-13 1.312E-12 6.430E-17-1.OOOE+00 1.200E-10 6.060E-13 THYROID 2.390E-15 6.590E-13 8.716E-13 4.270E-17-1.OOOE+00 9.400E-12 5.290E-14 REMAINDER 2.260E-15 6.682E-13 8.838E-13 4.330E-17-1.OOOE+00 2.280E-10 1.240E-09

CA06452 Rev. 000 Page 73 of 110 EFFECTIVE 2.390E-15 7.007E-13 9.267E-13 4.S40E-17-1.000E+00 1.570E-10 3.740E-10 SKIN(FGR) 6.580E-14 1.667E-10 2.204E-10 1.080E-14-1.OOOE+00 O.OOOE+00 O.OOOE+00 La-142 GONADS 1.400E-13 1.978E-11 2.034E-11 2.540E-15-1.OOOE+00 1.660E-11 6.990E-11 BREAST 1.570E-13 1.885E-11 1.938E-11 2.420E-15-1.OOOE+O0 1.130E-11 1.540E-11 LUNGS 1.420E-13 1.846E-11 1.898E-11 2.370E-15-1.OOOE+00 3.010E-10 8.400E-12 RED MARR 1.420E-13 1.900E-11 1.954E-11 2.440E-15-1.OOOE+O0 1.360E-11 1.93OE-11 BONE SUR 1.950E-13 2.484E-11 2.554E-11 3.190E-15-1.OOOE+00 1.11OE-11 7.400E-12 THYROID 1.450E-13 1.768E-11 1.818E-11 2.270E-15-1.OOOE+OO 8.740E-12 1.160E-12 REMAINDER 1.380E-13 1.853E-11 1.906E-11 2.380E-15-1.OOOE+00 8.070E-11 5.200E-10 EFFECTIVE 1.440E-13 1.916E-11 1.970E-11 2.460E-15-1.OOOE+00 6.840E-11 1.790E-10 SKIN(FGR) 2.160E-13 9.111E-11 9.368E-11 1.170E-14-l'.OOOE+00 O.OOOE+O0 O.OOOE+00 Ce-141 GONADS 3.380E-15 2.213E-12 4.332E-11 7.710E-17-1.OOOE+OO 5.540E-11 1.080E-10 BREAST 3.930E-15 2.170E-12 4.247E-11 7.560E-17-1.OOOE+00 4.460E-11 1.11OE-11 LUNGS 3.170E-15 1. 951E-12 3 .820E-11 6.800E-17-1.OOOE+00 1.670E-08 1.43OE-12 RED MARR 2.830E-15 1.860E-12 3.641E-11 6.480E-17-1.OOOE+OO 8.960E-11 3.390E-11 BONE SUR 9.410E-15 5.166E-12 1.011E-10 1.800E-16-1.OOOE+00 2.54OE-10 2.300E-11 THYROID 3.350E-15 2.003E-12 3.922E-11 6.980E-17-1.OOOE+00 2.550E-11 1.800E-13 REMAINDER 2.980E-15 1.894E-12 3.708E-11 6.600E-17-1.OOOE+0O 1.260E-09 2.500E-09 EFFECTIVE 3.430E-15 2.118E-12 4 .146E-11 7.380E-17-1.OOOE+00 2.420E-09 7.830E-10 SKIN(FGR) 1. 020E-14 3.788E-12 7.416E-11 1.320E-16-1.OOOE+00 O.OOOE+00 O.OOOE+OO Ce-143 GONADS 1.280E-14 7.900E-12 4.958E-11 2.980E-16-1.OOOE+00 7.530E-11 2.120E-10 BREAST 1.470E-14 7.688E-12 4.825E-11 2.900E-16-1.OOOE+00 1.660E-11 2.320E-11 LUNGS 1.230E-14 6.893E-12 4.325E-11 2.600E-16-1.OOOE+00 3.880E-09 3.820E-12 RED MARR 1.170E-14 6.787E-12 4 .259E-11 2.560E-16-1.OOOE+00 2.960E-11 5.070E-11 BONE SUR 2.520E-14 1.323E-11 8.302E-11 4.990E-16-1.OOOE+00 1.640E-11 1.610E-11 THYROID 1.280E-14 7.211E-12 4.525E-11 2.720E-16-1.OOOE+00 6.230E-12 4 .350E-13 REMAINDER 1.170E-14 6.734E-12 4.226E-11 2.540E-16-1.OOOE+00 1.420E-09 3.890E-09 EFFECTIVE 1.290E-14 7.396E-12 4.642E-11 2.790E-16-1.OOOE+OO 9.160E-10 1.230E-09 SKIN(FGR) 3.960E-14 1.058E-10 6.638E-10 3.990E-15-1.OOOE+OO O.OOOE+0O O.OOOE+OO Ce-144 GONADS 2.725E-15 6.328E-13 1.319E-11 6.088E-17-1.OOOE+00 2.390E-10 6. 987E-11 BREAST 3.129E-15 6.274E-13 1.307E-11 5.922E-17-1.OOOE+00 3.480E-10 1.223E-11 LUNGS 2.639E-15 5.228E-13 1.089E-11 5.362E-17-1.OOOE+00 7.911E-07 6.551E-12 RED MARR 2.507E-15 4.755E-13 9.907E-12 5.247E-17-1.OOOE+00 2.880E-09 8.923E-11 BONE SUR 5.441E-15 1.646E-12 3.429E-11 1.127E-16-1.OOOE+00 4.720E-09 1.280E-10 THYROID 2.753E-15 5.529E-13 1.152E-11 5.418E-17-1.OOOE+O0 2.920E-10 5.154E-12 REMAINDER 2.534E-15 5.086E-13 1.060E-11 5.283E-17-1.OOOE+00 1.910E-08 1.890E-08 EFFECTIVE 2.773E-15 5. 909E-13 1.231E-11 5.766E-17-1.OOOE+00 1.OlOE-07 5.711E-09 SKIN(FGR) 8.574E-14 7.648E-13 1.594E-11 1.250E-14-1.OOOE+00 O.OOOE+00 O.OOOE+OO Pr-143 GONADS 2.130E-17 2.264E-14 4.032E-13 7.930E-19-1.OOOE+00 4 .370E-18 8.990E-18 BREAST 2.550E-17 2.330E-14 4.149E-13 8.160E-19-1.OOOE+OO 2.220E-18 1.090E-18 LUNGS 1.860E-17 1.642E-14 2.923E-13 5.750E-19-1.OOOE+00 1.330E-08 1.910E-19 RED MARR 1.620E-17 1.493E-14 2.659E-13 5.230E-19-1.OOOE+OO 1.480E-11 1.030E-12 BONE SUR 5.930E-17 5.454E-14 9.711E-13 1.910E-18-1.OOOE+OO 1.490E-11 1.030E-12 THYROID 2.050E-17 1.802E-14 3.208E-13 6.310E-19-1.OOOE+OO 1.680E-18 2.660E-20 REMAINDER 1.760E-17 1.642E-14 2.923E-13 5.750E-19-1.OOOE+OO 1.970E-09 4 .220E-09 EFFECTIVE 2.100E-17 2.002E-14 3.564E-13 7.010E-19-1.OOOE+00 2.190E-09 1.270E-09 SKIN(PGR) 1.760E-14 5.711E-11 1.017E-09 2.OOOE-15-1.OOOE+OO O. OOOE+00 O.OOOE+OO Nd-147 GONADS 6.130E-15 4.218E-12 7.235E-11 1.480E-16-1.OOOE+00 8.410E-11 1.790E-10

CA06452 Rev.000 Page 74 of 110 BREAST 7.120E-15 4.132E-12 7.088E-11 1.450E-16-1.OOOE+00 3.450E-11 1.870E-ll LUNGS 5.820E-15 3.648E-12 6.257E-11 1.280E-16-l.OOOE+00 1.060E-08 2.440E-12 RED MARR 5.400E-15 3.50SE-12 6.013E-11 1.230E-16-l.OOOE+00 9.190E-11 5.050E-ll BONE SUR 1.320E-14 8.265E-12 1.418E-10 2.900E-16-l.O0E+00 3.260E-10 2.220E-11 THYROID 6.120E-15 3.876E-12 6.648E-11 1.360E-16-l.OOOE+00 1.820E-11 2.640E-13 REMAINDER 5.530E-15 3.562E-12 6.111E-11 1.250E-16-l.OOOE+00 1.760E-09 3.760E-09 EFFECTIVE 6.190E-15 3.961E-12 6.795E-11 1.390E-16-1.OOOE+00 1.850E-09 1.180E-09 SKIN(FGR) 1.950E-14 3.135E-11 5.377E-10 l.100E-15-l.OOOE+00 O.OOOE+OO O.OOOE+OO Np-239 GONADS 7.530E-15 4.691E-12 4.380E-11 1.710E-16-i.OOOE+00 7.450E-11 1.620E-10 BREAST 8.730E-15 4.636E-12 4.329E-11 1.690E-16-l.OOOE+00 1.630E-11 1.720E-11 LUNGS 7.180E-15 4.115E-12 3.842E-11 1.500E-16-l.COOE+00 2.360E-09 2.400E-12 RED MARR 6.500E-15 4.005E-12 3.740E-11 1.460E-16-l.OOOE+00 2.080E-10 4.660E-ll BONE SUR 2.0O0E-14 i.C0lE-ll 9.349E-11 3.650E-16-l.OOOE+00 2.030E-09 3.590E-ll THYROID 7.520E-15 4.197E-12 3.919E-11 1.530E-16-l.OOOE+00 7.620E-12 2.070E-13 REMAINDER 6.760E-15 4.005E-12 3.740E-11 1.460E-16-l.OOOE+00 9.590E-10 2.770E-09 EFFECTIVE 7.690E-15 4.471E-12 4.175E-11 1.630E-16-i.OOOE+00 6.780E-10 8.820E-10 SKIN(FGR) 1.600E-14 7.215E-12 6.737E-11 2.630E-16-i.OOOE+CO O.OOOE+OC O.OOOE+CO Pu-238 GONADS 6.560E-18 4.291E-14 9.011E-13 1.490E-l8-i.OOOE+00 1.040E-05 2.330E-09 BREAST 1.270E-17 5.558E-14 1.167E-12 1.930E-18-l.OOOE+00 4.400E-10 1.800E-13 LUNGS 1.060E-18 2.267E-15 4.759E-14 7.870E-20-l.OOOE+00 3.200E-04 8.640E-14 RED MARR 1.680E-18 5.587E-15 1.173E-13 1.940E-i9-1.OOOE+00 5.800E-05 1.270E-08 BONE SUR 9.300E-18 3.514E-14 7.378E-13 1.220E-18-l.OOOE+00 7.250E-04 1.580E-07 THYROID 4.010E-18 9.792E-15 2.056E-13 3.400E-19-1.OOOE+00 3.860E-10 7.990E-14 REMAINDER l.990E-18 9.216E-15 1.935E-13 3.200E-19-l.OOOE+00 2.740E-05 2.180E-08 EFFECTIVE 4.880E-18 2.413E-14 5.068E-13 8.380E-19-1.OOOE+00 7.790E-05 1.340E-08 SKIN(FGR) 4.090E-17 2.776E-13 5.830E-12 9.640E-18-l.OOOE+OO O.OOOE+CO O.OOOE+CC Pu-239 GONADS 4.840E-18 1.768E-14 3.713E-13 6.140E-19-l.OOOE+00 1.200E-05 2.640E-09 BREAST 7.550E-18 2.238E-14 4.699E-13 7.770E-l9-l.OOOE+00 3.990E-10 1.210E-13 LUNGS 2.650E-18 2.267E-15 4.760E-14 7.870E-20-l.OOOE+00 3.230E-04 7.890E-14 RED MARR 2.670E-18 3.456E-15 7.258E-14 1.200E-19-i.OOOE+00 6.570E-05 1.410E-08 BONE SUR 9.470E-18 1.673E-14 3.514E-13 5.810E-19-l.OOOE+00 8.210E-04 1.760E-07 THYROID 3.880E-18 5.126E-15 1.077E-13 1.780E-19-l.OOOE+00 3.750E-10 7.500E-14 REMAINDER 2.860E-18 4.838E-15 1.016E-13 1.680E-19-l.OOOE+00 3.020E-OS 2.120E-08 EFFECTIVE 4.240E-18 1.057E-14 2.220E-13 3.670E-19-l.OOOE+00 8.330E-05 1.400E-08 SKIN(FGR) 1.860E-17 1.057E-13 2.220E-12 3.670E-18-l.OOOE+OO O.OOOE+OO O.OOOE+CO Pu-240 GONADS 6.360E-18 4.118E-14 8.649E-13 1.430E-18-l.OOOE+00 1.200E-05 2.640E-09 BREAST 1.230E-17 5.328E-14 1.119E-12 1.850E-18-l.OOOE+00 4.330E-10 1.730E-13 LUNGS l.O90E-18 2.249E-15 4.723E-14 7.810E-20-l.OOOE+00 3.230E-04 8.220E-14 RED MARR 1.650E-18 5.386E-15 1.131E-13 1.870E-i9-1.OOOE+00 6.570E-05 1.410E-08 BONE SUR 9.260E-18 3.398E-14 7.137E-13 1.180E-18-l.OOOE+00 8.210E-04 1.760E-07 THYROID 3.920E-18 9.446E-15 1.984E-13 3.280E-19-l.OOOE+00 3.760E-10 7.510E-14 REMAINDER 1.960E-18 8.870E-15 1.863E-13 3.080E-19-l.OOOE+00 3.020E-05 2.130E-08 EFFECTIVE 4.750E-18 2.313E-14 4.857E-13 8.030E-19-l.OOOE+00 8.330E-05 1.400E-08 SKIN(FGR) 3.920E-17 2.644E-13 5.552E-12 9.180E-18-1.OOOE+OO O.OOOE+CO O.OOOE+OO Pu-241 GONADS 7.190E-20 6.653E-17 1.396E-15 2.310E-21-1.OOOE+00 2.760E-07 5.660E-ll BREAST 8.670E-20 7.229E-17 1.517E-15 2.510E-21-i.OOOE+00 2.140E-11 2.790E-iS LUNGS 6.480E-20 4.090E-17 8.584E-16 1.420E-21-1.OOOE+00 3.180E-06 4.4BCE-15 RED MARR 5.630E-20 4.003E-17 8.403E-16 1.390E-21-l.OOOE+00 1.430E-06 2.780E-10 BONE SUR 2.190E-19 1.385E-16 2.90SE-15 4.810E-21-l.OOOE+00 1.780E-05 3.480E-09

CAO6452 Rev.O00 Page 75 of 110 THYROID 6.980E-20 4.522E-17 9.491E-16 1.570E-21-1.OOOE+00 9.150E-12 1.010E-15 REMAINDER 6.090E-20 4.291E-17 9.007E-16 1.490E-21-1.OOOE+00 6.020E-07 1.850E-10 EFFECTIVE 7.250E-20 5.558E-17 1.167E-15 1.930E-21-1.OOOE+00 1.340E-06 2.070E-10 SKIN(FGR) 1.170E-19 2.033E-16 4.268E-15 7.060E-21-1.OOOE+00 O.OOOE+00 O.OOOE+00 Am-241 GONADS 8.580E-16 9.360E-13 1.966E-11 3.250E-17-1.OOOE+00 3.250E-05 2.700E-07 BREAST 1.070E-15 1.014E-12 2.129E-11 3.520E-17-1.OOOE+00 2.670E-09 2.620E-11 LUNGS 6.740E-16 5.789E-13 1.216E-11 2.010E-17-1.OOOE+00 1.840E-05 3.360E-11 RED MARR 5.210E-16 4.838E-13 1.016E-11 1.680E-17-1.OOOE+00 1.740E-04 1.450E-06 BONE SUR 2.870E-15 2.678E-12 5.625E-11 9.300E-17-1.OOOE+00 2.170E-03 1.810E-05 THYROID 7.830E-16 6.365E-13 1.337E-11 2.210E-17-1.OOOE+00 1.600E-09 1.320E-11 REMAINDER 6.340E-16 5.933E-13 1.246E-11 2.060E-17-1.OOOE+00 7.820E-05 6.660E-07 EFFECTIVE 8.180E-16 7.920E-13 1.663E-11 2.750E-17-1.OOOE+00 1.200E-04 9.840E-07 SKIN(FGR) 1.280E-15 2.396E-12 5.032E-11 8.320E-17-1.OOOE+00 O.OOOE+00 0.OOOE+O0 Cm-242 GONADS 7.830E-18 4.893E-14 1.013E-12 1.700E-18-1.000E+00 5.700E-07 5.200E-09 BREAST 1.480E-17 6.159E-14 1.275E-12 2.140E-18-1.000E+00 9.440E-10 8.950E-12 LUNGS 1.130E-18 3.022E-15 6.257E-14 1.050E-19-1.OOOE+00 1.550E-05 8.840E-12 RED MARR 1.890E-18 6.562E-15 1.359E-13 2.280E-19-1.OOOE+00 3.900E-06 3.570E-08 BONE SUR 1.060E-17 4.231E-14 8.759E-13 1.470E-18-1.OOOE+00 4.870E-05 4.460E-07 THYROID 4.910E-18 1.261E-14 2.610E-13 4.380E-19-1.OOOE+00 9.410E-10 8.820E-12 REMAINDER 2.270E-18 1.079E-14 2.235E-13 3.750E-l9-l.OOE+00 2.450E-06 4.020E-08 EFFECTIVE 5.690E-18 2.751E-14 5.697E-13 9.560E-19-1.OOOE+00 4.670E-06 3.100E-08 SKIN(FGR) 4.290E-17 2.700E-13 5.589E-12 9.380E-18-1.OOOE+00 O.OOOE+00 O.OOOE+00 Cm-244 GONADS 6.900E-18 4.522E-14 9.492E-13 1.570E-18-1.OOOE+00 1.590E-05 1.330E-07 BREAST 1.330E-17 5.702E-14 1.197E-12 1.980E-18-1.OOOE+00 1.040E-09 8.820E-12 LUNGS 7.080E-19 2.592E-15 5.441E-14 9.000E-20-1.OOOE+00 1.930E-05 8.810E-12 RED MARR 1.460E-18 5.875E-15 1.233E-13 2.040E-19-1.OOOE+00 9.380E-05 7.820E-07 BONE SUR 8.820E-18 3.859E-14 8.101E-13 1.340E-18-1.OOOE+00 1.170E-03 9.770E-06 THYROID 4.190E-18 1.146E-14 2.406E-13 3.980E-19-1.OOOE+00 1.010E-09 8.440E-12 REMAINDER 1.810E-18 9.821E-15 2.062E-13 3.410E-19-1.OOOE+00 4.780E-05 4.150E-07 EFFECTIVE 4.910E-18 2.529E-14 5.308E-13 8.780E-19-1.000E+00 6.700E-05 5.450E-07 SKIN(FGR) 3.910E-17 2.506E-13 5.260E-12 8.700E-18-1.OOOE+00 O.OOOE+00 O.OOOE+00 Xe-133m GONADS 1.420E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 BREAST 1.700E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 LUNGS 1.190E-15 O.OOOE+00 O.OOOE+00 0.000E+00-1.000E+00 O.OOOE+00 O.OOOE+00 RED MARR 1.100E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 BONE SUR 3.230E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 THYROID 1.360E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 REMAINDER 1.150E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 0.000E+00 EFFECTIVE 1.370E-15 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 1.040E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 Xe-135m GONADS 2.000E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 BREAST 2.290E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 LUNGS 1.980E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 RED MARR 1.910E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 BONE SUR 3.500E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 THYROID 2.040E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00 REMAINDER 1.890E-14 O.OOOE+00 O.OOOE+00 0.000E+00-1.000E+00 0.000E+00 O.OOOE+00 EFFECTIVE 2.040E-14 O.OOOE+00 O.OOOE+00 0.000E+00-1.000E+00 O.OOOE+00 O.OOOE+00 SKIN(FGR) 2.970E-14 O.OOOE+00 O.OOOE+00 O.OOOE+00-1.OOOE+00 O.OOOE+00 O.OOOE+00

CA06452 Rev.000 Page 76 of 110 Xe-138 GONADS 5.590E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BREAST 6.320E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO LUNGS 5.660E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO RED MARR 5.600E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO BONE SUR 8.460E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO THYROID 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO REMAINDER 5.490E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO EFFECTIVE 5.770E-14 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO SKIN(FGR) 1.070E-13 O.OOOE+OO O.OOOE+OO O.OOOE+OO-1.OOOE+OO O.OOOE+OO O.OOOE+OO

CA06452 Rev.000 Page 77 of 110 ATTACHMENT Q MSLBFF OUTPUT FILE Cumulative Dose Summary

1. 1. 1. iiffii######################ififfif############iifiiffi######i#i###########iifi#############fi eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem)

O.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 5.7282E-01 2.0342E-02 1.3485E-01 4.7889E-03 1.5416E+00 4.8540E-02 0.500 8.5839E-01 3.0317E-02 2.0208E-01 7.1372E-03 3.1108E+00 9.7878E-02 0.800 1.3708E+00 4.8024E-02 3.2271E-01 1.1306E-02 6.2297E+00 1.9583E-01 1.100 1.8812E+00 6.5466E-02 4.4287E-01 1.S412E-02 9. 5428E+00 2.9975SE-01 1.400 2.3898E+00 8.2689E-02 5.6259E-01 1.9466E-02 1.2939E+01 4.0613E-01 1.700 2.8964E+00 9.9723E-02 6.8186E-01 2.3476E-02 1.6366E+01 5.1339E-01 2.000 3.4012E+00 1.1659E-01 8.0071E-01 2.7447E-02 1.9802E+01 6.2079E-01 2.300 3.4012E+00 1.1659E-01 8.0839E-01 2.7702E-02 2.3084E+01 7.2331E-01 2.600 3.4012E+00 1.1659E-01 8.1605E-01 2.7956E-02 2.6170E+01 8.1963E-01 2.900 3.4012E+00 1.1659E-01 8.2368E-01 2.8207E-02 2.9160E+01 9.1288E-01 3.200 3.4012E+00 1.1659E-01 8.3129E-01 2.8457E-02 3.2100E+01 1.0045E+00 3.500 3.4012E+00 1.1659E-01 8.3887E-01 2.8705E-02 3 .5013E+01 1.0952E+00 3.800 3.4012E+00 1.1659E-01 8.4643E-01 2.8951E-02 3.7907E+01 1.1853E+00 4.100 3.4012E+00 1.1659E-01 8.5396E-01 2.9197E-02 4 .0789E+01 1.2750E+00 4.400 3.4012E+00 1.1659E-01 8.6147E-01 2.9440E-02 4.3659E+01 1.3642E+00 4.700 3.4012E+00 1.1659E-01 8.6895E-01 2.9683E-02 4.6519E+01 1.4531E+00 5.000 3.4012E+00 1.1659E-01 8.7641E-01 2.9924E-02 4.9370E+01 1.5417E+00 5.300 3.4012E+00 1.1659E-01 8.8385E-01 3.0164E-02 5.2212E+01 1.6299E+00 5.600 3.4012E+00 1.1659E-01 8.9127E-01 3.0403E-02 5.5046E+01 1.7178E+00 5.900 3.4012E+00 1.1659E-01 8.9866E-01 3.0640E-02 5.7870E+01 1.8055E+00 6.200 3.4012E+00 1.1659E-01 9.0603E-01 3.0877E-02 6.0687E+01 1.8928E+00 6.500 3.4012E+00 1.1659E-01 9.1338E-01 3.1113E-02 6.3494E+01 1.9798E+00 6.800 3.4012E+00 1.1659E-01 9.2071E-01 3.1347E-02 6.6294E+01 2.0666E+00 7.100 3.4012E+00 1.1659E-01 9.2801E-01 3.1581E-02 6.9085E+01 2.1531E+00 7.400 3.4012E+00 1.1659E-01 9.3530E-01 3.1814E-02 7.1869E+01 2.2393E+00 7.700 3.4012E+00 1.1659E-01 9.4256E-01 3.2046E-02 7.4644E+01 2.3252E+00 8.000 3 .4012E+00 1.1659E-01 9.4980E-01 3.2277E-02 7.7412E+01 2.4108E+00 8.300 3.4012E+00 1.1659E-01 9.5352E-01 3.2398E-02 7.9683E+01 2.4811E+00 8.600 3.4012E+00 1.1659E-01 9.5722E-01 3.2520E-02 8.1334E+01 2.5322E+00 8.900 3.4012E+00 1.1659E-01 9.6091E-01 3.2640E-02 8.2697E+01 2.5744E+00 9.000 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.3117E+01 2.5874E+00 9.300 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.3986E+01 2.6143E+00 9.600 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4387E+01 2.6267E+00 9.900 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4573E+01 2.6324E+00 10.200 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4658E+01 2.6351E+00 24.000 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4732E+01 2.6375E+00 96.000 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4732E+01 2.6375SE+00 720.000 3.4012E+00 1.1659E-01 9.6214E-01 3.2681E-02 8.4732E+01 2.6375E+00 Worst Two-Hour Doses i iff f fi i i if##i#i##ifif#f#f#f#f##ifififi#f#fi#ififf#f#f#i#i#i#i#i#iff#f#f###ifif#f###################if

1. 1. 1. 1. 1. 1. ifif#f##i#i

CA06452 Rev. 000 Page 78 of 110 eab Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 1.0609E-02 3.4012E+00 1.1659E-01

CA06452 Rev.000 Page 79 of 110 ATTACHMENT R MSLBPRI OUTPUT FILE

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. #######U#####i###############

Cumulative Dose Summary

1. 1. 1. 1. 1. 1. 1. 1. i###########i##############Uf###################U#######iff#i###

eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 2.8035E-04 1.5927E-05 6.5999E-05 3.7495E-06 7.5456E-04 2.4570E-05 0.733 6.1545E-04 3.4470E-05 1.4489E-04 8.1148E-06 2.7444E-03 8.9995E-05 1.033 8.6578E-04 4.8075E-05 2.0382E-04 1.1318E-05 4.4263E-03 1.4605E-04 1.333 1.1153E-03 6.1468E-05 2.6255E-04 1.4471E-05 6.1761E-03 2.0487E-04 1.633 1.3639E-03 7.4671E-05 3.2109E-04 1.7579E-05 7.9557E-03 2.6509E-04 1.933 1.6118E-03 8.7702E-05 3.7944E-04 2.0646E-05 9.7467E-03 3.2602E-04 2.000 1.6667E-03 9.0575E-05 3.9238E-04 2.1323E-05 1.0145E-02 3.3961E-04 2.300 1.6667E-03 9.0575E-05 3.9615E-04 2.1519E-05 1.1864E-02 3.9845E-04 2.600 1.6667E-03 9.0575E-05 3.9991E-04 2.1713E-05 1.3483E-02 4.5419E-04 2.900 1.6667E-03 9.0575E-05 4.0366E-04 2.1905E-05 1.5053E-02 5.0832E-04 3.200 1.6667E-03 9.0575E-05 4.0739E-04 2.2094E-05 1.6595E-02 5.6156E-04 3.500 1.6667E-03 9.0575E-05 4.1112E-04 2.2282E-05 1.8122E-02 6.1426E-04 3.800 1.6667E-03 9.0575E-05 4.1483E-04 2.2469E-05 1.9639E-02 6.6657E-04 4.100 1.6667E-03 9.0575E-05 4.1853E-04 2.2653E-05 2.1149E-02 7.1860E-04 4.400 1.6667E-03 9.0575E-05 4.2222E-04 2.2836E-05 2.2653E-02 7.7037E-04 4.700 1.6667E-03 9.0575E-05 4.2590E-04 2.3018E-05 2.4152E-02 8.2191E-04 5.000 1.6667E-03 9.0575E-05 4.2957E-04 2.3198E-05 2.5646E-02 8.7322E-04 5.300 1.6667E-03 9.0575E-05 4.3322E-04 2.3376E-05 2.7136E-02 9.2433E-04 5.600 1.6667E-03 9.0575E-05 4.3687E-04 2.3554E-05 2.8621E-02 9.7523E-04 5.900 1.6667E-03 9.0575E-05 4.4050E-04 2.3730E-05 3.0102E-02 1.0259E-03 6.200 1.6667E-03 9.0575E-05 4.4413E-04 2.3905E-05 3.1578E-02 1.0764E-03 6.500 1.6667E-03 9.0575E-05 4.4774E-04 2.4079E-05 3.3050E-02 1.1267E-03 6.800 1.6667E-03 9.0575E-05 4.5135E-04 2.4252E-05 3.4518E-02 1.1768E-03 7.100 1.6667E-03 9.0575E-05 4.5494E-04 2.4424E-05 3.5982E-02 1.2266E-03 7.400 1.6667E-03 9.0575E-05 4.5852E-04 2.4594E-05 3.7442E-02 1.2765E-03 7.700 1.6667E-03 9.0575E-05 4.6210E-04 2.4764E-05 3.8897E-02 1.3261E-03 8.000 1.6667E-03 9.0575E-05 4.6566E-04 2.4933E-05 4.0349E-02 1.3755E-03 8.300 1.6667E-03 9.0575E-05 4.6749E-04 2.5048E-05 4.1552E-02 1.4169E-03 8.600 1.6667E-03 9.0575E-05 4.6931E-04 2.5162E-05 4.2438E-02 1.4480E-03 8.900 1.6667E-03 9.0575E-05 4.7113E-04 2.5276E-05 4.3168E-02 1.4739E-03 9.000 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.3392E-02 1.4818E-03 9.300 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.3866E-02 1.4992E-03 9.600 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4095E-02 1.5084E-03 9.900 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4206E-02 1.5136E-03 10.200 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4260E-02 1.5167E-03 24.000 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4310E-02 1.5238E-03 96.000 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4310E-02 1.5238E-03 720.000 1.6667E-03 9.0575E-05 4.7173E-04 2.5313E-05 4.4310E-02 1.5238E-03 Worst Two-Hour Doses

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. fiffifiififi#UUU#ifU

CA06452 Rev.000 Page 80 of 110 eab Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 3.8893E-05 1.6667E-03 9.0575E-0S

CA06452 Rev.000 Page 81 of 110 ATTACHMENT S MSLBSEC OUTPUT FILE Cumulative Dose Summary eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 6.7625E-01 2.1067E-02 1.5920E-01 4.9595SE-03 2.9685E+00 9.1164E-02 0.733 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 5.3816E+00 1.6526E-01 1.033 6.7625E-01 2.1067E-02 1.5920E-01 4.9595SE-03 6.1463E+00 1.8874E-01 1.333 6.7625E-01 2.1067E-02 1.5920E-01 4.9S95E-03 6.5170E+00 2.0012E-01 1.633 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.6967E+00 2.0563E-01 1.933 6.7625E-01 2.1067E-02 1.5920E-01 4.9S95E-03 6.7838E+00 2.0831E-01 2.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.7960E+00 2.0868E-01 2.300 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8320E+00 2.0978E-01 2.600 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8494E+00 2.1032E-01 2.900 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8578E+00 2.1058E-01 3.200 6.7625E-01 2.1067E-02 1.5920E-01 4.9595SE-03 6.8619E+00 2.1071E-01 3.500 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8639E+00 2.1077E-01 3.800 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8649E+00 2.1080E-01 4.100 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8654E+00 2.1081E-01 4.400 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8656E+00 2.1082E-01 4.700 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8657E+00 2.1082E-01 5.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8657E+00 2.1082E-01 5.300 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 5.600 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 5.900 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 6.200 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 6.500 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 6.800 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 7.100 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 7.400 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 7.700 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 8.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 8.300 6 .7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 8.600 6.7625E-01 2.1067E-02 1.5920E-01 4.9595SE-03 6.8658E+00 2.1082E-01 8.900 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 9.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 9.300 6.7625E-01 2.1067E-02 1.5920E-01 4.9S95E-03 6.8658E+00 2.1082E-01 9.600 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 9.900 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 10.200 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 24.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595SE-03 6.8658E+00 2.1082E-01 96.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 720.000 6.7625E-01 2.1067E-02 1.5920E-01 4.9595E-03 6.8658E+00 2.1082E-01 f#fN#ff#####e###ff###f######f T####f-######uD####ose#s ffff#ff#t#l###f Worst Two-Hour Doses

1. 1. # ## # ## # ##f###########f###ffffff########ff#

ffffff#fl##f####f f#ffff######"#u#jt#f

CA06452 Rev. 000 Page 82 of 110 eab Time Whole Body Thyroid TEDE Mhr) (rem) (rem) (rem) 0.0 3.1755E-04 6.7625E-01 2.1067E-02

CA06452 Rev.000 Page 83 of 110 ATTACHMENT T MSLBPIS OUTPUT FILE Cumulative Dose Summary eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 1.6821E-02 5.5276E-04 3.9599E-03 1.3013E-04 4.5274E-02 1.4101E-03 0.733 3.6927E-02 1.2111E-03 8.6932E-03 2.8512E-04 1.6467E-01 5.1272E-03 1.033 5.1947E-02 1.7015E-03 1.2229E-02 4.0055E-04 2.6558E-01 8.2679E-03 1.333 6.6916E-02 2.1891E-03 1.5753E-02 5.1534E-04 3.7056E-01 1.1535E-02 1.633 8.1835E-02 2.6741E-03 1.9265E-02 6.2952E-04 4.7734E-01 1.4856E-02 1.933 9.6706E-02 3.1566E-03 2.2766E-02 7.4311E-04 5.8480E-01 1.8198E-02 2.000 1.OOOOE-01 3.2635E-03 2.3543E-02 7.6828E-04 6.0872E-01 1.8941E-02 2.300 1.OOOOE-0l 3.2635E-03 2.3769E-02 7.7561E-04 7.1182E-01 2.2147E-02 2.600 1.OOOOE-01 3.2635E-03 2.3995E-02 7.8290E-04 8.0900E-01 2.5167E-02 2.900 1.OOOOE-01 3.2635E-03 2.4219E-02 7.9016E-04 9.0315E-01 2.8092E-02 3.200 1.OOOOE-01 3.2635E-03 2.4444E-02 7.9739E-04 9.9569E-01 3.0967E-02 3.500 1.OOOOE-01 3.2635E-03 2.4667E-02 8.0459E-04 1.0873E+00 3.3812E-02 3.800 1.OOOOE-01 3.2635E-03 2.4890E-02 8.1175E-04 1.1783E+00 3.6637E-02 4.100 1.OOOOE-01 3.2635E-03 2.5112E-02 B.1889E-04 1.2689E+00 3.9449E-02 4.400 1.0000E-01 3.2635E-03 2.5333E-02 8.2600E-04 1.3592E+00 4.2249E-02 4.700 1.OOOOE-01 3.2635E-03 2.5554E-02 8.3308E-04 1.4491E+00 4.5039E-02 5.000 1.OOOOE-01 3.2635E-03 2.5774E-02 8.4013E-04 1.5388E+00 4.7819E-02 5.300 1.OOOOE-01 3.2635E-03 2.5993E-02 8.4715E-04 1.6281E+00 5.0590E-02 5.600 1.OOOOE-01 3.2635E-03 2.6212E-02 8.5415E-04 1.7172E+00 5.3352E-02 5.900 1.OOOOE-01 3.2635E-03 2.6430E-02 8.6113E-04 1.8061E+00 5.6105E-02 6.200 1.OOOOE-01 3.2635E-03 2.6648E-02 8.6807E-04 1.8947E+00 5.8850E-02 6.500 1.OOOOE-01 3.2635E-03 2.6864E-02 8.7500E-04 1.9830E+00 6.1586E-02 6.800 1.OOOOE-01 3.2635E-03 2.7081E-02 8.8190E-04 2.0711E+00 6.4314E-02 7.100 1.OOOOE-01 3.2635E-03 2.7296E-02 8.8877E-04 2.1589E+00 6.7033E-02 7.400 1.OOOOE-01 3.2635E-03 2.7511E-02 8.9562E-04 2.2465E+00 6.9744E-02 7.700 1.OOOOE-01 3.2635E-03 2.7726E-02 9.0245E-04 2.3338E+00 7.2447E-02 8.000 1.OOOOE-01 3.2635E-03 2.7939E-02 9.0925E-04 2.4209E+00 7.5142E-02 8.300 1.OOOOE-01 3.2635E-03 2.8049E-02 9.1284E-04 2.4931E+00 7.7377E-02 8.600 1.OOOOE-Ol 3.2635E-03 2.8158E-02 9.1642E-04 2.5463E+00 7.9021E-02 8.900 1.OOOOE-01 3.2635E-03 2.8267E-02 9.1998E-04 2.5901E+00 8.0378E-02 9.000 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6035E+00 8.0794E-02 9.300 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6319E+00 8.1673E-02 9.600 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6457E+00 8.2100E-02 9.900 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6523E+00 8.2308E-02 10.200 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6556E+00 8.2409E-02 24.000 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6586E+00 8.2508E-02 96.000 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6586E+00 8.2508E-02 720.000 1.OOOOE-01 3.2635E-03 2.8304E-02 9.2117E-04 2.6586E+00 8.2508E-02 Worst Two-Hour Doses

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. f########ffff ###### #####f#########ff

1. 1. 1. f ####ffff#fff###ff########

CA06452 Rev.000 Page 84 of 110 eab Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 1.6262E-04 l.OOOOE-01 3.2635E-03

CA06452 Rev.000 Page 85 of 110 A1TACHMENT U MSLBCIS OUTPUT FILE Cumulative Dose Summary eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 1.7970E-03 7.2324E-05 4.2304E-04 1.7026E-05 3.4278E-03 1.1044E-04 0.733 8.6608E-03 3.2592E-04 2.0389E-03 7.6727E-05 2.6931E-02 8.6165E-04 1.033 1.7139E-02 6.3079E-04 4.0349E-03 1.4850E-04 6.3602E-02 2.0291E-03 1.333 2.8441E-02 1.0309E-03 6.6956E-03 2.4268E-04 1.1897E-01 3.7873E-03 1.633 4 .2541E-02 1.5239E-03 1.0015E-02 3.5874E-04 1.9390E-01 6.1612E-03 1.933 5.9411E-02 2.1079E-03 1.3986E-02 4.9624E-04 2.8870E-01 9.1594E-03 2.000 6.3535E-02 2.2499E-03 1.4957E-02 5.2966E-04 3.1248E-01 9.9106E-03 2.300 6.3535E-02 2.2499E-03 1.5266E-02 5.4025E-04 4.2560E-01 1.3482E-02 2.600 6.3535E-02 2.2499E-03 1.5617E-02 5.5218E-04 5.4976E-01 1.7396E-02 2.900 6.3535E-02 2.2499E-03 1.6008E-02 5.6543E-04 6.8790E-01 2.1747E-02 3.200 6.3535E-02 2.2499E-03 1.6441E-02 5.7999E-04 8.4138E-01 2.6575E-02 3.500 6.353SE-02 2.2499E-03 1.6914E-02 S.9584E-04 1.0108E+00 3 .1898E-02 3.800 6.3535E-02 2.2499E-03 1.7427E-02 6.1297E-04 1.1963E+00 3.7724E-02 4.100 6.3535E-02 2.2499E-03 1.7980E-02 6.3136E-04 1.3980E+00 4.4052E-02 4.400 6.3535E-02 2.2499E-03 1.8573E-02 6.5100E-04 1.6159E+00 5.0880E-02 4.700 6.3535E-02 2.2499E-03 1.9204E-02 6.7188E-04 1.8498E+00 5.8207E-02 5.000 6.3535E-02 2.2499E-03 1.9875E-02 6.9399E-04 2.0996E+00 6.6028E-02 5.300 6.3535E-02 2.2499E-03 2.0585E-02 7.1731E-04 2.3652E+00 7.4339E-02 5.600 6.3535E-02 2.2499E-03 2.1332E-02 7.4184E-04 2.6466E+00 8.3137E-02 5.900 6.3535E-02 2.2499E-03 2.2118E-02 7.6756E-04 2.9436E+00 9.2418E-02 6.200 6.3535E-02 2.2499E-03 2.2942E-02 7.9447E-04 3.2560E+00 1.0218E-01 6.500 6.3535E-02 2.2499E-03 2.3803E-02 8.225SE-04 3.5839E+00 1.1241E-01 6.800 6.3535E-02 2.2499E-03 2.4702E-02 8.5180E-04 3.9270E+00 1.2312E-01 7.100 6.3535E-02 2.2499E-03 2.5637E-02 8.8221E-04 4 .2853E+00 1.3430E-01 7.400 6.3535E-02 2.2499E-03 2.6609E-02 9.1376E-04 4.6587E+00 1.4594E-01 7.700 6.3535E-02 2.2499E-03 2.7618E-02 9.4645E-04 5.0471E+00 1.5804E-01 8.000 6.3535E-02 2.2499E-03 2.8664E-02 9.8027E-04 5.4503E+00 1.7060E-01 8.300 6.3535E-02 2.2499E-03 2.9220E-02 9.9891E-04 5.7945E+00 1.8132E-01 8.600 6.3535E-02 2.2499E-03 2.9794E-02 1.0181E-03 6.0549E+00 1.8943E-01 8.900 6.3535E-02 2.2499E-03 3.0387E-02 1.0379E-03 6.2778E+00 1.9637E-01 9.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.3481E+00 1.9856E-01 9.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.3482E+00 1.9856E-01 9.400 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.5274E+00 2.0414E-01 9.700 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.5841E+00 2.0590E-01 10.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.6116E+00 2.0676E-01 10.300 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.6249E+00 2.0717E-01 24.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.6373E+00 2.0757E-01 96.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.6373E+00 2.0757E-01 720.000 6.3535E-02 2.2499E-03 3.0589E-02 1.0446E-03 6.6373E+00 2.0757E-01

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. T###ou###s######

Worst Two-Hour Doses

CA06452 Rev.OOO I Page 86 of 110 eab Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 2.5157E-04 6.3535E-02 2.2499E-03

CA06452 Rev.000 Page 87 of 110 ATTACHMENT V MSLBFFCS OUTPUT FILE Cumulative Dose Summary i###fii######ifi##########f###f################ifii~ffi########## ###f####ffi~ffiiiii#i###

eab lpz cr Time Thyroid TEDE Thyroid TEDE Thyroid TEDE (hr) (rem) (rem) (rem) (rem) (rem) (rem) 0.000 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 O.OOOOE+00 0.333 1.0321E-02 1.1715E-02 2.4296E-03 2.7578E-03 2.7794E-02 3.1019E-02 0.500 1.5483E-02 1.7574E-02 3.6449E-03 4.1373E-03 5.6144E-02 6.2659E-02 0.800 2.4773E-02 2.8119E-02 5.8319E-03 6.6197E-03 1.1259E-01 1.2566E-01 1.100 3.4062E-02 3.8663E-02 8.0187E-03 9.1019E-03 1.7274E-01 1.9278E-01 1.400 4.3350E-02 4.9206E-02 1.0205E-02 1.1584E-02 2.3458E-01 2.6180E-01 1.700 5.2638E-02 5.9748E-02 1.2392E-02 1.4066E-02 2.9721E-01 3.3170E-01 2.000 6.1925E-02 7.0290E-02 1.4578E-02 1.6547E-02 3.6020E-01 4.0200E-01 2.300 6.1925E-02 7.0290E-02 1.4720E-02 1.6708E-02 4.2058E-01 4.6938E-01 2.600 6.1925E-02 7.0290E-02 1.4862E-02 1.6869E-02 4.7753E-01 5.3294E-01 2.900 6.1925E-02 7.0290E-02 1.5004E-02 1.7030E-02 5.3290E-01 5.9474E-01 3.200 6.1925E-02 7.0290E-02 1.5146E-02 1.7191E-02 5.8754E-01 6.5571E-01 3.500 6.1925E-02 7.0290E-02 1.5288E-02 1.7352E-02 6.4183E-01 7.1631E-01 3.800 6.1925E-02 7.0290E-02 1.5429E-02 1.7513E-02 6.9597E-01 7.7673E-01 4.100 6.1925E-02 7.0290E-02 1.5571E-02 1.7674E-02 7.5003E-01 8.3706E-01 4.400 6.1925E-02 7.0290E-02 1.5713E-02 1.7835E-02 8.0405E-01 8.9735E-01 4.700 6.1925E-02 7.0290E-02 1.5855E-02 1.7996E-02 8.5806E-01 9.5762E-01 5.000 6.1925E-02 7.0290E-02 1.5997E-02 1.8157E-02 9.1205E-01 1.0179E+00 5.300 6.1925E-02 7.0290E-02 1.6138E-02 1.8318E-02 9.6604E-01 1.0781E+00 5.600 6.1925E-02 7.0290E-02 1.6280E-02 1:8479E-02 1.0200E+00 1.1384E+00 5.900 6.1925E-02 7.0290E-02 1.6422E-02 1.8640E-02 1.0740E+00 1.1986E+00 6.200 6.1925E-02 7.0290E-02 1.6564E-02 1.8801E-02 1.1280E+00 1.2589E+00 6.500 6.1925E-02 7.0290E-02 1.6705E-02 1.8962E-02 1.1819E+00 1.3191E+00 6.800 6.1925E-02 7.0290E-02 1.6847E-02 1.9123E-02 1.2359E+00 1.3793E+00 7.100 6.1925E-02 7.0290E-02 1.6989E-02 1.9283E-02 1.2899E+00 1.4395E+00 7.400 6.1925E-02 7.0290E-02 1.7131E-02 1.9444E-02 1.3438E+00 1.4997E+00 7.700 6.1925E-02 7.0290E-02 1.7272E-02 1.9605E-02 1.3978E+00 1.5600E+00 8.000 6.1925E-02 7.0290E-02 1.7414E-02 1.9766E-02 1.4517E+00 1.6202E+00 8.300 6.192SE-02 7.0290E-02 1.7487E-02 1.9850E-02 1.4961E+00 1.6697E+00 8.600 6.1925E-02 7.0290E-02 1.7560E-02 1.9934E-02 1.5284E+00 1.7058E+00 8.900 6.1925E-02 7.0290E-02 1.7632E-02 2.0018E-02 1.5552E+00 1.7356E+00 9.000 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5634E+00 1.7448E+00 9.300 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5805E+00 1.7639E+00 9.600 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5884E+00 1.7727E+00 9.900 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5921E+00 1.7768E+00 10.200 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5938E+00 1.7787E+00 24.000 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5952E+00 1.7803E+00 96.000 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5952E+00 1.7803E+00 720.000 6.1925E-02 7.0290E-02 1.7657E-02 2.0046E-02 1.5952E+00 1.7803E+00 Worst Two-Hour Doses ififif iff f f fif#i i i ififf f f iifififif f f fi i

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. f

CA06452 Rev. 000 Page 88 of 110 eab Time Whole Body Thyroid TEDE (hr) (rem) (rem) (rem) 0.0 1.2538E-03 6.1925E-02 7.0290E-02

CA06452 Rev.OOO Page 89 of 110 ATTACHMENT W ETP-97-064R CONTROL ROOM INLEAKAGE RESULTS

• GOPY AKF CALVERT CLIFFS NUCLEAR POWER PLANT TECHNICAL PROCEDURE

.. 14% ENGINEERING TEST PROCEDURE UNIT 0 ETP 97-064R CONTROL ROOM HVAC SYSTEM INLEAKAGE TEST REVISION 0 Effective Date I////fT7-Safety Related_ X Non-Safety Related ._:__

Writer. D. T. McElheny Sponsor: V. P. Spunar

-0c0opED i

I

CP5eo 9/.

FT-86 (Rev. 1 10197) - ACU911 Attachment 2 Page 37 of 40

' NUCON International, Inc.

. .eaTsDa

. D y

- . Decay Test Data' Estitihatdd duration oftest: *

'2,.bq=S Begnning cpncentr-ition (C ' -19.O vvb Ending concentration (tC(O)): 2 7ppb Time at start oftest: . 1inie"ze:ro" for decav test was at 01:15 hours on 18 Nov 97.

Time at end of test: J). 12..oiirs on 19 Nov 97 Sample time intervals: .15 nminuti t, except for last sample .

Time / Sample Concentration TimelConc. Tim&1Conc. TimelConc. Time/Conc.

01:151 19.0 . . .

01:301 14.8 01:451 12.1 I I.

I 02.Y0/ 8.3 _ . ..

02:15/ 6.7 '

02:30/ 5.1 . I . /

_/

03:12/ 2.7 /

(A) Air Change Rate (;/min) (Q)Inleakage Flow Rate (CFM) 0.0170 4300 95% Confidence Limit 95% Confidence Interval

(,)= 0.017Q aQ&QQ

• _ 4000 < Q< 4600 -

Comments: Decay sariIples taken at a sample port on the discharae off1 1 return fan. All sample concentrations in the ppb range.

Testpersonnel signature(s) and date: NUCON International Inc.

fS5C 9Z

-86 (Rev. 1 10/97) AiCU#12 Attachment 2 Page37 of 40 NUCON International, Inc.

C] i. ..

Decay Test Data Estimated duration of test - 1.4 hours4.62963e-5 days <br />0.00111 hours <br />6.613757e-6 weeks <br />1.522e-6 months <br /> Beginning concentration (Ct): . 40.5 ppb Ending concentration (C(O)): 14.2 rnb Time at start of test: . Time "zero" for decay test was at 23:16 hours on 19 Nov 97.

Tume at end of test: M-46-hoursm6iO Nov 97 . .

. Sample timeiintervals: 15 minute Time / Sample Concentration Time/Cone. -Time/Conc. Time/Cone. Time/Couc.

23:16/ 40.5 23:31/ 35.2 . . I I 23:46/ 21.2 / /- /

00:01/ 26.7 I I 00:16/ 20.3 I

00:31 / 16.7 /

00:46/ 14.2 (A) Air Change Rate (1/min) (Q) Inleakage Flow Rate (CFM 0.0118 .

• 3000 .

95% Confidence Limit 95% Confidence Interval (A4)= 0.DISB ,.Q2 .V22Q0 <Q < 3300 Comments: DecaOX xnibles taken at a sample port on the discharge oft#12 returm fan. Tbese samples were taken in c6iiuncfion wyith samInes taken in CAS and on both CSR remtum ducts.

The decay sample taken at 23:46 hours was disregarded due to a faulty Ras sample bag. -

OA*l O(

Test persorrnel signa e(s) and date: CON International Inc.

kp CALVERT CLIFFS NUCLEAR POWER PLANT TECHNICAL PROCEDURE ENGINEERING TEST PROCEDURE UNIT 0 ETP 97-064R 27 CONTROL ROOM HVAC SYSTEM INLEAKAGE TEST REVISION 0 Effective Date 1 ?

Safety RelatedZX Non-Safety Related

• ' ~COPY."

Writer: D.T. McElheny Sponsor V. P. Spunar i

bt / 6^A"V Ao>

a,f  ? -r 7 .

-7 NUCON International, Inc. TELEPHONE: (614) 846-5710 OUTSIDE OHIO: 1.800-992-5192 60 P.O. BOX 29151 7000 HUNTLEY ROAD COLUMBUS, OHIO 43229 U.SA.

FAX: (614) 431.0858

_E C

~Control Room In leakage Test Report performed for:

Baltimore Gas and Electric Company Calvert Cliffs Nuclear Power Station 1850 Calvert Cliffs Pkwv.

Lusby, Maryland 20657 P.O. No. 16582 20 April 1998 Distribution:

BG&E:

Dale McElheny (1)

• NUCON:

12BG847 MVF (1)

Field Test (1)

QA.. (1)

Marketing (1)

NUCON 12BG847 /02

6q-oGVL 4.O

• 6se- 9s 5' FT-86 (Rev. 1 10/97) ACU#11 Trip 2 Initial CharacterizationTest Attachment 2 Page 37 of 40 Decay Test Data -

Estimated duration of test: 120 minutes Beginning concentration (Ct): 25.0 ppb Ending concentration (C(O)): 4.1 Rpb Time at start of test: Time "zero" for decay test was at 22:03 hrs. on 10 Feb 98 Time at end of test: 00:03 hrs. on 11 Feb 98 Sample time intervals: 20 minutes apart Time / Sample Concentration Time/Conc. TimelConc. TimelConc. Time/Couc.

22:03 / 25.0 l

• 22:23 /17.9 22:43 /11.9 I.

/

23:03 / 9.7 I.

23:23 / 9.0 l */ I.

23:43 /5.7 /o_ /

00:03/ 4.1 /

(A) Air Change Rate ( 1/m.mn) (Q) Inleakage Flow Rate (CFM) 0.0143 _ ._

95% Confidence Limit 95% Confidence Interval

• (A) = 0.0143 E 0.0025 3000 <Q< -4T

• yzlo-o Comments: Decay samples taken at a samRle port on the discharge of #II return fan. All sample concentrations in the ppb range.

Test personnel signature(s) and date: NUCON International Inc.

44oi!Y'2 Avc.

Os 9; FT-86 (Rev. 1 10/97) ACU#12 Tri, 2n tial CharacterizationTest Attachment 2 Page 37 of 40 Decay Test Data Estimated duration of test: 120 minutes Beginning concentration (Ct): 47 ppb Ending concentration (C(O)): 12.6 ppb Time at start of test: Time "zero" for decay test was at 02:05 hrs. on 11 Feb 98 Time at end of test: 04:05 hrs. on 11 Feb 98 Sample time intervals: 20 minutes apart Time / Sample Concentration Time/Conc. Time/Cone. Time/Conc. Time/Cone.

02:05/ 47.0 /

/ / . -

02:25 / 33.2 /. /

02:45 / 27.4

/

03:05 /24.8 / I 03:25 / 21.4 / l

. 03:45/16.1 / / I 04:05/ 12.6 /

(A) Air Change Rate ( 1/min) (Q) Inleakage Flow Rate (CFM) 0.0101 2550 95% Confidence Limit 95% Confidence Interval

. (A)= 0.0101 E 0.0018 2100 <Q< 3000 Comments: Decay samples taken at a sample port on the discharge of #12 return fan. All sample concentrations in the ppb range.

Test personnel signature(s) and date: NUCON International Inc.

ciao 6 C/ft ANDez cao~W . *

/e d4A 7 CALVERT CLIFFS NUCLEAR POWER PLANT TECHNICAL PROCEDURE ENGINEERING TEST PROCEDURE UNIT 0' ETP 97-064R CONTROL ROOM HVAC SYSTEM INLEAKAGE TEST Sfl\

REVISION 0 Effective Date / /// 7

• Safety RelatedX Non-Safety Related __

LO Writer D.T. McElheny Sponsor V. P. Spunar

alt I, . c^. La

3) /1 A5 R .

TELEPHONE: (614) 846-5710 NUCON International, Inc.

El P.O. BOX 29151 7000 HUNTLEY ROAD COLUMBUS, OHIO 43229 U.S.A.

OUTSIDE OHIO: 1-800-992-5192 FAX: (614) 431.0858 Control Room Inleakage Test Report performed for:

Baltimore Gas and Electric Company Calvert Cliffs Nuclear Power Station 1850 Calvert Cliffs Pkwy.

Lusby, Maryland

'20657 P.O. No. 16582 20 April 1998 Distribution:

BG&E:

Dale McElheny (1)

NUCON:

12BG847 WF(1)

Field Test (1)

QA (1)

Marketing (1)

NUCON 12BG847 /02

£ G4a~5L tegzD

.FT-86 (Rev. 1 10/97) A CU #11 Trio 2 Test wlTemporaryModification In-Place Attachment 2 Page 37 of 40 Decay Test Data Estimated duration of test: 120 minutes Beginning concentration (Ct): 37.5 ppb Ending concentration (C(O)): 9.2 Pyb Time at start of test: Time "zero" for decaU test was at 01:15 hrs on 12 Feb 98 Time at end of test: 03:15 hrs on 12 Feb 98 Sample time intervals: 20 minutes apart Time / Sample Concentration Time/Conc. TimelConc. TimeIConc. TimelConc.

1:15 / 37.5 1:35 /28.1 /

/

1:55 / 24.7 /

2:15 / 19.3 l

/ /

2:35 / 15.7

/

• I /

2:55 / 11.7

/

3:15 / 9.2 (A) Air Change Rate ( min-) (Q) Inleakage Flow Rate (CFM) 0.0115 2.900 95% Confidence Limit 95% Confidence Interval (A)= 0.0115 + .0010. . 2650 <Q< 3150 Comments: Decay samples taken at a sample port on the discharge of #1 1 return fan. All sample concentrations in the pub range.

Test personnel signature(s) and date: NUCON International Inc.

r4 oy.5*z/le41CO FT-86 (Rev. 1 10/97) ACUt#12 trip 2 Test w/Temporary ModiricationIn-place Attachment 2 Page 37 of 40 Decay Test Data Estimated duration of test: 120 minutes Beginning concentration (Ct): 37.5 ppb Ending concentration (C(O)): 9.2 ppb Time at start of test: Time "zero" for decay test was at 21:25 hrs. on 11 Feb 98 Time at end of test: 23:25 hrs. on 11 Feb 98 Sample time intervals: 20 minutes apart Time / Sample Concentration

• Time/Conc. Time/Conc. Time/Cone. Time/Conc.

21:25 / 37.6 l 21:45/30.2 l /

22:05 /25.2 I

/ /

22:25 / 22.7 22:45 / 15.5 /

/

23:05 / 13.4 /

/ /

23:25 / 10.5 (A) Air Change Rate (1/min) (Q) Inleakage Flow Rate (CFM) 0.0109 2,750 95% Confidence Limit 95% Confidence Initerval (A)= 0.0109 4_ .0015 . 2370 <Q< 3130 Comments: Decay samples taken at a sample port on the discharge of #12 return fan. All samTle concentrations in the Dab range.

Test personnel signature(s) and date: NUCON International Inc.

CALVERT CLIFFS NUCLEAR POWER PLANT TECHNICAL PROCEDURE u( 6 ENGINEERING TEST PROCEDURE S UNIT 0 ETP 97-064R CONTROL ROOM HVAC SYSTEM INLEAKAGE TEST REVISION I Effective Date i,/i /oo Safety Related X Non-Safety Related CONTROLLED COPY Writer; D.T. McElheny Sponsor: T. R. Lupold Approved I Dafe

C)4(oC1S2 4 J/ d1 4 /a A1*7e4* ee /

tv I'

TELEPHONE: (614) 846-5710 NUCON International, Inc. TOLL FREE: 1-800-992-5192 K'11 P.O. BOX 29151 7000 HUNTLEY ROAD COLUMBUS, OHIO 43229 U.S.A.

FAX: (614) 431-0858 WEB SITE: www.nucon-Int.com Control Room Inleakage Test Report performed for:

Baltimore Gas and Electric Company Calvert Cliffs Nuclear Power Station 1850 Calvert Cliffs Pkwy. 3 I

Lusby, Maryland 20657 P.O. No. 16582 3 March 2000

. I Distribution:

BG&E:

Dale McElheny (1)

NUCON:

12BG658 MF (1)

Field Test (1)

QA (1)

Marketing '(1)

NUCON 12BG658 101

c4oys't /-K.7 5e/ J°3 FT-86 (Rev. 1 10/97) BG&E ETP-97-064R-REV1 Attachment 2 Page 37 of 40 Decay Test Data Estimated duration of test: 180 minutes Beginning concentration (Ct): 51.4 ppb Ending concentration (C(O)): 13.2 ppb Time at start of test: Time "zero" for decay test was at 01:05 hrs. on 26 Jan 00 Time at end of test: 04:05 hrs. on 26 Jan 00 Sample time intervals: 15 minutes apart Time / Sample Concentration Time/Cone. TimelConc. *Time/Cone. Time/Conc.

/ 120/23.8 /,

30/51.4 .135/21.0 / /

45/47.6 150/1I7.8 /

/ /

60/41.9 165/16.4 _

/ /

75/ 33.0 180113.2 90/ 30.7 l I l

105/ 29.3 I /

(A) Air Change Rate ( 1/min) (Q) Inleakage Flow Rate (CFMt 0.00896 2600 95% Confidence Limit 95 % Confidence Interval (A)= 0.00896 I .0.00065 2400 < Q < 2800 Comments: Decay samples taken at a sample port on the discharge off12 return fan. All sample concentrations in the ppb range.

Test personnel signature(s) and date: NUCON International Inc.

60C4'5s- Arto oa le-o/

FT-86 (Rev. 1. 10/97) BG&E ETP-97-064R-REV1 Attachment 2 Page 37 of 40 Decay Test Data Estimated duration of test: I 80 minutes

-Beginning concentration (Ct):. 59.2 R i), 15 minutes into test Ending concentration (C(O)): 8.8 spb ft 195 minutes into test Time at start of test: Time "zero" for deca' test was at 23:35 hrs. on 26 Jan 00 Time at end of test: 03:00 hrs. on 27 Jan 00 Sample time intervals: 15 minutes apart to 105 minutes then (i 140. 165. and 195 minutes Time / Sample Concentration Time/Conc. Time/Conc. Time/Conc. Time/Conc.

15/59.2 165/13.8 I 30/52.5. 195/8.8 l I 45142.8 I /

60/40.2 _ I 15/36.1 /

105 /26.2 / I

/ / /

140/ 17.4 (A) Air Change Rate ( I/min) (Q) Inleakage Flow Rate (CEM) 0.0103 3000 95% Confidence Limit 95 % Confidence Interval (A)= 0.0103 -O.OOb85 2750 < Q < 3250 -

Comments: Decan samples taken at a sample port on the discharge of #11 return fan. All sample concentrations in the ppb range.

pe Tes /sdt Test personnel signature(s) and date: NUCON International Inc.

CA06452 Rev.000 Page 105 of 110 ATTACHMENT X ETP 01-035R PERFLUOROCARBON TRACER GAS TESTING

.e -I I

C6,atr'5 ArzK CALVERT CLIFFS NUCLEAR POWER PLANT A 5 /°4 TECHNICAL PROCEDURE ENGINEERING TEST PROCEDURE UNIT 0 ETP 01-03SR PERFLUOROCARBON TRACER GAS TESTING REVISION 0 Effective Date 13/,/Z02 Safety Related x

• Non-Safety Related Writer: D. T. McElheny Sponsor: M. A. Junge Approved .(g4

• LII. I mf-o 2.

Date I-

. . ... .. I .. ' '.. .. . '. . - . .

• JUL 29 J02 03-37PM BNL 'DAS/ECD 426- . . I . .. . . . .. .. P.114 I.

- z I- 7' U-,-

V. . - u

, ACEIVIECAk LoLocY cENR-.

BRO6KI42AVFN NATIONAL LAB ORATOP.; .

.; . _'._ .  : :DATE.E 29y~, 1002  ;.

-T

-O: lohn E. Wynn Jr. . . ...  : ..

Aux Systens Engr Unit Calvert Cliffs Nuclear Power Plant Lusby, MD 20657 FAXNO: (410) 495 - 4727 MMSSAGE:

John, I'm on vacation this week but wanted to send you the. anal results but without my final asseisment. Remarkably, total inleakage was 2930 1185 cfm. Othei rlws, Wnc were:

Zone From'To- . CR lnleakat6. .1%of t61 - .. CR Oufliecagi.

• of tri **

"-1866+/--'4707 :t-.'64

.2 AB . 436 1$ .. 15 '366d:+/-248: A.3

• . :3 7B 1 5* 9491 5 `2 0...

. 4 WM.272 i.34

. 5 AC I 1. .- 74+33 9 '11

6. AC13 . 387-+/- 38 '13

.7 SWGRs 81-8+/--1i4 28 :2ii+/- I O More next week. I'll pUt a copy inthe mail also;.

• Tota no. of pages including this cover page:

From- Russell N. Diett - Head pho ie (6$ 2)44--3050 Te~

TracerTechno1o6. Center.

Atmospheric"Sciences Divisiond.

BrookhavenNational Laboratory :dietz~bnl.9ov,.Email Bldg 81,SE ~SecrtaryBarbara J.Rol~nd Upton, NY 11973 5000 Secretary's cmal rolad~bnL~gov

. I . ..

• • -.JL:L29 '02 3:37PM BNL,.DAS/ECD 426 * *-.z.

1...36:28 07-26-2002 PROJECT: CALVERT CLIFFS START: 09:00; f8-O8-19O2): BNL CODE: 'CPlAOO HOUSE:CALVERT CLIFFS *STOP: 1OOO (06-18-1902) ANALYZED: 06-27-1902

• • • $ RATES

• OVERALL INFILTRMTION RATE = %515978. L 58992.1 (n3/h)

(-CRALL AIR EXCHANGE RATE 1 .461 .. O..251( 1/h) b ZO SOURCE RATE EXFILIaATION .. .J1NFILTRATION---

N LOCATION K25C QlTY @T RTE SDAE SD ACH Sb

.1 CR . .0. 1. 1E 2 79%6610. anL D b ..O.o0C4 2 AB- 38 8 .0 4 973219. 30896..3 1048 6b 32707.5 1645.0 O 0.680 :O'. 2 44 3.TB  : S3870.0 .12 43399361;41.1130 88&.19.1 419373. 90345.6 1.482 .0

.328 4 MSIVs %458.O 4 189594 22087.4 105.68.3 .5694.9 . 8281.4 4.658- 6.77 S No.11 AC %2150.0 1 132691 308is.8 . 3244.8 32226.2. 3348.5 19.042 2.1 96 6 No.13 AC 6.4 30 12620 14492.4 1194.7 :8912.2 1907.4 2.460 0.541 7 SWGRz4 9.2 10 6435. 3381.7 10458.4 16598.8 1527.7 2.346 0.246 ZONE-ZONE RATE g .SD (m-3/h) ZONE-ZONE' RATE g SD (m-3/h) 1.- 2 622.2 421.7 2 1 741.3 267.9

1. *3 1018--70 . 3704 792.5. 292:2

~74.5.568756.2'

`1 5 32'3: 5n29.  :. 5 -'1 :56;_

Z -619.4 *19 2..0 .. 3.

• 4 73-:. 134  :"159< :. .6 -. 3 32870.3 2 1460.4" . 6 145 **46577.

2 4 31.1 3 4 19. .7 3. 7.1.'2- 448 3..

2-.2 56 ~ 121:2 .'2916057- . 6 .~ 3> 2684. 145.

3 '4 17034.A' %11594 .3 .- 4 .154.4 J21.

163.4 'I5 .116 7 . 807.0 2 5.2

- 6 416.2 1965.2 .6 31002.9 424.6 2 - 67 7215:4 568- 8 207 133.1 76 7.- 3 61 4' %621a38.9' 12674:.2 26 12.7 6.5 . 4' 755.3 506.8 4 7 30.9 19-1 7 4 -541'.5 547:'4 5 -6 60.8 11. 125.9 120.7

.5-7 .22.3 .7.0 ~ 7- 5- 7.6 62.7 6 -7 91.1 20.9 7 -6 .-*.O 214.7

'--- - -TOTAL- FLOW -IN OR.:OUT--.;

AONE RATE q SD (m-3/h) .ACI g SD(/h). ZONE -RATE SP (m^3/h) ACH SDth

-t9 :X973.4 310;p O..586' O.047 . 351i4.A2463.9. 'O*2

• 0730 0.262..:

%4'7 .'u322.6 -3 1.547 - Q.340 . 23l6.

.. S %1183.4. .18.966:.. 9.

115 .: ..:,.!:

5 32647.6 3389.9 219-291 2.223... .. 6 17439-5 1095. . 4.814 0.386 7 17547.1 1595.5 2.480 0.257 ANALYSIS: $**** ************'***

• V ol&, . ,U 1 5m '2

..i16>' " -**- .z HGARAM"C .:* ..c.'. . .: : ' .. .- .

'YO..

I CH . IPDPDB ccPDC9 PC 9490 ptPDCB 3A447 a 0.403 C.466 q 0.173 2.352 9 O.lI 0.186 q 0.078 0.386 s 0.014 0.101 q 0.005 0.108 9 -

009 0.13 s 0.090 0.046 q 0.026 0.009 q 0.004 0.008 q 0 48110 ?MCP 0.151 a 0.086 27.815 q 9.791 0.174 0.085 005 2B3000 ADfd 0.021 q 0.013 0.219 y 0.049 7.784 - 1.682 C qoO 0.001 0.009 q 0.001 0.002 1 0.001 0.011 q 0 009 1223 I-PC} 0.043 q 0.011 0.196 i 0.026 5.846 g 2.452 8.1& q 3.895 0.0339 ..0.009 0.025 q 0.011 0.000 a 0 000 1692 NCH0.009 q .0.001 0.017 q 0.003 0.067 q 0.021 0.6! a 0.0.005 4.065 0.389 0.003 q *Do03 0.000 I 0 001 3622 ocPDCH 0.0210 g 0.001 0.129 q 0.010 3.764 O' 0;259 .0.010 e O.001 0.019 g 0.002 0.725 9 0.035 0.006 q 0

.7 iPPe .0.023 q D0.0A 0.DA55 0.143 0.13$s 0.054 0.004 q 0.001 .0.867 q 0 30v

.!.J W1.

. JUL' 29 '02 03:38PM BNL DRSECD 426 CONMTRATION(PL/L) _ _ _ _ AV CATSM ptDHd MCP M T-PlCH PM ocPW .IM otP2CW xtPDCB a , 2-4 4277 7.147 A.699 2.68'8 0.637 0.3765 0.095 .0.083 0.000 :.273 7.315 . I.3A1:1DUE7D 180 7.142 4.630 2.584 1.290 0.335 0.090 0.115 0.000 8.045 .OODELTED TD085 18149 .217 4.402 2.249 0 733 0.399 '0.097 0.096 O.000 9:46a 8.384 .223 . '. . : .. -!: .' :. I .

' 4'.:" .1 '

' 12400 9.277 4.610 2.428 OB 0;415. 0.109. 0.107 ;0.000 10.964- B.730.. 244 'J 12321. 8.890 4.691 2.352 .0D794 . 0-391 0 .106 0.109 D.000 1O.46 9.361

• 28 A 12055 8.689 4.280 2.432 0.8041 0.393 0.I04 0.122 '0.000 10.329 4.15 0241  :

12631 8.324 4.340 2.500 0.777 0.319 .101 0.123 *0.000 98.86. .8.765' @.'22 ..

Me0181 I8M22 4.382 2.327 0.758 0.425 0.107. 0.103'. 0.000 9.774 '.664 <0.232'.

12057 .8.446 4.598 2.370 0.978' 0M3e 0.101 0.105 0.000 10.017. 8.883 O..04' 11079 7.998 4.410 2.484 0.712. .0.394 0.096 0.036 0.000 9.357 D8.28$ 0.218

- -8062 327 .169- -0.721 -0.383 -0,093 0.100 0.W -9.420 - 8,346 0.221 -

7.12 .404'i 2.238 0.777 0.392 0.100 0.105 0.000 9.924 8.800 0.237 520 7.126 a6'2.295 0.657 0.804 0.101 0.089 0.000 8.413 7.441 0.198.DETID I 2268 6.923 4.160 2.46A 0.644 0.528 0.110 0.081 0.000 8.174 7.227 0.194 DPLETEI 2138 7.555 4.335 2.589 0.698 0.55& 0.118 0.096 0.000 E.920 7;B96 L.211 DEIITD 3644 . 8.586 2.498 3.554 0.326 0.184 0.145 0.052 0.0oo 4o003 3.510 :0.094 DILD 12390 0.204 (1419 15.834 0.020 0.015 0.02 0.007 0.000 0.187 0.164 0.006'DERETED 12036 5.449 3.128 7.235 0.502 0.276 0.067 0.065. 0.000 6.274' 5.527 .J 49 DRUTD 1 30 5.1P i.0 5 22a Q45 _0.475 0.052 _ _ 5.OI7 5.2QO

'.j4D !Ik DELETED 12083

- 1.b V.6 3.481 0.090 0.S6. 0.310 C.018 Q.000 1.259 1.098 i.02 DELETED 4779 0.031 0.098 2.728 0.014 1.359 0.490 .0.005 Q.000 0.459 0.400 0.005 DEEED 4i27 3.552 2.287 1.977 0.323 1.448 0.122' .0.043 O.000 3.344 3.458 '0.092 DHLED 12497 2.791 1.837 1.829 0.249' 1.879 .0.106 0.031 0.000 3.014 2.637 0.070 DEVLTED 12163 0.030 11.417 0.020 0.002 0.009 0.001 0.003 . 0.000 0.000 0.000 .0.000 DEL 12063 0.028 10.242 0.141 0.001 0.014 0.002 0;007: 0.000 0:000 0.000 - O.COO DELETED 12393 0.028 1.611 1.856 0.098 1.488. 0.338. 0.005 -0.000 0.330 0289 .B.28'PRUED

.12009 0.072 183460 0.0Q9 0.076 .0-035 0.011. 0.014 0000. 0.000 0;000 .0;21 '"

12264 0.143 35.832 D.214 0 202 0.057 0O013 0.008 '.000 MOO. :0. . 056 .. :  :: I 12376 0.167 43.634 0:244 0.257 0.030 0o0S 0.008 00O06 0.000 0.000 '0.0.

12297 0.523 14.879 1 371 '0.A2 0.536 0.119 0.009' -C0.00 0.641 600.201. TE

'12191. '0.169 16.484 .1.166 0.638 -0.58 A1-0.01.OOB8 0:0 00269. 0.188'DBLEXD 12379. 0.S35 SO.172 0.222 0.061 'D088 0.012. 0CM. . 0.000 0.408 0.357 4.017.

12012 i.489 20.586 0.519 0.175 . 0295 0 030 0o 8 0.000 1.561 !.362. .049.D1LETE. .

12244 0.112 25.193 0.138 0.061 0:069 0.003 0.093 0.000 O.182 D0160 . 0.017 12155 0.107 26,430 0.094 .0.044 0.031 0.00. 0.003 0.000 0.161 0.159 0.012 12384 0.507 0.312 4.404 0.044 0.923 0.253 0.011 0.000 0.68B 0.600 . 0.012 DELTED 11218 4.13 2.583 1.088 0.367 0.203 0.049 0.067 000 :4.586 4.026 0.107 DELETED

'561 C 0.053 3.165 0.464 0.092. 0.219 0.070 0.008 0.000 0.124 0.109 0;025 DELETED' L :1 0 1?2 6- 0 0Q914 . -21? 9.9: OM 9.117 l:W Q45 II 11151 0.0185b.9 0.20 MUD O.U10 0.0U0 . ,Q2 U.UUU U.U UU1 U.Uz I 9590 0.019 03197 7.035 0.005 . 0.O09 0.002 .008 0.00 0.025 0.022 0.002 II 12402 0.020 0 '176 7.297 0.006 0.010 0.002 0.009 0.000 0.026 0,023 0.002 -

I 12337. 0.014 0.156 6.492 0.004 P.009 M.U02 .0.00 0.000 0.020 0.018 0,002.

12417 0.017 0.235 9.217 0.007 0.009 0.0030 '0.006 0.000 0,024' 0.022 .0.002 II 12O25 O.03Q 0.205 8.388 0.008 010 0.03' 0.005 .0,000 0.038 0.0034 :.  :

I- 12468 0. 062 0.381 15.438 0.009 . .0.009 .. '0.004' ODe O.O0o. 0:064. 0.05T :.0.003 .. 1LETED . T.:

I 12383 0;015 0.195 t.342 '.f005 0.007 . 0.001 0.011 0.000 0.021 0,019'0.002:'.

12203 0.055 0320 10.741 0.008'. 0.009 0.003-. 0.G04 . 0,000 0:050' ;003 :'.::

E.B58.: .. . *. .:.

i 12178 oM01S 0.279. 9.691 0.006: .0D09' .0,001 0;005 0.000 0.019 D0017 *.0 2  :

II 12288 .031 0. 82 12.712 4.013 0.008 *0.002 0.011 0.000 0.035 0.031 '-O004DILETD "..-.

I I

.1 fi1 0 019 0.081 0.0 4.4 0.007O .029 0.00Q 0.019 Q 1 0.00.1..

M7W n'AM ht'n A An 9 nAfli A) goofa A A Am0.00 0.014AA (I019 0 00l 7 90.128 0 4.011 0.009 0.021 .0.75 0.006 D.000 01 .. 534 0.004' 191 0..019 0.120 3.432 1 0.009 00172 .039 0.005 0,000 0.127 0.582 0 004 12340 0.013 0.970 0.178 0.022 0.010 0.004 0.325 OIUUO - 0.02? 0.025 0.006 12502 0.016 1.129 0.20S 0.027 0.009 0.005 0.378 0.000 0.034 0.031 0.008 12307 0.024 0.751 0.080 0.015 0.007 0.004' 0.399 0.000 0.040 0.035 0.005 12300 0.031 0.890 0.095 0.019 :' 0.008 .0 04 0.385 0.000 0.046. 0.041 06 2158 0.019 0.963 0.182 0.022 0.007 0.005 0.392 0.000 0.038 0.034 0.007

.6706 0.017 0.942 0.173 0.022' 0.008 0.005 0.389 0.000 0.037 0.033 0.007 7750 0.029 0.728 0.084 0.013 . 0.007 0.003 0.332 0.000 0.044 0,039 0.004 0.015 0.006 0.003 0.339 0.043 lMRAI A AM1

- -.1.1.

n 731 0 fl5

---

- 0.000

---

---- -L036 0.005 i.: PXD HoC P CH ecDCR piDCH OPMCH PTCH 0.74 0.74 O.n.7~-y.62 07 OM$%rE.8 60177

%A a . '.l  :-'4'

• * ** NOTES *********************** *****

~11 gas volumes are reported.at 21 5 C. and 1 atm.

'he standard deviation in.- the source strength has bee.n set'. at' 4 X.

standard deviation in the volume measurement has'been set at 5 %.

overall normalized condition number (,CC)/Nl.5)- 0.429

.(CVN = 1.136

.onal condition numbers are:

joNE _ . 4 5 6 7.

onditlon Numb~e- 1.053 1.017 1.379 1.248 1.005 1.124 1 -0444 . .

JUL 29 '02 03:39PM BNL.DRS/ECD 426 .P.4/4 ct4rs-z f¶yei/o r

I

FLOW-RATIO8 STD.DE.

?ILTEH/XXFILTRV D.147 0.1142 Q0.45S--

-1.0s j.020 0.0363 - .

lE 4 0.258 0.3540 15 5 L-045 0.0108 If 6 0.615 0.1209 1K7 t.908 15.1200 IM0RAL 2! 2- 1 O.832 0.4851 3/3- ! 1.285 0.9277 4, 4- 1 Q.161 0.0983

.5/ 5-1 0.069 0.0093 6/ 6- 1 0.029 0.0209 7/ 7- 1 0.026 0.0122 3/3- *19. 43 -2.. 994T 4t4- 2 0.082 ~O. 1957 I. .

5/5 C;036 . 0;0273 8/ 6-2 0.036 0.0723 717- 2 0.s03 0.7688 .

At 4- 3 .119.353 89.6471 5/ 5- 3 0.203 0.1401

• 61 6- 3 8;392 3.1446 7/ 17- 3 0.017 0.0174

-.4 0.495 0.2269 6,' 6-4 0.017 0.0085 7/7- 4 -0.057 0:0552 6/ 6- 5 0.483 0.4655 7/:7-~ 5 . C 80.0 1.8474 7/7-:6 12.5Th 396.7011 kNDAXD DEIATIOX OF ptPDCS IS10OE 2 IS GUAM hN 251.

WDARD DVIATI3 OF pLCStIF ZONE 3 1S EAR TEAR 25 X NDARD DEVIATIOR 07 ptPDCHJ N ZEI 4 ISGR TE TM.251 IRDA DAVIATION Of ptIDCH ZOXE ?7.1 AS TM RTEAI 25 %

1DARDDEVIATIJO OF PEP INZE 2 IS G TE TME A 25 2

%DARD DEIATION 01 PDCB IN ZON3 2 IS GETER TRAR 251 INDARD DEVIATION OF FDCB I ZONE 4 IS GRTER TE 25 X IJIDARD VIATO OF PDG IN 20! 5 IS GEATR TS 25 X BDI DIATION OF -PDCD II ZWE 7I IS GRATR TRN 25 X ANDARD DIVIATION OF T-7 IN NNE 2 IS GWR EHU 25 X AXDARD *DEATIDN OF 7-PCH 1 ZO 4 1 MRESTER TAR 25 X ASDAPD IATIN oP 1-PM 1R Z0NE 518 GRIATER TEAS 25 X ANDAXD VIATION OF }FMINZONE 2 IS GAT TA 25 X ANDARD DVIATIOI OF PO IN ZONE 4 IS GEAT TMS251 ANDAD DEVIATIM 0oolDOD IN1ZOE 2 IS ATER TMS 25 1 AJDARD DEVIATIOW 01 oTDC IN Z0NE 3 IS GBATER AN 25 1 ANDARD DVIATION OF oPDGH 1 ZONE 4 IS 6WAATIAN 25 X ANDARD DEVATIMN 01 ocPDCE INZONE B IS MTER MN 25 X AUDARD DEVIA7ION O iOPf INZONE 2 IS GREATE ITAR 25 X

'MDDEVIATION Of VPCH INZONE 3 IS GATIR TER 25 X

h. _D EVITIOR OF ICH IN ZONE 5 IS GE1AIEX MN 25 X